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Chapter 1 
GENERAL INTRODUCTION 
 
At birth, infants can be classified either by gestational age (GA) or by weight. Neonates born 
< 37 weeks are classified as preterm, < 28 weeks as very preterm and < 26 weeks as extremely 
preterm infants. Prematurely born infants can also be classified by birth weight as follows (1): 
- Low birth weight (LBW) < 2500 g 
- Very low birth weight (VLBW) < 1500 g 
- Extremely low birth weight (ELBW) < 1000 g 
However, both classifications are used arbitrary in the clinical setting and obviously the infant 
born very prematurely has most likely a birth weight < 1500 g.  
Over the past 25 years life support in the neonate born prematurely has improved 
tremendously and has created major advantages in medical treatment possibilities and 
survival. Nowadays it is generally accepted to treat the very preterm infant and even the 
extremely preterm infant since survival rates for these infants are still increasing. During the 
eighties mortality rate of preterm infants born at GA of 25-27 wk was 52.1% (n = 169) and 
these rates decreased dramatically to 31.8% (n = 88) in 1990 (2). The mortality in infants at 28-
31 wk GA decreased as well, although less impressive from 15.2% (n = 559) to 11.3% (n = 388) 
(2). On the flip side of the coin, morbidity in these infants is still high with 64% in infants born 
at GA 22-25 wk at the time of discharge (3). Another recent study showed that the survival 
chance of infants born with GA < 26 wk free from serious neonatal morbidity at the time of 
hospital discharge was < 15% (4). Overal surival rate for infants born with GA ≤ 26 wk is         
39-54% (3, 4) and 89% for infants born with GA < 32 wk (2). The National Institute of Child 
Health and Human Development Neonatal Research Network showed in 4438 infants 
weighing 501 to 1500 g at birth that 84% survived until discharge (1). Survival to discharge 
increased with birth weight and showed improvement, particularly in infants weighing           
< 1000 g. The incidence of chronic long disease (23%), necrotizing enterocolitis (7%) and 
severe intracranial hemorrhage (11%) did not change. However, 99% of the infants weighing 
< 1000 g showed poor postnatal growth. Very recently Saigal et al. (5) reported in a study on 
the long-term outcomes on ELBW young adults that most former ELBW infants have 
overcome their earlier difficulties to become functional young adults. Another study (POPS 
cohort at 19 years of life) supported this concept of coping behavior of ex preterm infants in 
later life. They showed that the vast majority (> 95%) of young adolescents born premature 
were very satisfied with their lives and a just a minority (< 10%) suffered from major 
disabilities (6). 
 
Along with the major advances in life support measures, nutrition has attracted more 
attention in the care of ELBW and VLBW infants. However, to date neonatologists are more 
focused on mechanical ventilation and infections. Nutrition is still considered as relatively 
unimportant. Until recently, it was believed that premature infants do not tolerate much 
parenteral feeding and total parenteral nutrition was standard regimen after a couple of days 
post partum.  
Birth involves the transition from intrauterine to extrauterine life and requires rapid 
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 adaptation of several organs. Before birth, the fetus receives a continuous supply of nutrients 
from the placenta and at birth this is suddenly terminated and the gastrointestinal tract 
needs to adapt to enteral feeding. The final maturation of the gastrointestinal tract for 
enteral nutrition is shortly before or at term. Preterm birth is associated with immaturity of 
the gastrointestinal tract involving complications such as immature digestion, absorption 
and motility. It seems that enteral feeding in infants born prematurely is mandatory for the 
development of the gastrointestinal tract (7, 8). The clinical condition of the preterm infant 
frequently allows mainly parenteral feeding and hardly enteral feeding during the first week. 
Parenteral feeding is associated with several complications, including increased risk of 
infection, mucosal atrophy and cholestatic jaundice. Introduction of enteral feeding is 
therefore required as soon as possible. Also, enteral feeding stimulates postnatal 
gastrointestinal development. However, enteral feeding in these infants is associated with 
detrimental morbidity, like necrotizing enterocolitis (9). 
 
Early nutrition is pivotal for preterm infants’ survival but has also profound influence on their 
later developmental and intelligence outcome (10). It is of utmost importance to offer 
optimal nutrition to enhance growth. However, rapid early growth in term infants born small 
for gestational age is related to the development of metabolic syndrome (hypertension, 
dyslipidemia, obesity and insulin resistance) and non-insulin dependent diabetes later in life 
(11, 12). Whether this phenomenon concerns the preterm infant is under debate. 
Controversial results have been published whether preterm birth is related to insulin 
resistance (13, 14). Hofman et al. (14) showed in children 4 to 10 years old who were born 
prematurely, whether their birth weight was low or appropriate, that insulin resistance was 
presented. As compared with control children who were born at term and appropriate for 
gestational age, infants who had been born prematurely had a reduction in insulin sensitivity, 
irrespective of their birth weight. These findings should be interpreted with care because 
epidemiologic studies have not yet indicated that there is an increased incidence of type 2 
diabetes mellitus or other manifestations of the fetal-programming hypothesis among long-
term survivors of prematurity. Besides, the era of increasing survival of preterm infants is too 
short to examine long-term consequences of prematurity. The development of diabetes type 
2 could also be induced by entirely different mechanisms, rather than those related to 
intrauterine growth restriction. In addition, the authors comment little on the effect of 
interactions between birth weight and early postnatal growth on subsequent insulin 
sensitivity. Subsequently, it was speculated that insulin resistance is associated with early 
nutrition and diet composition (15). It is therefore important to determine the specific 
nutrient requirements, i.e. carbohydrates, protein and fat.  
 
The goal in estimating the nutritional needs of the preterm infant is not only to provide the 
quantity and quality of nutrients needed to achieve fetal rates of tissue growth and nitrogen 
accretion (16), but also to provide a functional development as the infant would have in case 
he was not born prematurely. In view of the protein quantity, in the past years it has become 
clear that the minimum and maximum protein concentration in preterm infant formula  
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Figure 1. Weight gain is dependent on protein intake (18-21). 
 
should be 2.5 g/100 kcal and 3.6 g/100 kcal, respectively (17). A new guideline will be 
published, advising to administer an average protein intake of 3.8-4.5 g/(kg·d) to infants 
weighing less than 1800 g (2008 ESPGHAN guideline on enteral preterm nutrition). 
Inadequate amino acid intake impairs protein synthesis, which is pivotal for growth. Protein 
intake is related to weight gain as depicted in Figure 1. 
An optimal intake of amino acids is thus necessary for adequate protein accretion in 
neonates but might also prevent diseases. However, the specific amino acid requirements for 
ELBW and VLBW infants to meet their metabolic needs are poorly defined. 
 
 
AMINO ACIDS 
 
Amino acids are molecules where the amino and carboxyl groups are attached to the same 
carbon atom, which is called the α–carbon. The various alpha amino acids differ in which side 
chain is attached to their alpha carbon. α-Amino acids are the building blocks for proteins. 
There are twenty standard α–amino acids used by cells in protein biosynthesis and these are 
specified by the general genetic code The genetic code is the set of rules by which 
information encoded in genetic material (DNA or RNA sequences) is translated into proteins 
(amino acid sequences) by living cells. These twenty amino acids can be either 
biosynthesized from simpler molecules or must be obtained from the diet. The carbon 
skeleton of indispensable amino acids cannot be synthesized endogenously in the body and 
must therefore be supplied by the diet. Dispensable amino acids can be synthesized de novo 
in the human body from other amino acids. The eight indispensable amino acids in the 
human are: isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and 
valine. The dispensable amino acids are: alanine, arginine, asparagine, aspartate, cysteine, 
histidine, glutamate, glutamine, glycine, proline, serine and tyrosine. However, some 
dispensable amino acids are considered conditionally indispensable during specific 
circumstances, e.g. rapid growth or critical illness. Endogenous synthesis then will 
11 
General introduction 
C
ha
p
te
r 1
 temporarily not be sufficient to meet the requirement. Conditionally dispensable amino acids 
during early development, because of the biochemical immaturity of the preterm infant 
include arginine, cysteine, glutamine, glycine, histidine and tyrosine (22-24).  
 
 
ESTIMATING REQUIREMENTS 
 
How to estimate the specific nutritional requirements in preterm infants? Different methods 
have been used to estimate dietary requirements, eg the nitrogen balance method, weight 
gain rate, plasma amino acid patterns and the factorial approach. Snyderman et al. (25) were 
in 1953 the first to describe requirements for specific amino acids in infants. They reported 
amino acid requirements in infants (Table 1) by means of nitrogen balance and weight gain 
(26-31). 
  
Table 1. The minimal requirements of certain amino acids for infants (22-27). 
 
Nitrogen balance is the difference between the amount of nitrogen consumed and the total 
nitrogen losses (including urine, feces and miscellaneous such as skin, hear, sweat, breath). 
The principle of the nitrogen balance method is to increase the test amino acid intake from 
deficient to adequate, whereupon nitrogen balance and growth rate will progressively 
increase until the requirement is reached. A disadvantage of this method is that it is difficult 
to determine the nitrogen losses accurately. In most studies these losses are measured only 
in urine and feces but not through skin, hear and sweat and often some urine or feces are lost 
and therefore not included in the balance. On the other hand, nitrogen intake is often not 
accurate estimated but overrated because of spilling or vomiting. A combination of these 
errors results in overestimating or underestimation (assuming that the provided intake is 
truly consumed) of the nitrogen retention. Another drawback is that it requires 7 to 10 days 
for the body to adapt to the nitrogen quantity of test diet (32). Currently, this method is not 
applicable anymore to estimate the requirements for preterm infants because present-day 
practice will not accept to maintain neonates on either deficient or excess amino acid intakes 
for a minimum of 7 days.  
Amino acid Estimated minimal requirement 
mg/(kg·d) 
Histidine 17-35 
Isoleucine 79-126 
Lysine 90-105 
Methionine 32-49 
Phenylalanine 63-91 
Threonine 45-87 
Valine 85-105 
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A different method to determine requirements is to measure biological or physiological 
responses to graded intakes of the nutrient under study. Several studies have been done to 
investigate the profile of plasma amino acid concentrations in preterm infants during 
different feeding regimens, ie parenteral, human milk or formula feeding. The goal was to 
compare amino acid pattern in these infants to term breast-fed infants (33-35). However, it is 
not plausible to compare the infant born prematurely to those born term because of the 
different metabolic needs and developmental stage. 
At present, it is generally believed that the growth rate of the preterm infant should mimic at 
least the growth rate of the intrauterine fetus at the same gestational age (36), but that at the 
requirement level the infant should be provided with enough nutrients to sustain a 
functional development similar to that of a normal newborn (ESPGHAN 2008). Nutrient 
requirements are currently based on the factorial method (37, 38). In this method the 
obligatory nutrient losses (maintenance requirement) is added to the nutrients required for 
protein synthesis (growth requirement) (39). The factorial model to define the protein 
requirements for preterm infants is based on fetal body composition during normal 
intrauterine development. Body composition data derived by chemical analysis from body 
carcass of stillborn preterm infants are quite old (40). Ziegler (41) has used various of these 
data to create a reference fetus. However, these analysis are not completely reliable because 
they were done when the gestational age could not be exactly determined by advanced 
techniques and was completely dependent on maternal history. Another difficulty is that the 
reason for preterm birth was not recorded and differentiation in intrauterine growth 
restriction was not made. Subsequently, these date were re-analyzed by Sparks (42) and 
corrected for these confounders. Nonetheless, the fact is that these data are still old and for 
some amino acids data are not available.  
Figure 2. Fetal data from carcass analysis. Data reviewed by te Braake et al. (43) 
 
Recently, a new method to determine dispensable amino acid requirements have been 
developed: the indicator amino acid oxidation (IAAO) (44). Kim et al. (45-47) were the first to 
describe the determination of amino acid requirements of young piglets using the IAAO. This 
method is based on measurements of amino acid oxidation. The indicator is a stable 
isotopically labeled indispensable amino acid and is different from the amino acid under 
13 
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 study. The indicator needs to follow the same pathway as the identical unlabeled 
dispensable amino acid. At the same time, oxidation needs to result in the release of labeled 
CO2 and without intermediary metabolism, such as methionine. The indicator is independent 
of the different intake levels of the test amino acid. The IAAO method is based on the 
assumption that the partition of any indispensable amino acid between oxidation and 
protein synthesis is sensitive to the level of the most limiting amino acid in the diet (44). If an 
indispensable amino acid is deficient in the diet, this will limit overall protein synthesis and all 
other amino acids will be subsequently oxidized. Increasing the dietary intake of the test 
amino acid will linearly decrease oxidation of the indicator until requirement of the test 
amino acid is met. A limitation of this method is the necessity of providing all amino acid in 
excess, except for the one under study. Consequently, insufficient intake of indispensable 
amino acids could result in another indispensable amino acid than the test amino acid being 
limiting for protein synthesis. Leucine, lysine and phenylalanine are mainly used to serve as 
an indicator. The choice of the best indicator is still under debate; in piglets phenylalanine 
was demonstrated to be the best indicator (48), and a study in humans demonstrated that 
leucine was not a good choice as the indicator (49). In our view, phenylalanine is still the best 
choice to use as the indicator. After Kim et al. (45-47) introduced the IAAO, Zello et al. (50) 
introduced the method to use in human studies. With the use of this method the 
requirements of tryptophan, threonine, lysine and sulfur amino acid of human adults have 
been determined (51-54). Further adaptations have led to a non-invasive method for 
measuring indispensable amino acid requirements in compromised populations (55-57). 
Despite the minimally invasive method to determine requirement, only the tyrosine 
requirements in parenterally fed preterm infants have been established so far (58). It is of 
great importance to determine the specific indispensable amino acid requirements in 
preterm infants to meet their needs, because temporary metabolic and physiological 
immaturity of these infants often leads to a delayed onset of adequate endogenous synthesis 
of amino acids. Although there is a vast amount of guidelines recommending total protein 
intake for preterm infants, hardly any data are available on specific amino acid requirements. 
 
 
SULFUR AMINO ACIDS 
 
Sulfur amino acids have gained much interest in the last couple of years mainly because of 
the link to cardiovascular disease (59) and neurological diseases, e.g. Alzheimer (60). More 
recently, it has been shown that homocysteine also plays an important role in pregnancy 
complications (61, 62) and neural dysfunction (63, 64). The sulfur amino acids in mammals 
are: methionine, homocysteine and cysteine. However, methionine and cysteine are the only 
proteinogenic sulfur amino acids. Homocysteine is not incorporated in proteins and 
functions as an intermediary in methionine metabolism. Sulfur is an essential element of all 
living cells. The free sulfur moiety in cysteine is important in the formation of disulfide bonds, 
for instance in stabilizing protein structures. One cysteine molecule can form a disulfide with 
another cysteine molecule and is called cystine.  
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Methionine is the only indispensable sulfur-containing amino acid in humans because the 
carbon skeletal cannot be synthesized in the human body. It is an important methyl donor for 
several biosynthetic processes and its sulfur is essential for cysteine synthesis. Cysteine on 
the other hand, is a dispensable sulfur amino acids in (adult) humans because it can be 
synthesized de novo from methionine via homocysteine and serine. As mentioned 
previously, it is believed that cysteine is a conditionally indispensable amino acid in infants 
born prematurely. Enzymatic pathways involved in endogenous cysteine synthesis are 
absent or activity is limited (65, 66). Cysteine is a key amino acid for premature infants since it 
is the precursor for glutathione, which plays a major role in the antioxidant defense system. 
Some complications of premature birth are based upon oxidant damage, like retinopathy of 
the premature (ROP) and bronchopulmonary dysplasia (BPD).  
Figure 3. Major pathways of sulfur-containing amino acids. MAT methionine adenosyltransferase, MS 
methionine synthase, BHMT betaine-homocysteine methyltransferase, CBS cystathionine ß-synthase, CGL 
cystathionine γ-lyase, MTHFR methylenetetrahydrofolate reductase, THF tetrahydrofolate. 
 
Sulfur amino acids pathways  
The major metabolic pathways of sulfur amino acids are depicted in Figure 3.  Methionine is 
converted to homocysteine via S-adenosylmethionine (SAM) by transmethylation. SAM is the 
major methyl donor in cells; methylations are essential for biosynthesis of various cellular 
compounds including, carnitine, creatine, phospholipids, epinephrine, proteins, DNA and 
RNA (67). Homocysteine is not used for protein synthesis but is a key compound in the 
regulation of methionine and cysteine plasma concentrations. It is removed by remethylation 
or transsulfuration. Remethylation is the reformation of methionine, which is catalyzed by the 
enzyme methionine synthase and conserves a methyl group from either 5N-methyl-
tetrahydrofolate or betaine. Methionine synthase (EC 2.1.1.13) utilizes methylcobalamin as a 
prosthetic group, and requires vitamin B12. The methyl group utilized by methyl synthase is 
15 
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 provided from the folic acid pool. Methylenetetrahydrofolate reductase (EC 1.5.1.20), which 
reduces 5,10-methylene-tetrahydrofolate to 5-methyl-tetrahydrofolate, contains flavin 
adenine dinucleotide (FAD) as a prosthetic group. FAD is a coenzyme derived from riboflavin 
(vitamin B2) (68). Homocysteine can also be irreversibly catabolized in the transsulfuration 
pathway yielding cysteine. The irreversible transsulfuration pathway involves the enzymes 
cystathionine β-synthase (E.C. 4.2.1.22) and cystathionine γ-lyase (E.C. 4.4.1.1), and regulates 
cysteine synthesis. If methionine is in excess, homocysteine is condensed with serine to form 
cystathionine, which is catalyzed by the enzyme cystathionine β-synthase (CBS). 
Cystathionine is then hydrolyzed by cystathionine γ-lyase to form cysteine. This includes 
transfer of the sulfur moiety from homocysteine to the carbon skeleton of serine. CBS is the 
rate-limiting enzyme for cysteine synthesis and decreased activity might lead to insufficient 
cysteine production to meet the requirements. The carbons derived from homocysteine are 
catabolized to α-ketobutyrate, which enters the tricarboxylacid (TCA) cycle. The enzymes 
involved in the transsulfuration pathway require pyridoxal 5’phosphate (PLP), which is the 
active co-enzyme form of vitamin B6. It is not surprising that the concentrations of vitamin 
B2, B6, B12 and folic acid have a major impact on sulfur amino acid metabolism resulting in 
elevated homocysteine concentrations. 
 
Cysteine 
There are different pathways of cysteine utilization. First, it plays a key role in cellular protein 
function and redox status because of its thiol (-SH) moiety (69). Furthermore, it is a one of the 
three amino acid components of the tripeptide glutathione (glutamate-cysteine-glycine), a 
major intracellular antioxidant. Also, it is a precursor for the production of taurine as well as 
coenzyme A and sulfate. These metabolites have important physiological roles in 
detoxification, bile acid formation, membrane stabilization and neurotransmission (70). In 
humans almost all cells are capable of transmethylation and remethylation, thought 
transsulfuration is restricted to certain tissues. Several in vitro studies showed that CBS and 
cystathionine γ-lyase activity was predominantly reserved to the liver (71-73). 
As mentioned previously, cysteine is believed to be a conditionally indispensable amino acid 
in preterm infants caused by biochemical immaturity of CBS. Sturman et al. (65) and Gaull et 
al. (66) were the first to report in vitro results about CBS activity in preterm infants. They 
found that CBS activity was absent in fetal liver tissues, suggesting that cysteine might be a 
conditionally indispensable amino acid in preterm infants due to absent CBS activity. Zlotkin 
et al. (72) also reported limited enzyme activity in liver tissues of deceased infants born 
prematurely and found that this increased rapidly after birth, reaching mature levels at the 
age of three months. These results indicate that CBS activity is related to gestational age and 
that the cysteine need probably decreases with postnatal age. In addition, in vivo studies 
confirmed that cysteine synthesis was limited in preterm infants (74-76). Cysteine is 
indispensable for protein synthesis and is an important precursor for glutathione. If cysteine 
is a conditionally indispensable amino acid in preterm infants it could be the limiting factor 
for adequate glutathione production. Preterm birth and critical illness, including oxygen 
supplementation, might lead to higher glutathione requirement in these infants. If cysteine 
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concentration is inadequate, glutathione quantity might be insufficient to prevent oxidative 
stress. 
 
 
SULFUR AMINO ACIDS REQUIREMENTS 
 
The first minimal total sulfur amino acid requirements for adult humans (approximately        
15 mg/(kg·d)) were reported in the fifties and was established by nitrogen balance (77). 
Recent studies have determined that the methionine requirements in school-aged children 
(78) are similar to young man (12.6 mg/(kg·d) (53). Initial data on methionine requirements 
for term infants fed adequate amounts of cystine date from 1964 and were based on 
nitrogen balance and weight gain rate (30). The methionine requirement in these infants 
ranged from 32 to 49 mg/(kg·d), so two to three fold higher than in older children and adults.  
 
Cysteine is a dispensable amino acid in children and adults and therefore there is no need to 
determine cysteine requirements in these populations. If methionine is supplied in adequate 
amounts, cysteine availability will be guaranteed. On the other hand, since it is believed that 
cysteine is indispensable in infants born prematurely, the cysteine requirements for these 
infants are highly important. 
Snyderman et al. (79) were the first to report cyst(e)ine requirements for preterm infants. 
They found in 2- to 4-month-old infants born prematurely that after a period of cyst(e)ine 
depletion intakes of 44 or 66 mg cyst(e)ine/(kg·d) did not restore nitrogen retention and 
weight gain to control values. They recommended a minimal intake of 85 mg cyst(e)ine/
(kg·d). However, as they did not provide methionine intake, this recommendation might be 
overestimated in view of the risk of inadequate methionine intake. The cystine requirement 
for normal growth by full-term infants fed a soy-isolate formula has been reported to be less 
than 25 mg/100 kcal on a diet of 1.62 g of protein/100 kcal (80). Several years later, the same 
group determined the requirement for sulfur amino acids in two-month-old term infants fed 
2.8 g of isolated soy protein/100 kcal and recommended a sulfur amino acids intake of              
588 μmol/100kcal when methionine intake is 264 μmol/100kcal (39 mg/100 kcal). 
 
The current sulfur amino acid requirements in infants and children are based on the factorial 
approach (81). Because no fetal cysteine accretion rate is available the factorial method is not 
applicable to estimate the cysteine requirements for preterm infants. To date, the cysteine 
requirement recommendation for preterm infants, i.e. 66-95 mg/(kg·d), a twofold higher than 
for term neonates and is based on the minimum and maximum amounts of each amino acid 
present in the amounts of human milk protein corresponding to the recommended 
minimum and maximum protein contents of 3.0 g/(120 kcal) and 4.3 g/(120 kcal), 
respectively (17). However, more direct estimates are warranted to fulfill the minimal cysteine 
need in these infants, particularly in regard with the presumable high turnover of cysteine 
due to oxidative stress. In this thesis the cysteine requirements for preterm infants are 
determined with use of the IAAO method. 
17 
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 INTESTINAL (SULFUR AMINO ACIDS) METABOLISM 
 
The gastrointestinal tract has important metabolic functions during growth. For instance, it 
controls amino acid absorption, regulates the metabolic fates of amino acids in enterocytes 
and it also manages the availability of amino acids for peripheral tissues. Arginine 
supplementation in preterm infants seems to prevent necrotizing enterocolitis (82, 83) and 
enteral glutamine supplementation reduces the incidence of serious infections (84, 85). Thus, 
enteral feeding is obligatory for intestinal maturation, growth and development of other 
organs; so much effort should be directed towards understanding the nutritional needs of 
the intestine of preterm infants. Regarding the different metabolic fates of absorbed amino 
acid by enterocytes, it seems likely that the intestinal utilization of amino acids might 
influence the requirements for specific amino acids, for instance sulfur amino acids. Early 
studies by Mudd et al. (71) showed that CBS and cystathionine-lyase are active mainly in 
human liver tissue, and to a lesser extent, in extra hepatic tissues such as the small intestine. 
However, Stegink and den Besten (86) were the first to report in vivo evidence to implicate 
splanchnic tissues (intestine and liver) as a key site of methionine transsulfuration by 
demonstrating that plasma cysteine concentrations are significantly higher in human 
subjects fed a methionine-containing, cystine-free diet enterally versus intravenously (Figure 
4). However, subsequent metabolic studies with stable isotopic tracers also have indirectly 
suggested that a substantial fraction of the dietary methionine undergoes transmethylation 
and remethylation during first-pass splanchnic metabolism in adult humans (87, 88). More 
recent studies show that whole-body methionine requirement and circulating homocysteine 
concentrations are significantly higher in piglets fed enterally than parenterally, 
demonstrating that splanchnic methionine metabolism is nutritionally significant (89, 90). If 
this phenomenon does occur in the preterm infant it will have tremendous effects on route 
of feeding in these infants. 
Figure 4. Plasma cystine concentrations (mean ± SD) in normal male subjects given parenteral alimentation 
solution. Solid circles are data for subjects fed first by nasogastric tube and then by intravenous infusion; the 
order of feeding routes was the reverse for other subjects (open circles). With permission,  Science 1972 (86). 
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Methods to study intestinal metabolism 
The intestine is unique in its simultaneous nutrient supply; amino acids are derived from both 
the diet (luminal site) and the systemic circulation (basolateral site). To study intestinal 
metabolism, one need to know the intestinal input and output and the latter is difficult to 
measure in humans. In piglets it is possible to study metabolism of the portal drained viscera 
(intestine, spleen, pancreas and stomach) with the use of a portal vein catheter to obtain 
portal blood. However, for ethical reasons it is not possible to study portal drained viscera 
metabolism in human subjects. Instead, the amino acid uptake by the splanchnic tissues 
(stomach, small intestine and liver) in first-pass, which is the amount of substrate used by the 
splanchnic tissues before it reaches the systemic circulation, can be determined with dual 
stable isotope infusions technique. This method is highly suitable to study metabolism in 
neonates. It requires an enteral infusion of a labeled amino acid of interest together with an 
intravenous infusion of the same amino acid but with a different labeling. The simultaneous 
infusion of these two tracers allows calculation of the splanchnic first-pass uptake of the 
amino acid under study. Enteral infusion of a labeled amino acid should result in the same 
plasma isotopic enrichment as the intravenous infused labeled amino acid if nothing is 
consumed in first pass. However, if the splanchnic bed utilizes a certain amount of the 
enterally administered tracer, less tracer enters the systemic circulation and eventually results 
in lower plasma enrichment than the intravenous administered tracer. This method assumes 
complete absorption and digestion of proteins. Incomplete digestion and absorption results 
in an overestimation of first pass utilization. Complete digestion may be assumed from the 
fact that less than 1% of enteral administered tracer is found in stools of adults (91) and that 
approximately 98% of the ingested human milk proteins are digested and absorbed in 
infants (92, 93). However, this does not concern free amino acid mixtures. In general, it 
appears that amino acid absorption from peptides is more rapid than from amino acid 
mixtures (94). Metges et al. (95) investigated the metabolic fate of dietary [1-13C]leucine 
ingested together with either a mixture of free amino acids, intrinsically labeled protein or 
with unlabeled intact protein. They reported a higher leucine oxidation rate when [1-13C]-
leucine was ingested together with the L-amino acid mixture compared to the intrinsically 
labeled protein. To what extent the oxidation difference is due to a difference in absorption 
rate per se is not clear.   
 
Intestinal utilization 
Although the portal drained viscera (PDV) account for only 4-6% of the body weight, they 
utilize 10-20% of whole body energy expenditure and contribute for 20-50% to whole body 
protein turnover (96, 97). The high energy expenditure rate reflects the high metabolic 
activity of these tissues. Studies in neonatal piglets and humans showed that the PDV and 
splanchnic tissues extract large amounts of the dietary amino acids (98). As depicted in Table 
2, splanchnic utilization rates among various dietary amino acids differ, and clearly both 
indispensable and dispensable amino acids are extensively extracted in first-pass. Studies in 
piglets have shown that nearly all threonine, glutamate and aspartate were extracted in first- 
pass metabolism (99, 100, 105) and only half of the dietary lysine was utilized by the PDV (97).  
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 Comparable results have been reported in adult humans; splanchnic tissues retained 20-90% 
of the dietary intake of both indispensable and dispensable amino acids (Table 2). The first 
pass utilization of amino acids regulates the systemic availability, and thus the supply to 
other organs. In this view it is important to determine the splanchnic dietary amino acid 
extraction in preterm infants. Regrettably, only a few studies have determined the splanchnic 
uptake rates of some amino acids.  
 
Table 2. First-pass splanchnic uptake in piglets, adults and preterm infants. 
 
Intestinal energy sources 
Given the nutritionally significant proportion of the dietary amino acid intake that is 
extracted by the PDV and splanchnic tissues, it is of particular interest to determine the 
metabolic fate of these amino acids metabolized by these tissues. The possible metabolic 
fates of the sequestered amino acids in the gastrointestinal tissues in first-pass are: protein 
synthesis, intermediate metabolism, and irreversible oxidation to CO2 and ammonia. 
Obviously, the intestine is an energy demanding organ. It is of particular interest which 
sources of energy the intestine utilizes to fulfill the high energy demand. Windmueller and 
Spaeth (111, 112) investigated the metabolic fate of amino acid in the intestine  rats. They 
showed that luminal glutamate and aspartate and arterial glutamine were the major fuel 
sources for the enterocytes, and that glucose was a minor oxidative substrate. Subsequently, 
studies in neonatal pigs have revealed a similar pattern (97, 100). Glutamate appeared to be 
the major oxidative substrate and in a lesser extent glucose, lysine and leucine. In contrast, 
dietary threonine utilized in first-pass was not used for oxidative purposes but was 
predominantly used for intestinal mucosal proteins (99). Obviously, amino acids and glucose 
are the predominant fuel sources for the intestine in piglets. 
It is of particular interest which fuels the splanchnic tissues of the preterm infants utilize. 
Previously, the splanchnic oxidation rates of glucose, lysine and threonine in preterm infants 
Amino acid First pass splanchnic uptake of dietary intake (%) Reference 
  Piglet Adult  Preterm infant   
Leucine 43 21 42-48 (101, 102) 
Lysine 46 32 18 (97, 103) 
Cysteine < 20 44 - (88, 104, 105) 
Methionine this thesis 33 this thesis (88, 105, 106) 
Phenylalanine 51 29 - (101, 106) 
Threonine 80   70 (99, 107) 
Aspartate  95 - this thesis  (100, 105) 
Glutamate 92 96 this thesis (100, 105, 108) 
Glutamine - 64 53 (109, 110) 
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have been investigated (103, 113). Approximately 80% of the utilized glucose in first-pass 
was oxidized and is therefore a major source of energy for the splanchnic tissues of preterm 
infants (113). Like in piglets, lysine (103) and threonine (107) were not used as an oxidative 
substrate in the splanchnic bed. Apparently, other substrates than glucose need to be used 
for energy generation in these tissues. It is likely that the same pattern seen in piglets 
resembles that of the preterm infant. However, no data are available on substrate oxidation 
in these infants, except for lysine and glucose. It needs to be evaluated in what extent the 
dietary dispensable amino acids glutamate and aspartate are used for fuel in the intestine in 
preterm infants in order to be able to meet the metabolic needs. 
It is well recognized that enteral feeding has a major influence on short-term and long-term 
outcome in preterm infants. Nutrient requirements are higher in these infants than in term 
infants as a result of rapid growth and illness. It is therefore of great importance to provide 
adequate nutrition to meet their specific requirements to optimize growth and outcome. The 
studies in this thesis investigate cysteine requirements for preterm infants with different 
gestational ages at different postnatal ages were determined. Furthermore, we aimed to gain 
more insight into splanchnic sulfur amino acids metabolism in neonatal pigs and preterm 
infants. In view of the high intestinal energy expenditure, the role of dispensable amino 
acids, such as glutamate and aspartate, as oxidative substrates in splanchnic tissues of 
preterm infants was investigated to understand the pivotal metabolic role of these organs.  
 
 
OUTLINE AND AIMS OF THE THESIS 
 
The overall aims of the work presented in this thesis are: 
1. To determine the cysteine requirements for preterm infants during the first three months 
of life. 
2. To study sulfur amino acid metabolism in neonatal piglets and preterm infants.  
3. To quantify the role of the intestine in sulfur amino acid metabolism in both neonatal 
piglets and humans. 
4. To determine whether dispensable amino acids such as glutamate and aspartate 
contribute significantly to the high energy needs of the intestine. 
 
The main hypotheses that will be tested are:  
1. Cysteine is a indispensable amino acid for newborn preterm infants. 
2. Cysteine requirements change with postnatal age. 
3. The intestine is an important site for cysteine synthesis. 
4. Methionine is extensively utilized in first pass metabolism. 
5. The dispensable amino acids glutamate and aspartate are major energy sources for the 
splanchnic tissues in preterm infants. 
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 Chapter 2 describes a study to validate the enteral infusion of labeled sodium bicarbonate. 
This was done in order to reduce the invasiveness of the method that is used to determine 
individual carbon dioxide production. This is usually determined by intravenous infusion of 
labeled sodium bicarbonate. We wanted to infuse the tracer enterally so no catheter was 
needed for the study.  
 
Part 1.   Cysteine requirements 
The first part of this thesis describes studies to determine the cysteine requirement in (very) 
low birth weight preterm infants with different gestational ages and postnatal ages. In 
Chapter 3, the cysteine requirement is determined in infants born with gestational ages of 
32-34 weeks, at the age of one month postnatally. Chapter 4 describes the cysteine 
requirement in infants born with gestational ages of 26-29 weeks, determined at the age of 
four and eight weeks postnatally. The two studies provide information whether cysteine 
requirements are depending on gestational age and/or postnatal age.  
 
Part 2.   Sulfur amino acid metabolism 
The second part describes the sulfur amino acid metabolism in piglets and preterm infants. 
Chapter 5 describes the study investigating that the intestine, rather than the liver, is the 
major site of cysteine synthesis from methionine and serine. This study was performed in 
neonatal pigs. Chapter 6 describes a study to determine the splanchnic first-pass methionine 
uptake in fully enterally fed preterm infants and links with chapter 5. The conversion of 
methionine and serine into cysteine was also investigated in these infants. 
 
Part 3.   Splanchnic metabolism of dispensable amino acids 
This part describes the splanchnic metabolism of the dispensable amino acids glutamate and 
aspartate in preterm infants. Chapter 7 describes the splanchnic first-pass metabolism of 
dietary glutamate in preterm infants. In Chapter 8 the splanchnic first-pass metabolism of 
aspartate is presented. 
 
Part 4.   Discussion and Summary 
In the general discussion, Chapter 9, the results obtained in this thesis are discussed on the 
basis of relevant reviewed literature. Also, suggestions of future nutritional research in 
preterm infants are proposed. Finally, the results of the studies are summarized in Chapter 
10. 
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ABSTRACT 
 
The metabolic fate of substrates in humans can be examined using stable isotopes, one of 
which, [13C]bicarbonate, may serve to estimate CO2 production rate. In view of minimizing 
the burden of metabolic studies for preterm infants, the authors determined whether 
intragastric and intravenous infusions of [13C]bicarbonate would achieve the same 13CO2 
enrichment in expired air during steady state. A second aim of this study was to determine 
the minimum time required to reach steady state during intragastric infusion. 
Ten preterm infants received a primed continuous [13C]bicarbonate infusion intragastrically, 
followed by an intravenous infusion the next day. Breath samples were obtained every 30 
min by the direct sampling method. 13CO2 isotopic enrichment, expressed as atom percent 
excess, was measured by isotopic ratio mass spectrometry. Two-tailed t tests were used to 
detect statistically significant differences between the infusion routes. 
The isotopic enrichment at plateau did not differ between intragastric and intravenous 
infusion. A steady state of 13CO2 enrichment was achieved after 60 min of intravenous 
infusion and after 120 min of intragastric infusion. 
In conclusion, intragastric infusion of [13C]bicarbonate may serve to estimate whole-body 
CO2 production rate in preterm infants. To reach 13CO2 steady state, a minimum of 120 min 
of bicarbonate administration is required. 
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INTRODUCTION 
 
The past two decades have seen increased use of stable isotopes to study amino acid 
metabolism in humans. These isotopic tracer techniques have greatly enhanced our 
understanding of nutrient daily requirements and metabolism (1).  
For determining the oxidation rates of specifically labeled substrates such as amino acids or 
glucose, we need to quantify substrate oxidation in each individual by measuring the 13CO2 
production rate during intravenous (IV) infusion of labeled bicarbonate (2). The production of 
13CO2 is made up of total CO2 production rate and 13CO2 enrichment in expired breath. 
Although total CO2 production rate is traditionally assessed by indirect calorimetry, 13CO2  
enrichment is measured by isotopic ratio mass spectrometry. A certain amount of CO2, and 
thus 13CO2 as well, is retained in the body. Because this amount is related to caloric intake, a 
correction factor is necessary to calculate substrate oxidation rates (3). A method that makes 
correction factors and indirect calorimetry superfluous is the infusion of NaH13CO3 before the 
labeled substrate infusion (4). 
Kien et al. (5) published a study where they compared intragastric (IG) infusion of [13C]-
bicarbonate to indirect calorimetry by the use of a correction factor. This study showed the 
validation of the use of dilution stable tracer technique to estimate CO2 production. However, 
those authors did not compare the 13CO2 enrichment during IV infusion with IG infusion of 
[13C]bicarbonate. 
The general purpose of this study was to determine whether in preterm infants IG infusion of 
NaH13CO3 yields the same enrichment as IV infusion at steady state. To this aim, we compared 
13CO2 enrichment in expired breath during IG and IV infusion of labeled bicarbonate at 
plateau. In addition, we quantified the minimal tracer infusion time required to establish 
steady state during IG infusion.  
We hypothesized that 13CO2 enrichment at steady state would not differ between IG 
administration and IV administration of [13C]bicarbonate.   
 
 
METHODS 
 
Subjects 
We studied 10 preterm infants (8 male, 2 female) admitted to the Neonatal Intensive Care 
Unit of the Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands. Their mean 
gestational age was 27 wk (range: 26-30 wk, SD + 1.3 wk), and they were free of 
gastrointestinal diseases and were clinically stable during the 2-day study. Five of them 
needed artificial ventilation and five breathed spontaneously with O2 supplementation by 
nasal prong (n=5). Eight infants tolerated full enteral feeding and two infants received partial 
enteral and partial parenteral feeding. For all neonates, the feeding regimen was the same on 
both study days. All infants were fed through a nasogastric feeding tube, because this is a 
standard procedure in our unit. The study protocol was approved by the Erasmus MC 
Institutional  Review  Board,  and  written   and  informed  consent  was  obtained  from both   
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parents of all neonates. 
 
Tracer Protocol 
For the purpose of validating this route of labeled sodium bicarbonate the study was 
designed as a randomized, crossover study. The 10 infants received a primed                           
(10 μmol/(kg·min)) continuous (10 μmol/(kg·h)) infusion of [13C]bicarbonate (sterile pyrogen 
free, 99% atom percent excess (APE); Cambridge Isotopes, Woburn, MA). The study was set 
up as a true crossover design: in five infants the IV infusion was started for 6 hours on the first 
day, followed by the IG infusion on the second day. The other five infants received the IG 
infusion the first day and the IV infusion the second day. One hour before start of the study, 
the usual hourly feeding regimen was changed into continuous dripfeeding. Enterally 
infused tracer was mixed with the milk (either fortified or non fortified breast milk, or preterm 
infant formula; Nenatal, Nutricia Nederland B.V, Zoetermeer, the Netherlands) and infused 
continuously via the nasogastric tube.  
Breath samples were obtained by use of the direct sampling method described by van der 
Schoor et al. (6). Briefly, in mechanically ventilated neonates, a syringe was connected to the 
ventilator tubing, and breath was taken slowly during expiration with a total volume of         
15 mL. When infants were breathing spontaneously, a 6F gastric tube (6 Ch Argyle; Cherwood 
Medical, Tullamore, Ireland) was placed 1 to 1.5 cm into the nasopharynx and end-tidal 
breath was taken slowly with a syringe connected at the end. Collected air was transferred 
into 10 mL sterile, non-silicon-coated evacuated glass tubes (Van Loenen Instruments, 
Zaandam, the Netherlands) and stored at room temperature until analysis. 
Baseline samples were obtained 15 and 5 min before tracer infusion was started. During the 
experiment, duplicate 13C-enriched breath samples were collected every 30 min and every    
15 min during the last 45 min of tracer infusion.  
 
Analytical Methods 
13CO2 isotopic enrichment in expired air was measured by isotope ratio mass spectrometry 
(ABCA; Europe Scientific, Van Loenen Instruments, Leiden, the Netherlands) and expressed as  
APE above baseline. The APE was plotted relative to time. Steady state was defined as three 
or more consecutive points with a slope not different from zero. Estimated body CO2 
production (mmol/(kg×h) was calculated for each infant with the following equation (7): 
 
Estimated body CO2 production = [ IE infusate/ IE breath bicarbonate -1 ] x tracer infusion rate x 1000 
                
where IE infusate is the 13C enrichment of the tracer (APE), IE breath bicarbonate is the 13C 
enrichment in the expired air (APE), and tracer infusion rate is the rate of [13C]bicarbonate 
infusion (mmol/(kg·h)). 
 
Statistical analysis 
Descriptive data are expressed as mean ± SD. To define the slope of the curve of the two 
different methods a repeated measurements linear model was used. Steady state was 
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achieved when the linear factor of the slope was found to be not significantly different from 
zero (p  > 0.05) (8). Whole-body CO2 production and baseline enrichments between the two 
methods were analyzed by paired t tests.  
Differences in steady state between IG and IV administration were also analyzed by paired      
t tests. Statistical significance was defined as p  < 0.05. Pitman’s test (9) was used to test the 
null hypothesis if the variance of two-paired measurements (IG and IV infusion) were the 
same. To detect significant differences between the two-paired measurements, a paired t test 
could be performed. Pearson’s correlation coefficient was performed to show correlation 
between IG and IV. The analysis of Bland and Altman (10) was performed to show accuracy 
between the two different infusions. All statistical analyses were performed by the use SPSS 
(version 11.0; SPSS Inc, Chicago, IL).  
 
 
RESULTS 
 
The clinical characteristics of the subjects are given in Table 1. The mean study weight of the 
infants was 1.18 + 0.32 kg. The postnatal age at the start of the study was 28 ± 20 d. Their 
energy intakes did not differ between both study days (p = 0.75). The mean 13C enrichments, 
expressed as atom percent (AP), in breath CO2 from time point t=60 to t=360 min are shown 
in Figure 1. All neonates achieved isotopic steady state in both administration routes. 
Baseline enrichments did not differ between IG and IV infusion (1.0875 AP + 0.0022 versus 
1.0869 AP + 0.0338, p = 0.29). 
The mean APE at plateau (t120-360) during IG infusion was 0.0365 + 0.0055; during IV infusion it 
was 0.0371 + 0.0067. IG enrichment was slightly lower, though not significantly, than IV 
enrichment (p = 0.59).  
Figure 1. Breath 13CO2 enrichments of 10 infants, expressed as mean AP + SD. IV (·) versus IG (º) infusion of [13C]-
bicarbonate. At plateau (t120-t360) 13C enrichment IV is not significantly different from  IG (p = 0.59). 
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The pitman’s tests (9) showed no significant difference between variance in IV and IG infusion 
(p = 0.308), and Pearson’s correlation coefficient was 0.359. Agreement between the two 
different routes of administration was determined by the analysis of Bland and Altman (10). 
Figure 2 shows on the x axis the average of IV plateau and IG plateau (n=10), whereas the       
y axis shows the difference between the two measurements (n=10). The mean difference is 
0.0006 APE. Note that all measurements lie between the range of the mean difference + 2SD 
(0.0076 APE) and the mean difference – 2SD (-0.0064 APE). The 95% CI of the mean difference 
is –0.0019 to 0.0031 APE. Therefore, from 120 min onward, there was no statistically 
significant difference in CO2 enrichment in expired air between IV or IG infusion, nor did we 
find a sequence effect (no significant difference in 13CO2 between infants who received 
NaH13CO3 IV the first day or those who received NaH13CO3 IG the first day). 
The estimated CO2 production did not differ between the IG (27.68 + 5.38 mmol/(kg·h)) and 
IV (27.67 + 5.64 mmol/(kg·h)) infusions (p = 0.99).  
Steady state was achieved from 60 min onward when the tracer was infused IV and from    
120 min onward when infused IG. 
Figure 2. Analysis of Bland and Altman showing the dfference between IG and IV enrichments of 13CO2 in 
breath of 10 infants. The mean difference is 0.0006 APE (dotted line). All measurements are within two 
standard deviations: + 2 SD (0.0076 APE) and – 2 SD (-0.0064 APE). The 95% CI of the mean difference is -0.0019 
to 0.0031 APE. 
 
 
DISCUSSION 
 
The main purpose of this study was to validate the use of IG administration of [13C]-
bicarbonate compared with IV administration for metabolic oxidation studies in preterm 
infants. Clinical studies in addition to experimental research are of great value in elucidating 
metabolism and nutrition in preterm infants. Information about amino acid metabolism and 
protein synthesis and oxidation is needed to provide these infants with optimal nutrition and 
consequently improved growth and survival.  
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A principal goal of many tracer kinetic experiments is to determine the oxidation rate of the 
tracer substance by the appearance in breath of labeled C originating from the tracer (11). 
The gold standard for determining whole-body CO2 production is by indirect calorimetry (3). 
An alternative method is a primed continuous IV infusion of NaH13CO3. We found the 
estimated body CO2 production (27.67 ± 5.64 mmol/(kg·h)) to be similar to that previously 
described (0.725 + 0.021 mol/(kg·d)) (12). Also, others have shown that NaH13CO3 can be 
adequately used as a method of determining CO2 production rate (4, 5, 13). The infusion of 
labeled bicarbonate before a 13C-labeled substrate carries the advantage that no correction 
factor is needed to calculate substrate oxidation. In addition, IG infusion of the tracer reduces 
the invasiveness of metabolic studies. Finally, in studying the metabolic fate of an enteral 
substrate it is preferable to administer the tracer enterally as well. 
Hoerr et al. (11) studied in adults the effects of IG and IV infusion of labeled bicarbonate on 
recovery of 13C in breath and concluded that administration route did not affect recovery. 
When it is considered that placing an intravenous catheter in preterm infants is highly 
invasive, it is very important to search for methods minimizing discomfort.  
To achieve steady state during IG administration, tracer infusion should last at least 120 min. 
Sample collection is accomplished during steady state. Consequently, breath samples should 
be obtained from 120 min onward. To prevent intrasubject variation, at least four breath 
samples should be obtained at 10-min intervals, thus between 120 and 160 min of infusion.  
We need to emphasize the small sample size of this study. However, we presented a 95% CI  
(-0.0019 to 0.0031 APE) of the mean difference to obtain an impression of a type II error. We 
considered a difference of < 10% between IG plateau and IV plateau acceptable. We 
calculated the difference of the minimal (-5%) and maximal (8%) of the 95% CI limit of the 
average plateau of IG and IV (0.0368 APE). As we assumed, the plateau of IV and IG infusion 
can vary from –5% to 8% in the general population. 
Additionally, we wish to stress that in metabolic studies in parenterally fed infants, [13C]-
bicarbonate should preferably be administrated IV. 
In conclusion, our findings are consistent with the absence of significant differences in 13CO2 
enrichment between IG and IV infusion after 120 min of infusion, and therefore it would be 
valid to infuse [13C]bicarbonate IG for the determination of whole-body CO2 production rate 
in preterm infants. 
 
Acknowledgments  
The authors would like to thank Chris van den Akker, Frans te Braake and Ineke van Vliet for 
their support; Paul Mulder for statistical help; and Ko Hagoort for critical review of the 
manuscript. 
 
 
 
 
 
35 
Intravenous vs enteral [13C]bicarbonate infusion in preterm infants 
C
ha
p
te
r 2
 
REFERENCES 
 
1. Kleinman RE, Barness LA, Finberg L. History of pediatric nutrition and fluid therapy. Pediatr Res 
2003;54:762-72. 
2. Kingdon CC, Mitchell F, Bodamer OA, Williams AF. Measurement of carbon dioxide production in very 
low birth weight babies. Arch Dis Child Fetal Neonatal Ed 2000;83:F50-5. 
3. Van Aerde JE, Sauer PJ, Pencharz PB, et al. The effect of energy intake and expenditure on the recovery of 
13CO2 in the parenterally fed neonate during a 4-hour primed constant infusion of NAH13CO3. Pediatr 
Res 1985;19:806-10. 
4. van Goudoever JB, Sulkers EJ, Chapman TE, et al. Glucose kinetics and glucoregulatory hormone levels in 
ventilated preterm infants on the first day of life. Pediatr Res 1993;33:583-9. 
5. Kien CL, McClead RE. Estimation of CO2 production in enterally fed preterm infants using an isotope 
dilution stable tracer technique. JPEN J Parenter Enteral Nutr 1996;20:389-93. 
6. van der Schoor SR, de Koning BA, Wattimena DL, Tibboel D, van Goudoever JB. Validation of the direct 
nasopharyngeal sampling method for collection of expired air in preterm neonates. Pediatr Res 
2004;55:50-4. 
7. van Goudoever JB, Stoll B, Henry JF, Burrin DG, Reeds PJ. Adaptive regulation of intestinal lysine 
metabolism. Proc Natl Acad Sci U S A 2000;97:11620-5. 
8. Hoerr RA, Matthews DE, Bier DM, Young VR. Leucine kinetics from [2H3]- and [13C]leucine infused 
simultaneously by gut and vein. Am J Physiol 1991;260:E111-7. 
9. Pitman E. A note on the normal correlation. Biometrika 1939;31:9-12. 
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical 
measurement. Lancet 1986;1:307-10. 
11. Hoerr RA, Yu YM, Wagner DA, Burke JF, Young VR. Recovery of 13C in breath from NaH13CO3 infused by 
gut and vein: effect of feeding. Am J Physiol 1989;257:E426-38. 
12. Shew SB, Beckett PR, Keshen TH, Jahoor F, Jaksic T. Validation of a [13C]bicarbonate tracer technique to 
measure neonatal energy expenditure. Pediatr Res 2000;47:787-91. 
13. Spear ML, Darmaun D, Sager BK, Parsons WR, Haymond MW. Use of [13C]bicarbonate infusion for 
measurement of CO2 production. Am J Physiol 1995;268:E1123-7. 
 
 
 

Cysteine  requirements 

Chapter 3 
 
 
Cysteine: a conditionally essential amino acid  
in low birth weight preterm infants? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maaike A. Riedijk, Ron H.T. van Beek, Gardi Voortman, Henrica M.A. de Bie, 
Anne C.M. Dassel, Johannes B. van Goudoever 
 
Am J Clin Nutr 2007; 86:1120–5. 
40 
Chapter 3 
C
ha
p
te
r 3
 
ABSTRACT 
 
Cyst(e)ine can be synthesized de novo from methionine and serine and is, therefore, a 
nonessential amino acid in human adults. Several studies have suggested that cyst(e)ine 
might be a conditionally essential amino acid in preterm infants because of biochemical 
immaturity. No data are available on cyst(e)ine requirements in low-birth-weight (LBW) 
preterm infants. 
The aim was to determine cyst(e)ine requirements in LBW infants with gestational ages 
from 32 to 34 wk, measured 1 month after birth with the use of indicator amino acid 
oxidation technique. 
LBW infants were randomly assigned to 1 or 2 of the 5 formulas containing graded cystine 
concentrations (11, 22, 32, 43, 65 mg cyst(e)ine/100 mL) and generous amounts of 
methionine. After 24-h adaptation, cyst(e)ine requirement was determined by 13CO2 release 
from [1-13C]phenylalanine in expired breath. 13CO2 enrichment was measured by isotopic 
ratio mass spectrometry. 
Cyst(e)ine requirement was determined in 25 LBW infants with a mean (± SD) gestational 
age of 33 ± 1 wk and birth weight of 1.78 ± 0.32 kg. Fractional oxidation of [1-13C]-
phenylalanine did not differ between the 5 groups. 
There is no evidence for limited endogenous cyst(e)ine synthesis in 4-wk-old LBW preterm 
infants born at gestational ages from 32 to 34 wk. It is safe to conclude that the cyst(e)ine 
requirement is < 18 mg/(kg·d) providing generous amounts of methionine and that          
cyst(e)ine is probably not a conditionally essential amino acid in fully enterally fed LBW 
preterm infants born at 32-34 wk. 
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INTRODUCTION 
 
Note: ‘Cyst(e)ine’ is used throughout to designate any undefined combination of cysteine 
and cystine; the term ‘cysteine’ and ‘cystine’ are used to designate the specific amino acids. 
Cyst(e)ine is a sulfur-containing amino acid that is not essential in humans. The human body 
synthesizes cyst(e)ine de novo from methionine, the only essential sulfur-containing amino 
acid, and serine. Cyst(e)ine has several important metabolic functions. First, like all other 
amino acids it is involved in growth and protein synthesis. Furthermore, it is a precursor for 
the tripeptide glutathione, an important intracellular antioxidant. Then, it is also a precursor 
for the production of taurine, another anti-oxidant, and sulfate. 
Some nonessential amino acids are classified as conditionally essential. These amino acids 
may become temporarily essential when synthesis during rapid growth or critical illness is 
insufficient. Cyst(e)ine is believed to be conditionally essential in preterm infants because of 
biochemical immaturity of the enzyme cystathionase (EC 4.4.1.1) that is involved in cyst(e)ine 
synthesis (1-3). It is, therefore, important to know the exact cyst(e)ine requirement of preterm 
infants and also in view of the higher amino acid requirement as a result of rapid growth and 
development.  
Different methods are used to estimate individual amino acid requirements, e.g. the nitrogen 
balance method, growth rate, plasma amino acid patterns, and the factorial approach. The 
first reports on amino acid requirements in neonates were based on nitrogen balance and 
weight gain rate (4, 5). Nitrogen balance has several limitations (6), for instance it requires      
7-10 d to adapt to the test diet (7). Because present-day practice will not allow neonates to be 
maintained on either deficient or excess intakes of amino acids for a minimum of 7 d, no 
recent requirement studies have used this method in preterm infants.  
At present, the factorial approach is used to define amino acid requirements in infants (8). 
This model is based on fetal protein accretion during normal intrauterine development. 
Accretion data are derived from body carcass analysis of stillborn preterm infants, some born 
> 100 years ago (9, 10). Not all data are suitable as reference material; gestational age and 
cause of death were not accurately obtained (11), and in view of this study, cysteine content 
of the body was not determined. The current recommendation for cyst(e)ine requirement for 
preterm infants, ie, 66-95 mg/(kg·d), is based on the minimum and maximum amounts of 
each amino acid present in the amounts of human milk protein corresponding to the 
recommended minimum and maximum protein contents of 3.0 g/120 kcal and                       
4.3 g/120 kcal, respectively (8). 
Because methionine is the precursor of cyst(e)ine, the methionine intake needs to be taken 
into account as well. The current estimated methionine requirement for preterm infants is 48
-69 mg/(kg·d) (8). To ensure an adequate methionine intake, the study formula supplied an 
amount of 70 mg methionine/(kg·d). Shoveller et al. (12) determined the total sulfur amino 
acid requirement in enterally fed neonatal piglets when no dietary cysteine was provided. 
The extrapolation from this piglet study results in a methionine intake of 84 mg/(kg·d) for the 
human neonate, which is slightly above the current recommendations (8).  
The objective of the present study was to use indicator amino acid oxidation (IAAO) with       
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[1-13C]phenylalanine to estimate cyst(e)ine requirements in fully enterally fed low-birth-
weight (LBW) infants supplied with an adequate methionine intake. We hypothesized that 
cyst(e)ine is a conditionally essential amino acid for these infants. 
 
 
SUBJECTS AND METHODS 
 
Subjects 
Subjects eligible for the study were LBW infants with gestational age (GA) between 32 and 34 
wk, admitted to the neonatal department of the Amphia Hospital, Breda; Vlietland Hospital, 
Vlaardingen; or Deventer Hospital, Deventer (all: the Netherlands). The infants needed to be 
clinically stable during the study, and those with any congenital or gastrointestinal disease 
were excluded. All tolerated full enteral feeding and were partly fed through a nasogastric 
feeding tube and partly bottle-fed. The study protocol was approved by The Central 
Committee on Research Involving Human Subjects (CCMO) and the Erasmus MC Institutional 
Review Board. Written and informed consent was obtained from both parents of each 
subject. 
 
Study formula 
We used 5 study formulas containing graded cyst(e)ine concentrations: 11, 22, 32, 43 and 65 
mg cystine/100 mL (Xcys/Neocate, Nutricia Nederland BV, Zoetermeer, the Netherlands/SHS 
International, Liverpool, United Kingdom). Infants were enrolled in the study when they 
tolerated full enteral feeding (>150 mL/(kg·d)). Except for cyst(e)ine concentration, the 5 
formulas did not differ as to amino acid composition (Table 1), and consequently the 
nitrogen content increased slightly from 0.37 mg nitrogen/100 mL (formula 1) to 0.38 mg 
nitrogen/100 mL (formula 5). The graded cyst(e)ine concentrations of the study formula were 
based on the current estimated cyst(e)ine requirement for preterm infants (8), which is 66-95 
mg/(kg·d), and is based on the minimum and maximum amounts of each amino acid present 
in the amounts of human milk protein corresponding to the recommended minimum and 
maximum protein contents of 3.0 g/120 kcal and 4.3 g/120 kcal, respectively. We decided to 
test 3 cyst(e)ine intakes above and 2 cyst(e)ine intakes below the estimated cyst(e)ine 
requirements for formula-fed preterm infants. Methionine content was similar in all formulas 
and was supplied generously. 
 
Study design and tracer protocol 
Cyst(e)ine requirement was measured approximately 1 month after birth (range: 35-37 wk 
postmenstrual age). Infants were randomly assigned to at least one of the study formulas. 
The study diet was initiated 24 h before start of the oxidation study, and the dietary intake 
was not changed until the tracer protocol was finished. All subjects received approximately 
170 mL formula/(kg·d) to ensure that all essential amino acids other than cyst(e)ine were in 
excess (Table 1) and, therefore, were not limiting for protein synthesis. Before the 
introduction of the study formula, almost all infants received their mothers’ (expressed) 
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Amino acid 
(mg/170 mL) 
Formula 1 
 
Formula 2 
 
Formula 3 
 
Formula 4 
 
Formula 5 
 
L-alanine 166 166 166 166 166 
L-arginine 292 292 292 292 292 
L-aspartic acid 274 274 274 274 274 
L-cystine 18 36 54 72 109 
L-Glycine 259 259 259 259 259 
L-Histidine 168 168 168 168 168 
L-Isoleucine 266 266 266 266 266 
L-Leucine 435 435 435 435 435 
L-Lysine 300 300 300 300 300 
L-Methionine 70 70 70 70 70 
L-Proline 313 313 313 313 313 
L-Phenylalanine 197 197 197 197 197 
L-Serine 194 194 194 194 194 
L-Threonine 215 215 215 215 215 
L-Tryptophan 88 88 88 88 88 
L-Tyrosine 197 197 197 197 197 
L-Valine 282 282 282 282 282 
L-Asparagine 0 0 0 0 0 
L-Citrulline 0 0 0 0 0 
L-Carnitine 3 3 3 3 3 
L-Taurine 8 8 8 8 8 
L-Glutamine/ 
glutamate 
371 371 371 371 371 
Total (g/170 mL) 4.12 4.13 4.14 4.17 4.21 
Table 1. Amino acid profiles of the study formulas. 
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breast milk and only a few infants received standard preterm formula (Nenatal; Nutricia, 
Zoetermeer, the Netherlands). The cyst(e)ine concentration of human milk varies widely, but 
the preterm formula provided 35 mg cyst(e)ine/100 mL. 
The IAAO technique uses as indicator a labeled essential amino acid that is different from the 
test amino acid. The indicator is independent of the different intake amounts of the test 
amino acid. If the test amino acid is deficient in the diet, this will limit overall protein 
synthesis and all other essential amino acids will be oxidized. Increasing the dietary intake of 
the test amino acid will linearly decrease oxidation of the indicator until requirement of the 
test amino acid is met. We chose [1-13C]phenylalanine as the indicator (13). 
After 24-h adaptation, subjects received a primed (10 μmol/kg) continuous (10 μmol/(kg·h)) 
enteral infusion of [13C]bicarbonate (sterile pyrogen free, 99% atom percent excess (APE); 
Cambridge Isotopes, Woburn, MA) for 2.5 h to quantify individual carbon dioxide production. 
We infused the tracer enterally to minimize invasiveness, which has been validated by our 
group (14). The labeled sodium bicarbonate infusion was directly followed by a primed       
(30 μmol/kg) continuous (30 μmol/(kg·h)) enteral infusion of [1-13C]phenylalanine (93% APE; 
Cambridge Isotopes) for 5 h. One hour before start of the oxidation study the feeding 
regimen was changed into continuous drip-feeding. Enterally infused tracer was mixed with 
the study formula and infused continuously by an infusion pump through the nasogastric 
tube. All infants were breathing spontaneously and 14 infants needed supplemental oxygen 
by a nasal prong.  
Breath samples were obtained with the use of the direct sampling method described by van 
der Schoor et al. (15). In brief, a 6F gastric tube (6 Ch Argyle; Cherwood Medical, Tullamore, 
Ireland) was inserted 1 to 1.5 cm into the nasopharynx, and end-tidal breath was taken slowly 
with a syringe connected at the end. Collected air was transferred into 10-mL sterile, non-
silicon-coated evacuated glass tubes (Van Loenen Instruments, Zaandam, the Netherlands) 
and stored at room temperature until analysis. Baseline samples were obtained 15 and 5 min 
before starting tracer infusion. Duplicate 13C-enriched breath samples were collected every 
30 min and every 15 min during the last 45 min of the tracer infusion. 
 
Analytical methods and calculations 
13CO2 isotopic enrichment in expired air was measured by isotope ratio mass spectrometry 
(ABCA; Europe Scientific, Van Loenen Instruments, Leiden, the Netherlands) and expressed as 
APE above baseline (15). APE was plotted relative to time.  
It is necessary to determine the individual carbon dioxide production to determine the rate 
of substrate oxidation. In general, the rate of oxidation is calculated by multiplying the 
isotopic enrichment of carbon dioxide in breath by the total rate of carbon dioxide excreted, 
the latter needs to be determined by indirect calorimetry to estimate the rate of carbon 
dioxide production. Alternatively, body carbon dioxide production can be determined by 
quantifying the excretion of 13CO2 in expired air during [13C]sodium bicarbonate infusion, 
which avoids the quantification of total expired air (15). 
Estimated body carbon dioxide production (in mmol/(kg·h) was calculated as described 
previously (14). The rate of fractional [1-13C]phenylalanine oxidation was calculated as 
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follows: 
 
Fractional phenylalanine oxidation (%) = [IEPHE x iB ]/[ iPHE x IEB] x 100 (1) 
 
where IEPHE is the 13C isotopic enrichment in expired air during [1-13C]phenylalanine infusion 
(in APE), iB is the infusion rate of [13C]bicarbonate (in μmol/(kg·h)), iPHE is the infusion rate of   
[1-13C]phenylalanine (in μmol/(kg·h)) and IEB is the 13C isotopic enrichment in expired air 
during [13C]bicarbonate infusion (16). 
 
Statistical analysis 
Descriptive data are expressed as mean ± SD. Steady state of 13CO2 in expired breath during 
the [1-13C]phenylalanine was achieved when the linear factor of the slope was found not to 
be significantly different from zero (p > 0.05). Cyst(e)ine requirement was determined with 
the IAAO method. The indicator oxidation rate is plotted against the varying dietary intakes 
of cyst(e)ine. The inflection or breakpoint in the indicator oxidation rate represents the 
physiological requirement of cyst(e)ine (17). Data were analyzed with the use of mixed model 
analysis of variance in SPSS software (version 14.0; SPSS Inc, Chicago, IL), while encoding the 
patients who participated twice with the same number. Repeated measures analysis of 
variance was performed on primary and derived variables to assess the effects of dietary 
intake and of subjects. Regression analysis was performed to analyze oxidation rates. Power 
calculation revealed that, assuming 5 formula groups with a group variance of 16, an 
intergroup variance of 5.5 and a power of 80%, a breakpoint should be detected with               
6 subjects per group. Statistical significance was assumed at 5% level of significance (p ≤ 
0.05). 
 
 
RESULTS 
 
We included 25 LBW infants (12 boys, 13 girls) born at mean (± SD) GA of 33 ± 1 wk           
(range: 32-34 wk). They were studied at mean postmenstrual age 36 ± 1 wk (range: 35-38 wk), 
ie, approximately at postnatal age 1 month. Subject characteristics are depicted in Table 2. 
Five infants participated twice and received 2 different study formulas. Aiming at 6 
measurements per formula, we performed a total of 30 labeled phenylalanine oxidation rate 
measurements in these 25 infants. 
GA, study age, birth weight, and study weight did not differ between the 5 formula groups as 
shown in Table 2. In addition, the total enteral intake did not differ between the 5 formulas  
(p = 0.07). Although the nitrogen content of study formula 5 was somewhat higher, the 
nitrogen intake did not differ significantly between the formula groups (p = 0.25). 
To detect any differences between the 5 groups receiving the different formulas we 
corrected for sex, study age, and study weight. The baseline 13C enrichment in expired breath 
did not differ between the 5 formula groups (-17.24 ± 0.56, -16.77 ± 0.62, -17.95 ± 1.38,             
-17.87 ± 1.01 and –17.58 ± 1.55 Pee Dee Belemnite respectively; p = 0.67) after correction      
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for birth weight and study weight (Table 3). Each subject reached a plateau during both                     
[13C]bicarbonate and [1-13C]phenylalanine tracer infusions. As an illustration, the 13C 
enrichments in expired breath during the infusion of [1-13C]phenylalanine of 6 subjects 
receiving 54 mg cyst(e)ine/(kg·d)) are shown in Figure 1.  
 
Table 3. Whole-body carbon dioxide production and fractional [13C]phenylalanine (phe) oxidation rates of 5 
different cyst(e)ine intakes. 
Data expressed as mean ± SD. 13CO2, enrichment of 13C in expired air; PDB, Pee Dee Belemnite; bicarb, sodium 
bicarbonate; APE, atom percent excess; phe, phenylalanine. No significant differences were detected in 
baseline (p=0.67), CO2 production (p=0.61) and fractional oxidation of labeled phenylalanine (p=0.73) between 
the five formula groups. 
 
The mean fractional [1-13C]phenylalanine oxidation did not differ between the groups            
(p = 0.73). Regression of the data did not show a linear decrease in indicator oxidation rate 
and, consequently a breakpoint is missing (Figure 2). A trend in the formula could not be 
detected (p = 0.90). This implies that the cyst(e)ine requirement under these circumstances is 
already met at an intake of 18 mg cystine/(kg·d). At the intakes of 18-109 mg/(kg·d), cyst(e)ine 
is not the limiting amino acid for protein synthesis and is therefore not deficient in the diet.   
Figure 1. Mean 13C enrichments in expired breath during enteral [1-13C]-phenylalanine infusion in six infants 
receiving 54 mg cyst(e)ine/(kg·d). Data are expressed as mean ± SD. APE, atom percent excess. 
Cyst(e)ine 
intake 
 
mg/(kg·d) 
Baseline 13CO2 
 
 
PDB 
13CO2 [13C]bicarb 
 
 
APE 
CO2 production 
 
 
mmol/(kg·d) 
13CO2 [1-13C]phe 
 
 
APE 
Fractional 
oxidation of 
 [1-13C]phe 
% 
18 (n=6) -17.24 ± 0.56 0.0331 ± 0.0046 30.78 ± 5.31 0.0209 ± 0.0080 20.32 ± 5.26 
36 (n=6) -16.77 ± 0.62 0.0353 ± 0.0030 28.19 ± 2.61 0.0200 ± 0.0058 18.73 ± 5.03 
54 (n=6) -17.95 ± 1.38 0.0339 ± 0.0035 29.83 ± 3.08 0.0206 ± 0.0043 20.33 ± 4.15 
72 (n=6) -17.87 ± 1.01 0.0329 ± 0.0023 30.20 ± 1.97 0.0210 ± 0.0049 21.48 ± 5.70 
109 (n=6) -17.58 ± 1.55 0.0344 ± 0.0028 29.24 ± 2.22 0.0197 ± 0.0054 19.07 ± 4.93 
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Figure 2. Fractional [1-13C]phenylalanine oxidation plotted against increasing cyst(e)ine intake. Data                
are expressed as mean ± SD. No differences could be detected between the fractional oxidation of                          
[1-13C]phenylalanine of the 5 different cyst(e)ine intakes (n = 6 per intake; p = 0.73). 
 
 
DISCUSSION 
 
To our knowledge this the first study to determine the exact cyst(e)ine requirement in LBW 
infants. With the use of the IAAO method, we found it to be < 18 mg/(kg·d) 1 month after 
birth, which suggests that cyst(e)ine is not a conditionally essential amino acid in these 
infants at this age who are receiving generous amounts of methionine. The IAAO method is 
based on the assumption that the partition of any essential amino acid between oxidation 
and protein synthesis is sensitive to the amount of the most limiting amino acid in the diet 
(17, 18). Thus, a limitation of this method is the necessity of providing all amino acid in 
excess, except for the one under study. Accordingly, insufficient amounts of essential amino 
acids could have resulted in another essential amino acid than cystine being limiting for 
protein synthesis. However, we do not believe this is the case in this study, seeing that the 
fractional [1-13C]phenylalanine oxidation did not differ between the 5 test diets and that 
essential amino acids were supplied in excess of the estimate dietary requirements for 
preterm infant formula (19). Although the dietary intake of formula 1 (170 mL/(kg·d)) was 
higher than formula 4 (163 mL/(kg·d), it did not significantly differ. We do not believe that 
this had a major influence on the obtained results. The higher intake of formula 1 could have 
resulted in a lower phenylalanine oxidation rate because of a slightly higher cyst(e)ine intake 
compared with formula 2. However, we did not find a difference in the phenylalanine 
oxidation.   
The current guidelines on requirements of individual amino acids for infants are based on the 
factorial method. To calculate the deposit of each amino acid, growth rate is assumed to be 
constant at 15 g/(kg·d) for a fetus from 900 to 2400 g and protein retention at 70% of total 
protein intake. Furthermore, the protein maintenance requirement in preterm infants ranges 
from 0.55 to 0.75 g/(kg·d) (20). Fetal amino acid accretion during normal intrauterine growth 
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was determined by Widdowson (21). Cyst(e)ine accretion by the human fetus was not 
determined, however, and thus the requirement could not be estimated by the factorial 
approach. 
Little is known, too, about the biosynthetic capacity of non-essential amino acids in preterm 
infants. In the early 1970s several investigators reported that the transsulfuration pathway 
might be immature in preterm infants because of limited enzyme activity of cystathionase    
(1-3). Some found cystathionase activity to be absent in fetal liver tissues (2, 3). Zlotkin and 
Andersson (1) showed that cystathionine activity was limited but not isolated to the liver and 
was also present in extrahepatic tissues (kidneys and adrenals). They also found in term and 
preterm infants that this activity increased after birth. Furthermore, Stegink and Den Besten 
(22) showed that plasma cysteine concentrations in adult humans fed a cystine deficient diet 
intragastrically were significantly higher than in those fed the same diet intravenously. This 
finding suggests an important role in cyst(e)ine production for the gut and was confirmed in 
animal experiments. Neonatal piglets fed a cysteine-free diet enterally showed significantly 
higher plasma cysteine concentrations than did parenterally fed piglets (23). In addition, 
dietary methionine and plasma cysteine concentrations were positively correlated in 
enterally fed piglets but not in parenterally fed piglets.  
Earlier studies that investigated whether cyst(e)ine is an essential amino acid in preterm 
infants were all performed during parenteral nutrition. Several of those studies reported low 
plasma cysteine concentrations, with or without cysteine supplementation (24-26). Pohlandt 
(26) observed no differences in plasma cystine concentrations between preterm infants 
receiving only glucose intravenously and preterm infants fed a mixture of synthetic amino 
acids free from cystine. In both groups cystine plasma concentrations were low, < 5 μmol/L, 
indicating limited endogenous synthesis from methionine. Furthermore, Viňa et al. (25) and 
Miller et al. (27) reported impaired cysteine metabolism in premature infants on total 
parenteral nutrition. All those studies indicate that limited cystathionase activity makes     
cyst(e)ine a conditionally essential amino acid in preterm infants. Zlotkin et al. (28), 
nevertheless, reported that cysteine supplementation did not affect growth rate and 
nitrogen balance in parenterally fed term and preterm infants. It did slightly increase urinary 
3-methylhistidine excretion, however, suggesting that either muscle protein catabolism or 
muscle mass had increased. Also Malloy et al. (29) did not find an improved nitrogen balance 
with cysteine supplementation, although plasma-free cyst(e)ine concentration increased. 
Contradictorily, findings from a recent study suggest that the transsulfuration pathway 
produces sufficient amounts of cysteine in the parenterally fed preterm infant (30). 
Our study was performed when neonates received full enteral feeding supplied with a 
generous amount of methionine and shows that the cyst(e)ine synthesis pathway is active 
and sufficient at this time. We studied the indicator oxidation during 5 h when infants were 
continuously fed. The standard feeding regimen of these infants in our neonatal intensive 
care unit dictates feeding every hour or every 2 h, depending on clinical considerations. Thus, 
we studied neonates under physiologic circumstances. In our view, therefore, the absence of 
a postabsorptive state in these preterm infants does not necessitate the study of oxidation 
during 24 h.  
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In conclusion, our findings reject our hypothesis that cyst(e)ine is a conditionally essential 
amino acid in 1-mo-old fully enterally fed LBW preterm infants with a mean GA of 33 wk. 
These findings show indirectly that activity of the enzyme cystathionase is sufficient to 
synthesize adequate amounts of cyst(e)ine in these infants supplied with a generous amount 
of dietary methionine.  
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ABSTRACT 
 
Optimal nutrition is of utmost importance for the preterm infant’s later health and 
developmental outcome. Amino acid requirements for preterm infants differ from those for 
term and older infants, because growth rates differ. Some nonessential amino acids, 
however, cannot be sufficiently synthesized endogenously. Cyst(e)ine is supposed to be 
such a conditionally essential amino acid in preterm infants. 
The objective of this study was to determine, at 32 and 35 weeks’ postmenstrual age,        
cyst(e)ine requirements in fully enterally fed very-low-birth-weight preterm infants with 
gestational ages of < 29 wk. 
Infants were randomly assigned to 1 of the 5 graded cystine test diets that contained 
generous amounts of methionine. Cyst(e)ine requirement was determined with the 
indicator amino acid oxidation technique ([1-13C]phenylalanine) after 24-h adaptation.  
Fractional [1-13C]phenylalanine oxidation was established in 47 very-low-birth-weight 
preterm infants (mean gestational age: 28 ± 1wk SD; birth weight: 1.07 ± 0.21 kg SD). 
Increase in dietary cyst(e)ine intake did not result in a decrease in fractional [1-13C]-
phenylalanine oxidation. 
These data do not support the hypothesis that endogenous cyst(e)ine synthesis is limited in 
very-low-birth-weight preterm infants with gestational ages of < 29 wk, both at 32 and 35 
wk postmenstrual age. It is safe to conclude that cyst(e)ine requirement is < 18 mg/(kg·d) in 
enterally fed very-low-birth-weight preterm infants who are older than 32 wk 
postmenstrual age and whose methionine intake is adequate. Therefore, cyst(e)ine is 
probably not a conditionally essential amino acid in these infants. 
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INTRODUCTION 
 
Note: Cyst(e)ine is used throughout to designate any undefined combination of cysteine and 
cystine. 
Early nutrition is pivotal for preterm infants’ survival but also has profound influence on their 
later developmental and intelligence outcomes (1, 2). The quantity of administered essential 
amino acids is also of relevance; however, some nonessential amino acids are considered 
conditionally essential during specific circumstances (eg, rapid growth or critical illness) (3). 
Endogenous synthesis then will temporarily not be sufficient to meet the requirement.      
Cyst(e)ine is believed to be such a conditionally essential amino acid in preterm infants, 
because preterm infants show biochemical immaturity of cystathionase (EC 4.4.1.1), the 
enzyme catalyzing the final step in cyst(e)ine synthesis pathway (ie, transsulfuration 
pathway) (4-6). Cyst(e)ine is a sulfur-containing amino acid that is nonessential in humans. It 
is synthesized de novo from methionine, which is the only essential sulfur-containing amino 
acid, and from serine. Cyst(e)ine has several important metabolic functions. First, like all other 
amino acids, it is involved in growth and protein synthesis. Furthermore, it is one of the 
amino acid components of the tripeptide glutathione, an important intracellular antioxidant. 
It is also a precursor for taurine and sulfate. 
It is, therefore, important to know the exact cyst(e)ine requirements of preterm infants at 
various postnatal ages, considering that cystathionase maturation occurs postnatally. 
Previous estimates of amino acid requirements were based on less accurate methods than 
are currently available. We performed a study aiming at estimating cyst(e)ine requirements in 
very-low-birth-weight (VLBW) preterm infants at 4 and 8 weeks postnatally, using the 
indicator amino acid oxidation (IAAO) method. This method was used to reestimate 
individual essential amino acid requirements in adults (7-9) and was introduced by Zello et al. 
(10). We hypothesized that cyst(e)ine is an essential amino acid for VLBW preterm infants 
early in life; however, it depends on postmenstrual age (PMA), and it becomes a nonessential 
amino acid after maturation of the transsulfuration pathway. 
 
 
METHODS 
 
Subjects 
Patient who were eligible for the study were VLBW infants who were born at gestational age 
(GA) of < 29 wk and admitted to the neonatal intensive care unit of the Erasmus MC-Sophia 
Children’s Hospital (Rotterdam, the Netherlands) in the first days of life. At the time of the 
study, a number of patients had already been transferred to affiliated hospitals in the region: 
Amphia Hospital (Breda), Albert Schweitzer Hospital (Dordrecht) or the Medical Center 
Rijmond-Zuid (Rotterdam), all in the Netherlands. In that case, the study was conducted in 
the hospital of relevance. 
We determined cyst(e)ine requirements in patients who were aged 1 month (group 1) and 
patients who were aged 2 months (group 2) postnatally. They needed to be clinically stable 
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and were excluded in case of congenital or gastrointestinal diseases. Infants were enrolled in 
the study when they tolerated full enteral feeding (> 150 mL/(kg·d)). Feeding was either 
completely through a nasogastric feeding tube or partly by bottle, depending on 
postconceptual age. During the study, all infants were breathing spontaneously for at least   
8 h. The study protocol was approved by the Central Committee on Research Involving 
Human Subjects, the Erasmus MC institutional review board and review boards from the 
affiliated hospitals. Written informed consent was obtained from both parents of each 
patient. 
 
Study formula 
In this study, we used 5 elemental study formulas that contained graded cyst(e)ine 
concentrations: 11, 22, 32, 43 and 65 mg cyst(e)ine/100 mL (Xcys/Neocate; Nutricia 
Nederland BV, Zoetermeer, the Netherlands/SHS International, Liverpool, United Kingdom). 
The cyst(e)ine content was monitored by SHS International. The study formulas were not 
totally isonitrogenous. Except for cyst(e)ine concentration, the 5 formulas did not differ as to 
amino acid composition. Methionine intake was similar for all formula groups (71 mg/(kg·d)) 
and was supplied generously according to the estimated methionine requirement for 
preterm infants (48-69 mg/(kg·d)) (11).  
 
Study design and tracer protocol 
Infants who were eligible for the study were included and cyst(e)ine requirement was 
determined ~ 1 month after birth (PMA range: 30-32 wk) or 2 months after birth (PMA range: 
35-37 wk). Infants were randomly assigned to at least one of the study formulas. The study 
diet was initiated 24 h before start of the study so that the patient could adapt to the diet. 
Cyst(e)ine intake and the dietary intake was not changed until the tracer protocol was 
finished. The adaptation period of 24 h was selected according to studies by the group of 
Pencharz (12, 13). 
All patients received ~ 170 mL/(kg·d) formula to ensure that all other essential amino acids, 
particularly methionine, were in excess and, therefore, not limiting for protein synthesis. 
Before the introduction of the study formula, almost all infants received their mother’s 
(expressed) breast milk, and only a few infants received standard preterm formula (Nenatal; 
Nutricia, Zoetermeer, the Netherlands). The cyst(e)ine concentration of breast milk varies 
widely, but the preterm formula provided 35 mg cyst(e)ine/100 mL. 
The IAAO method is based on a labeled essential amino acid that is different from the test 
amino acid. This indicator is independent of the different intake levels of the test amino acid. 
If the test amino acid is deficient in the diet, then this will limit overall protein synthesis and 
all other essential amino acids will be oxidized. As dietary intake of the test amino acid 
increases, oxidation of the indicator will decrease linearly until requirement of the test amino 
acid is met. We chose [1-13C]phenylalanine as the indicator (14). 
After 24-h adaptation, patients received a primed (10 μmol/(kg)) continuous (10 μmol/(kg·h)) 
enteral infusion of [13C]bicarbonate (sterile pyrogen free, 99% atom percent excess (APE); 
Cambridge Isotopes, Woburn, MA) for 2.5 h to quantify individual CO2 production. We 
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infused the tracer enterally to minimize invasiveness of the experiment. This method has 
been validated by our group (15). The labeled sodium bicarbonate infusion was directly 
followed by a primed (30 μmol/(kg)) continuous (30 μmol/(kg·h)) enteral infusion of [1-13C]-
phenylalanine (93% APE; Cambridge Isotopes) for 5 h. One hour before start of the oxidation 
study, the feeding regimen was changed into continuous dripfeeding. Enterally infused 
tracer was mixed with the study formula and infused continuously by an infusion pump 
through the nasogastric tube. 
Breath samples were obtained using the direct sampling method described by Van der 
Schoor et al (16). In brief, a 6F gastric tube (6 Ch Argyle; Cherwood Medical, Tullamore, 
Ireland) was inserted 1 to 1.5 cm into the nasopharynx and end-tidal breath was taken slowly 
with a syringe connected at the end. Collected air was transferred into 10-mL sterile, non-
silicon-coated evacuated glass tubes (Van Loenen Instruments, Zaandam, the Netherlands) 
and stored at room temperature until analysis. Baseline samples were obtained 15 and 5 min 
before start of tracer infusion. Duplicate 13C-enriched breath samples were first collected 
every 30 min, and every 15 min during the last 45 min of tracer infusion. 
 
Analytical methods and calculations 
13CO2 isotopic enrichment in expired air was measured by isotope ratio mass spectrometry 
(ABCA; Europe Scientific, Van Loenen Instruments, Leiden, the Netherlands) and expressed as 
APE above baseline (16). APE was plotted relative to [1-13C]phenylalanine infusion time.  
Estimated body CO2 production (mmol/(kg×h) was calculated as described previously (15). 
The rate of fractional [1-13C]phenylalanine oxidation was calculated as follows: 
 
 Fractional phenylalanine oxidation (%) = [IEPHE x iB ]/[ iPHE x IEB] x 100 
 
where IEPHE is the 13C isotopic enrichment in expired air during [1-13C]phenylalanine infusion 
(APE), iB is the infusion rate of [13C]bicarbonate (μmol/(kg·h)), iPHE is the infusion rate of [1-13C]-
phenylalanine (μmol/(kg·h)) and IEB is the 13C isotopic enrichment in expired air during [13C]-
bicarbonate infusion. 
  
Statistical analysis 
Descriptive data are expressed as mean ± SD. The steady state of 13CO2 release in expired 
breath during the [13C]bicarbonate and [1-13C]phenylalanine infusions were achieved when 
the linear factor of the slope was found not to be significantly different from zero (p > 0.05). 
The cyst(e)ine requirement was determined with the use of the IAAO method. The indicator 
oxidation rate was plotted against varying dietary cyst(e)ine intakes (mg/(kg·d)). The 
inflection or breakpoint in the indicator oxidation rate represents the physiological cyst(e)ine 
requirement (17).  
Data were analyzed with the use of mixed model analysis of variance in SPSS software 
(version 14.0; SPSS Inc. Chicago, IL), while encoding the patients who participated twice with 
the same number. Repeated measures analysis of variance was performed on primary and 
derived variables to assess the effects of dietary intake and of patients. Regression analysis 
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was performed to analyze oxidation rates. Power calculation revealed that assuming 5 
formula groups with a group variance of 16, an intergroup variance of 5.5, and a power of 
80%, a breakpoint should be detected with 5 patients per group. Statistical significance was 
assumed at 5% level of significance (p ≤ 0.05). 
 
 
RESULTS 
 
We determined the cyst(e)ine requirements in VLBW infants ~ 1 month after birth (group 1) 
and 2 months after birth (group 2). We included in total 47 VLBW infants: 20 infants in group 
1 and 27 infants in group 2. Patient characteristics are depicted in Tables 1 and 2. Seven 
infants were studied at both time points, and in each group three children participated twice 
and were assigned to 2 different formulas. Infants were randomly assigned to one or two 
study formulas providing ~ 18, 36, 54, 72 or 109 mg cystine/(kg·d) at an intake of 168          
mL/(kg·d). The mean GA of all infants in both groups was 28 ± 1 wk, and mean birth weight 
was 1.07 ± 0.21 kg (data not shown). Weight gain rate of the infants during the days before 
the study was > 10 g/(kg·d). 
We performed 23 measurements in 20 infants (14 male, 6 female) at mean PMA 32 ± 0 wk 
(range: 31-32 wk). Numbers of patients who received each formula are given in Table 1, either 
4 or 5 per formula. We performed 6 measurements per formula in 27 infants (18 male,              
9 female) at mean PMA 35 ± 1 wk (range: 35-38 wk), so in total we studied 30 [1-13C]-
phenylalanine oxidation rates in this group (Table 2). 
In both groups, GA, birth weight and study weight did not differ among the 5 formula groups 
(Tables 1 and 2); however, by chance, in group 1, the PMA of formula 2 was slightly higher 
compared with formula 5 (p = 0.04). We do not believe that this would have had any affect on 
the results because of the small difference in PMA and because the patients’ cyst(e)ine intake 
was randomly selected. The total enteral intake of both groups did not differ among the 5 
formula groups ( group 1: p = 0.14, group 2: p = 0.08).  
To compare outcome parameters between the five formulas within each group, we corrected 
the model for gender, study age, and study weight. In both groups, the baseline 13C 
enrichment in expired breath did not differ among the formulas (Table 3). Each patient 
reached plateau during both [13C]bicarbonate and [1-13C]phenylalanine tracer infusions. For 6 
patients (group 2) who received 72 mg/(kg·d) cystine, the 13C enrichments in expired breath 
during the infusion of [1-13C]phenylalanine are shown in Figure 1.  
In group 1, the fractional oxidation rates of [1-13C]phenylalanine among the 5 formulas did 
not significantly differ (p = 0.19). Regression did not show a linear decease of the fractional 
oxidation rate when cyst(e)ine intakes increased (Figure 2). The regression line was not 
different from zero (p = 0.09) but showed a slightly positive trend in oxidation rate with 
increasing cyst(e)ine intake (p = 0.05). This trend seems to refute our hypothesis that the 
oxidation rate would decrease with increasing cyst(e)ine intake. In group 2, the fractional      
[1-13C]phenylalanine oxidation did not differ among the 5 different cyst(e)ine intake groups 
(p = 0.84). Again, regression of the data did not show a linear decrease in oxidation of the        
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Table 1. Patient characteristics at ~ 1 months’ PMA for group 1. 
Data are mean ± SD (n = 20, measurements = 23). GA, p = 0.99; PMA, p = 0.04; Birth weight, p = 0.61; Study 
weight, p = 0.66. 
 
 
 
 
 
 
Table 2. Patient characteristics ~ 2 months’ PMA for group 2.  
Data are mean ± SD (n = 27, measurements = 30). GA, p = 0.33; PMA, p = 0.30; Birth weight, p = 0.53; Study 
weight, p = 0.35. 
 
 
 
 
Diet 
 
 
No. of trials 
 
 
GA 
  
wk 
PMA 
  
wk 
Birth weight 
  
kg 
Study weight 
  
kg 
Enteral 
intake  
mL/(kg·d) 
Cyst(e)ine 
intake 
mg/(kg·d) 
1 5 27 ± 1 31 ± 1 1.14 ± 0.28 1.31 ±0.18 167 ± 2 18 ± 0 
2 5 28 ± 2 32 ± 0 1.20 ±0.13 1.53 ± 0.17 168 ± 0 36 ± 0 
3 4 27 ± 1 32 ± 0 1.06 ± 0.05 1.45 ± 0.22 166 ± 2 54 ± 1 
4 5 27 ± 1 32 ± 0 1.03 ± 0.10 1.38 ± 0.34 168 ± 0 72 ± 0 
5 4 28 ± 1 31 ± 1 1.13 ± 0.17 1.33 ± 0.12 167 ± 2 108 ± 2 
Mean   27 32 1.12 1.40 167   
SD   1 0 0.16 0.22 1   
Diet 
 
 
No. of trials 
 
 
GA 
  
wk 
PMA 
  
wk 
Birth weight 
  
kg 
Study weight 
  
kg 
Enteral 
intake    
ml/(kg·d) 
Cyst(e)ine 
intake 
mg/(kg·d) 
1 6 28 ± 1 35 ± 1 1.03 ± 0.26 2.21 ± 0.43 168 ± 2 18 ± 0 
2 6 29 ± 1 36 ± 1 1.14 ±0.18 2.09 ± 0.47 168 ± 1 36 ± 0 
3 6 29 ± 0 35 ± 0 1.12 ± 0.22 1.78 ± 0.22 166 ± 3 53 ± 1 
4 6 28 ± 2 36 ± 1 0.97 ± 0.25 2.13 ± 0.35 168 ± 1 72 ± 0 
5 6 27 ± 2 35 ± 1 0.99 ± 0.26 2.09 ± 0.54 167 ± 1 108 ± 1 
Mean   28 35 1.05 2.06 167   
SD   1 1 0.23 0.41 2   
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Figure 1. Mean 13C enrichments in expired breath during enteral [1-13C]phenylalanine infusion in 6 infants 
(mean PMA: 35 wk) who received 72 mg/(kg·d) cyst(e)ine (formula 4). 
Figure 2. Relationship between the cystine intake and the individual fractional [1-13C]phenylalanine oxidation 
in VLBW infants with a mean GA of 28 wk at 32 (A) and 35 (B) weeks’ PMA. A, The fractional oxidation of [1-13C]-
phenylalanine in VLBW infants at ~ 32 weeks’ PMA (group 1). Five, 5, 4, 5, and 4 measurements were taken for 
cyst(e)ine intakes of 18, 36, 54, 72 and 109 mg/(kg·d), respectively. B, The fractional oxidation of [1-13C]-
phenylalanine in VLBW infants at ~ 35 weeks’ PMA (group 2). Six measurements were taken for each cyst(e)ine 
intake. 
A 
B 
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indicator (Figure 2), and the regression line was also not significantly different from zero. A 
trend in the formula could not be detected (p = 0.24). Consequently, in both groups, an 
inflection of the curve is missing and no breakpoint could be calculated.  
These results suggest that the cyst(e)ine requirement in VLBW infants who are older than 32 
PMA is already met under these circumstances (ie, at 18 mg cyst(e)ine/(kg·d) intake together 
with 71 mg/(kg·d) methionine at a total enteral intake of 170 mL/(kg·d)). At the intakes of 18 
to 109 mg/(kg·d), cyst(e)ine is not the limiting amino acid for protein synthesis and is 
therefore not deficient in the diet.  
 
 
DISCUSSION 
 
In this study, application of the IAAO method showed that a cyst(e)ine intake of 18 mg/(kg·d) 
did not limit endogenous cyst(e)ine synthesis and that the cyst(e)ine requirement was             
< 18 mg/(kg·d). Hence, it is presumably safe to say that cyst(e)ine is not a conditionally 
essential amino acid in fully enterally fed VLBW preterm infants who are older than 32 weeks’ 
PMA. 
The IAAO method is based on the assumption that essential amino acids participate between 
protein synthesis and oxidation (18). If one essential amino acid is deficient in the diet, then 
this will limit overall protein synthesis and all remaining essential amino acids are in excess 
and thus will be oxidized. Generous amounts of each essential amino acid must be applied, 
therefore, except for the one under study. We could not determine a decrease in fractional   
[1-13C]phenylalanine oxidation with increasing cystine intake. Thus, an amino acid other than 
cystine or other co-factors for protein synthesis could have been limiting and hence no 
change in oxidation rate could be detected; however, weight gain rates in both groups were 
not compromised, indicating no major limitations for protein synthesis. In addition, the 
amount of methionine provided by a daily intake of 168 mL/(kg·d) was 70 mg/(kg·d), ~ 20% 
in excess of the methionine requirement estimated on fetal accretion rate and obligatory 
losses (59 mg/(kg·d)) (19). We propose, therefore, that methionine intake is not the limiting 
factor for endogenous cyst(e)ine synthesis. Another explanation for our finding might lie in 
the duration of the adaptive period to a different cystine intake. At 24 h it might have been 
too short; however, Zello and colleagues (18, 20) did not see an effect of previous adaptation 
to various levels of the test amino acid and suggested 4 h to be enough to establish a new 
steady state.  
Over the years, various methods have been used to estimate individual amino acid 
requirements (eg, the nitrogen balance method, growth rate, plasma amino acid patterns, 
the factorial approach). In 1971 Snyderman et al. (21) reported amino acid requirements for 
neonates on the basis of nitrogen balance and weight gain rate, yet nitrogen balance usually 
overestimates nitrogen retention, and growth rate also depends on factors other than amino 
acid intake. Moreover, 7 to 10 days’ adaptation is needed to establish nitrogen equilibrium 
(22). Because present clinical practice does not accept maintaining neonates on either 
deficient or excess amino acid intakes for a minimum of 7 d, no such requirement studies 
63 
Cyst(e)ine requirements in very-low-birth-weight preterm infants 
C
ha
p
te
r 4
 
have been reported in preterm infants since then. 
Current dietary requirement estimates for humans so far are based on the factorial approach 
(11). For preterm infants, this approach uses data on body composition of the fetus in utero 
of approximately the same age. These data are derived from body carcass analysis of stillborn 
preterm infants, some born > 100 years ago (23-25). In many cases, GA of the analyzed 
fetuses was not accurately known; therefore, not all data could serve as standard reference 
(26). Because fetal accretion rate of cyst(e)ine is not available, the current cyst(e)ine 
requirement for preterm infants (66-95 mg/(kg·d) is based on the minimum and maximum 
amounts of each amino acid present in the amounts of breast milk protein corresponding to 
the recommended minimum and maximum protein contents (g/503 kJ) of 3.0 and 4.3 g, 
respectively (27). This estimation, however, does not take into account the influence of 
postnatal maturation.  
Until now, cyst(e)ine was believed to be a conditionally essential amino acid in preterm 
infants. Snyderman (21) was the first to show that cyst(e)ine might be required for preterm 
infants. She found lower rates of nitrogen retention and weight gain in 2- to 4-month-old 
infants who were born preterm and enterally fed a synthetic diet without cyst(e)ine. The    
cyst(e)ine intakes of 44 or 66 mg/(kg·d) did not restore nitrogen retention and weight gain to 
control values. She recommended a minimal intake of 85 mg cyst(e)ine/(kg·d); however, 
because she did not provide methionine intake, this recommendation might be 
overestimated in view of the risk of inadequate methionine intake. Several in vitro studies 
then reported that the enzyme cystathionase was absent in fetal liver in these infants, in 
contrast to term infants (4-6). Cystathionase activity seems to be a postnatal phenomenon, 
reaching mature levels at ~ 3 months of age (5, 6). Cyst(e)ine requirement in these infants 
thus would depend on GA and should decrease with postnatal age. Obviously, we did not 
confirm this hypothesis. 
Several in vivo studies demonstrated low plasma cyst(e)ine concentrations in preterm infants 
with or without cyst(e)ine supplementation, suggesting that limited cystathionase activity 
had impaired cyst(e)ine synthesis (28-31). Conversely, Zlotkin et al. (32) did not find 
differences in nitrogen balance for the parenterally fed term and preterm infants with or 
without cysteine supplementation. They showed slightly higher urinary 3-methylhistidine 
excretion in cysteine supplemented infants but failed to detect an evident relation. Although 
Malloy et al. (33) showed that cysteine supplementation increased free cysteine plasma 
concentration and sulfur balance in preterm infants, it did not improve nitrogen retention. A 
study in parenterally fed VLBW infants who received an isotopically labeled glucose infusion 
showed incorporation of isotopic label in plasma cysteine and in hepatically derived            
apo B-100 cysteine (34). In agreement with our results, the authors concluded that these 
infants were certainly capable of sufficient endogenous cyst(e)ine synthesis, which was 
directly related to birth weight . 
Cyst(e)ine is an important sulfur-containing amino acid. Indispensable for protein synthesis, it 
also serves as a significant precursor for glutathione synthesis. If cyst(e)ine is a conditionally 
essential amino acid in preterm infants, then it could be the limiting factor for adequate 
glutathione production. Preterm birth and critical illness including oxygen supplementation 
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might lead to higher glutathione requirement might be increased in these infants. If            
cyst(e)ine concentration is inadequate, then glutathione quantity might be insufficient to 
prevent oxidative stress; however, Shew et al. (34) consider the minimum capacity for 
cysteine synthesis enough to counteract oxidative stress. For confirmation of this statement, 
future studies should investigate incorporation of quantities of cysteine in glutathione in 
both parenterally and enterally fed preterm infants. 
A limitation of this study is that we did not include a formula providing for cyst(e)ine intake of 
< 18 mg/(kg·d). The formulas used were based on current nutrient recommendations for 
preterm formula (27). At the onset of the study, we decided not to incorporate a study 
formula without cyst(e)ine for ethical reasons. Whether cyst(e)ine requirement is > 0 but        
< 18 mg/(kg·d) has to be determined with the aid of a cyst(e)ine-free formula yet with 
sufficient methionine. 
From the findings of this study, we may safely conclude that the cyst(e)ine requirement for 
enterally fed VLBW preterm infants who are older than 32 weeks’ PMA is < 18 mg/(kg·d), 
provided that methionine intake is adequate. 
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ABSTRACT 
 
Methionine is an indispensable sulfur amino acid that functions as a key precursor for the 
synthesis of homocysteine and cysteine. Studies in adult humans suggest that splanchnic 
tissues convert dietary methionine to homocysteine and cysteine by means of 
transmethylation and transsulfuration, respectively. Studies in piglets show that significant 
metabolism of dietary indispensable amino acids occurs in the gastrointestinal tissues (GIT), 
yet the metabolic fate of methionine in GIT is unknown. We show here that 20% of the 
dietary methionine intake is metabolized by the GIT in piglets implanted with portal and 
arterial catheters and fed milk formula. Based on analyses from intraduodenal and 
intravenous infusions of [1-13C]methionine and [2H3]methionine, we found that the whole-
body methionine transmethylation and remethylation rates were significantly higher 
during duodenal than intravenous tracer infusion. First-pass splanchnic metabolism 
accounted for 18% and 43% of the whole-body transmethylation and remethylation, 
respectively. Significant transmethylation and transsulfuration was demonstrated in the 
GIT, representing ~27% and ~23% of whole-body fluxes, respectively. The methionine used 
by the GIT was metabolized into homocysteine (31%), CO2 (40%), or tissue protein (29%). 
Cystathionine ß-synthase mRNA and activity was present in multiple GITs, including 
intestinal epithelial cells, but was significantly lower than liver. We conclude that the GIT 
consumes 20% of the dietary methionine and is a significant site of net homocysteine 
production. Moreover, the GITs represent a significant site of whole-body transmethylation 
and transsulfuration, and these two pathways account for a majority of methionine used by 
the GITs. 
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INTRODUCTION 
 
The sulfur amino acids, methionine, homocysteine, and cysteine, have attracted considerable 
interest in the last decade. Methionine is an indispensable amino acid and is transmethylated 
intracellularly to homocysteine via S-adenosylmethionine (SAM), an important methyl donor 
for most biological methylation reactions (1). Homocysteine can be further catabolized to 
cysteine through transsulfuration, which is regulated by the enzymes cystathionine                  
β-synthase (CBS) (EC 4.2.1.22) and cystathionine γ-lyase (EC 4.4.1.1). Homocysteine can also 
be used for methionine synthesis through remethylation. Consequently, homocysteine 
represents a critical regulatory control point for methionine and cysteine synthesis and folate 
metabolism.  
Homocysteine is normally present in human plasma at low concentrations. However, 
elevated plasma homocysteine concentrations have important implications for human 
health and disease. Clinical studies indicate that hyperhomocysteinemia is strongly 
associated with increased risk of cardiovascular disease, with ischemic and hemorrhagic 
stroke in infants and children (2-4), and, more recently, Alzheimer’s disease and other 
neurological diseases in adults (5). Genetic defects in methionine metabolism related to 
methionine synthase, N5,10-methylene-tetrahyrdofolate, also result in neural dysfunction, 
mental retardation, and pregnancy complications (6-8). Recent studies have linked 
homocysteine, folate, and DNA methylation with gastrointestinal diseases, namely 
inflammatory bowel disease and colon cancer (9-13). The underlying mechanism linking 
homocysteine to inflammatory disease may be the induction of leukocyte adhesion 
molecules and proinflammatory cytokines in vascular endothelial cells (10).  
Methionine is also a precursor for cysteine, which plays a key role in cellular protein function 
and redox status by virtue of its thiol (-SH) moiety. In addition, it also serves as a precursor of 
glutathione, a major cellular antioxidant, as well as CoA, taurine, and inorganic sulfur. Several 
tissues in the body are capable of cysteine synthesis (14), which is why cysteine is considered 
nutritionally dispensable. However, increasing evidence that oxidant stress is linked to many 
disease pathologies and aging has focused attention on the antioxidant functions of cysteine 
and its product, glutathione, leading some to suggest that cysteine is a conditionally 
indispensable dietary nutrient (15-17).  
Most cells in the body are capable of transmethylation and remethylation, yet homocysteine 
metabolism via transsulfuration seems limited to certain tissues. Early studies by Mudd et al. 
(18) showed that CBS and cystathionine γ-lyase are active mainly in human liver tissue, and to 
a lesser extent, in extra hepatic tissues including pancreas, kidney, small intestine, brain, and 
lung. Stegink and Den Besten (19) first reported in vivo evidence to implicate splanchnic 
tissues as a key site of methionine transsulfuration by demonstrating that plasma cysteine 
concentrations are significantly higher in human subjects fed a methionine-containing, 
cystine-free diet enterally versus intravenously. However, subsequent metabolic studies with 
stable isotopic tracers also have indirectly suggested that a substantial fraction of the dietary 
methionine undergoes transmethylation and remethylation during first-pass splanchnic 
metabolism in adult humans (20, 21). More recent studies show that the whole-body 
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methionine requirement and circulating homocysteine concentrations are significantly 
higher in piglets fed enterally than parenterally, demonstrating that splanchnic methionine 
metabolism is nutritionally significant (22, 23).  
Despite the clear evidence that splanchnic tissues play a major role in methionine 
transmethylation and transsulfuration, the relative contribution of the gastrointestinal tissues 
(GIT) remains unclear. Our previous studies have shown that GIT extensively metabolize 
dietary indispensable amino acids, namely lysine, threonine, and leucine (24-26). In the case 
of methionine, our studies and those of others suggest that substantial metabolism and even 
oxidation of dietary methionine occurs in the gut (26, 27). However, the extent of 
transmethylation and transsulfuration in the GIT and its relative contribution to whole-body 
methionine metabolism has not been established. In this report, we have coupled our piglet 
model of arteriovenous balance across the GIT with an established stable isotopic tracer 
approach using [1-13C and methyl-2H3]methionine to investigate the metabolic fate of 
methionine in the gut and the contribution to the whole-body rates of transmethylation and 
transsulfuration. We hypothesized that there is substantial transmethylation, transsulfuration, 
and remethylation of dietary methionine by GIT and that dietary rather than systemically 
derived methionine is preferentially metabolized.  
 
 
RESULTS 
 
Whole-body methionine metabolism  
Mean weight of the animals on the first and second days of the experiment were                  
6.74 ± 1.89 kg and 7.52 ± 1.99 kg, respectively. No significant differences between 
intravenous (IV) and intraduodenal (ID) infusions were observed in mean whole-body CO2 
production (IV 46.55 ± 1.16 mmol/(kg·h) and ID 45.50 ± 0.97 mmol/(kg·h)) and CO2 
production by the portal drained viscera was 6.95 ± 0.57 mmol/(kg·h) IV and                           
6.73 ± 0.55 mmol/(kg·h) ID. As shown in Figure 1, steady-state of plasma isotopic enrichment 
(expressed as mole percent excess, MPE) of [1-13C]methionine and [2H3]methionine was 
achieved after 5 h during both infusion modes. 
Methionine plateau was defined as the mean plasma enrichment between 5 and 6 h. Steady-
state of [1-13C]homocysteine was not achieved after6hofinfusion (data not shown), and these 
values were not used to estimate the tissue intracellular precursor enrichment for whole-
body fluxes as done previously (28). However, the plasma [1-13C]homocysteine enrichments 
were used to calculate methionine kinetics in the GIT, because the assumption of steady-
state is not necessary. Whole-body methionine kinetics are depicted in Table 1, and rates are 
expressed as μmol/(kg·h). Whole-body methionine transmethylation, remethylation, and 
incorporation into protein synthesis were significantly (p < 0.05) higher during ID than IV 
tracer infusion, indicating first-pass splanchnic metabolism. Whole-body transmethylation 
represented 25% and 27% of methionine flux when infused IV and ID, respectively. Whole-
body transsulfuration represented 21% and 20% of methionine flux when infused IV and ID, 
respectively, and was not significantly different between the infusion groups. Most of whole-
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body methionine flux (~80%) was used for protein synthesis and only ~20% was metabolized 
through transmethylation and transsulfuration.  
Figure 1. Time course of mean plasma tracer enrichments during IV (upper) and ID (lower) infusion of                
[1-13C]methionine (filled circles) and [methyl-2H3]methionine (open circles). Enrichments expressed as mole 
percent excess (MPE). Mean ± SEM (n = 16). 
 
Table 1. Whole-body methionine kinetics. 
Data are mean ± SEM (n = 16). Rates are expressed as μmol/(kg·h) for IV and ID tracer administration. *P < 0.01 
IV vs. ID. †P < 0.05 IV vs. ID 
 
Methionine metabolism in the GIT  
Methionine kinetics of the GIT are shown in Table 2 and Figure 2. Total net methionine 
utilization by the GIT accounted for 20% of the dietary methionine intake. However, there 
was no first-pass metabolism of dietary methionine in the GIT. After correction for recycling 
and arterial uptake of ID methionine tracer absorbed into the portal blood, the net 
methionine uptake was 16 μmol/(kg·h), indicating that the GIT preferentially metabolized 
systemic methionine rather than dietary methionine. Release of [13C]homocysteine and   
13CO2 by the GIT, which is a reflection of transmethylation, accounted for 67% of the GIT                
  IV ID 
[methyl-2H3]methionine flux 130 + 4 147 + 2 * 
[1-13C]methionine flux 122 + 3 133 + 2 * 
Transmethylation 33 + 3   40 + 3 † 
Transsulfuration 26 + 2 26 + 2 
Remethylation   8 + 1    14 + 1 * 
Protein Synthesis 97 + 3 107 + 2 † 
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[13C]-methionine uptake. Transsulfuration was measured as the 13CO2 release by the portal 
drained viscera, which was 38% of the [13C]methionine uptake by the GIT. The contribution of 
GIT to whole-body metabolism is shown in Figure 3. The rate of GIT methionine uptake 
represented 20% of the dietary methionine intake, whereas ~49% and 32% of the dietary 
methionine intake was metabolized in the whole body via transmethylation and 
transsulfuration, respectively. The GIT represented 27% and 23% of whole-body rates of 
transmethylation and transsulfuration, respectively.  
 
Table 2. Steady-state methionine and homocysteine concentrations and isotopic enrichments in plasma and 
tissue. 
Data are mean ± SEM (n = 16 plasma and n = 6–8 tissues) for IV and ID tracer administration. 
 
The isotopic enrichments of free [1-13C] and [methyl-2H3]methionine in the intestinal and liver 
tissues were not different between IV and ID groups (Table 2). However, the enrichment of 
[2H3]methionine was significantly (p < 0.01) lower than [13C]methionine in both the intestine 
(ratio [2H3]methionine/[13C]methionine = 0.12) and liver (ratio [2H3]methionine/[13C]-
methionine = 0.05); the ratio of [2H3]methionine/[13C]methionine was significantly (p < 0.001) 
lower in the liver than intestine. This relationship also was observed for protein-bound [13C]-
methionine and [2H3]methionine in the intestinal and liver tissue (data not shown). The net 
portal fluxes of methionine, homocysteine, and CO2 are shown in Table 3. Consistent with 
tracer flux, the net rate of methionine absorption from the GIT was 78% and 82% of the 
  IV ID 
Arterial methionine     
    Concentration, μM 202 ± 9 200 ± 8 
    [1-13C]methionine, MPE 7.56 ± 0.19 6.94 ± 0.09 
      [methyl-2H3]methionine, MPE 7.05 ± 0.17 6.25 ± 0.08 
Portal methionine     
    Concentration, μM 208 ± 16 210 ± 17 
    [1-13C]methionine, MPE 6.37 ± 0.16 7.75 ± 0.24 
      [methyl-2H3]methionine, MPE 5.97 ± 0.15 7.19 ± 0.22 
Arterial homocysteine     
    Concentration, μM 7.80 ± 0.91 6.54 ± 0.48 
    [1-13C]homocysteine, MPE 5.60 ± 0.19 5.52 ± 0.11 
Portal homocysteine     
    Concentration, μM 8.48 ± 0.76 8.16 ± 0.57 
    [1-13C]homocysteine, MPE 5.58 ± 0.19 5.63 ± 0.10 
Intestine [1-13C]methionine, MPE 3.25 ± 0.29 3.07 ± 0.48 
Intestine [methyl-2H3]methionine, MPE 0.34 ± 0.03 0.38 ± 0.09  
Liver  [1-13C]methionine, MPE 4.34 ± 0.16 3.79 ± 0.16 
Liver [methyl-2H3]methionine, MPE 0.24 ± 0.01 0.20 ± 0.01 
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dietary intake in IV and ID groups, respectively. The net homocysteine flux was significantly 
positive, indicating net production by the GIT; the homocysteine flux represented 20–25% of 
the respective GIT methionine utilization rate.  
Figure 2. Schematic representation of the metabolic fate of enteral and systemic methionine kinetics in the 
GIT (n = 16). Dietary methionine intake (A); arterial methionine flux through the GIT (B); portal methionine 
outflow (C); unidirectional, first-pass uptake of dietary methionine by the GIT (D); dietary methionine not 
metabolized by the GIT in first pass (E); unidirectional uptake of arterial methionine by the GIT (F); arterial 
methionine not metabolized by the GIT (G); recycled methionine derived from proteolysis (H); and methionine 
that is converted to homocysteine (I), CO2 (J), and protein (K) by the GIT. Rates expressed as μmol/(kg·h). 
Dietary intake includes [1-13C] and [methyl-2H3]methionine tracers. Detailed explanation of equations and 
assumptions used for calculating the methionine kinetic in the GIT are included in supporting information (SI) 
Appendix. 
Figure 3. The absolute rates and relative proportions of dietary methionine intake,  transmethylation, and 
transsulfuration in the whole body (filled bars) and GIT (open bars). Rates expressed as μmol/(kg·h). 
Percentages above filled bars represent whole-body rates relative to dietary methionine intake, whereas those 
above open bars represent GIT rates relative to the respective whole-body rates. Mean ± SE M(n = 16). 
 
The mRNA expression and activity of CBS in various GI tissues are expressed in Figure 4. A 
single PCR product of 76 bp derived from a sequence spanning exons 6 and 7 of the porcine 
CBS gene was measured in all tissues (Figure 4A). The relative expression of CBS mRNA in 
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liver tissue was ~10-fold higher than in any GI tissue measured. However, the CBS activity in 
liver tissue was only 3-to 5-fold higher than in GITs. Interestingly, both liver and intestinal 
epithelial cell CBS activity was markedly (~6-fold) increased above the basal rate by 
coincubation with 1.0 mM SAM, a known allosteric activator of the enzyme (28).  
  
Table 3. Dietary methionine intake and net portal fluxes of methionine, homocysteine, and CO2. 
Data are mean ± SEM (n = 16). Rates are expressed as μmol/(kg·d) except where indicated. 
 
  IV ID 
Enteral methionine intake 62 82 
Portal plasma flow (liter/(kg·h) 2.58 ± 0.16 2.44 ± 0.12 
Net portal methionine absorption 48 ± 3 67 ± 3 
Methionine intake, % 78 ± 4 82 ± 3 
Net portal methionine utilization 14 ± 3 15 ± 3 
Methionine intake, % 22 ± 4 18 ± 3 
Net portal homocysteine release 2.7 ± 0.5 3.9 ± 0.5 
Portal methionine uptake, % 20 ± 3 25 ± 4 
Net portal CO2 release 6,948 ± 226 6,725 ± 204 
Figure 4. CBS mRNA abundance and enzymatic activity in liver and selected GITs. (A) The relative amounts of 
CBS mRNA product derived from 100 ng of RNA of representative tissue samples from liver (L), jejunum (J), 
stomach (St), pancreas (P), and intestinal epithelial cells (IEC) after RT-PCR and separation on agarose gel. (B) 
Abundance of CBS mRNA expressed relative to 18S RNA in liver, jejunum, stomach, pancreas, and IEC (n = 4). 
(C) CBS enzymatic activity determined in liver, jejunum, stomach, pancreas, and IEC (n = 4). (D) Relative 
changes in CBS enzymatic activity determined in liver tissue and intestinal epithelial cells in the absence and 
presence of 1.0 mM SAM (n = 3). Mean ± SEM. 
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DISCUSSION 
 
The main objective of this study was to quantify the metabolic fate of methionine in the GIT 
by using our established in vivo model coupling organ balance and isotopic tracer kinetics. 
Our results demonstrate in vivo that the GIT is a metabolically significant site of methionine 
transmethylation and transsulfuration. Moreover, we show in vivo evidence that the GIT is 
not only a site of intracellular homocysteine synthesis but also of net release into the 
circulation. This finding provides evidence for the metabolic role of the GIT in the etiology of 
homocysteinemia and how this may be impacted by gastrointestinal disease states. This 
study also extends our previous work with other indispensable amino acids, e.g., lysine, 
leucine, threonine, and phenylalanine, and shows that, in addition to the liver, the GIT is an 
active site of methionine metabolism in the body (24-26, 29, 30).  
Our results indicated that the GIT metabolize ~20% of the dietary methionine intake. Recent 
studies in neonatal piglets fed cysteine-free diets demonstrated that the whole-body 
methionine requirement is ~40% lower in total parenterally fed (TPN) compared with 
enterally fed pigs (31). The difference in this case was attributed to GIT metabolism, because 
TPN bypasses the gut and results in gut atrophy. A subsequent study showed that feeding an 
excess of dietary cystine significantly decreased the methionine requirement consistent with 
the methionine-sparing effect of cysteine (22). However, even with excess dietary cystine, the 
methionine requirement in TPN-fed pigs was still ~28% lower than enterally fed pigs, again 
implying that the GIT represents 28% of body methionine metabolism. The latter study is 
comparable to our current study where dietary cystine was in excess of the methionine 
intake. The difference between our direct estimate of 20% and the indirect estimate of 28% 
GIT metabolism could be due to the nature and composition of the diets (formula versus 
elemental diet) or that our pigs were slightly older (4 versus 1 wk old).  
The finding of significant transmethylation and transsulfuration in the GIT is supported by 
previous reports and our current evidence showing the presence of enzymes involved in 
methionine metabolism in stomach, pancreas, and intestinal epithelial cells (18, 32). Recent 
evidence from colonic cell (Caco-2) culture studies also showed the presence of methionine 
transmethylation and transsulfuration activity (33). The finding of net homocysteine 
production potentially implicates the gut in homocysteinemia. It also explains why enteral 
nutrition results in significantly higher circulating homocysteine concentrations than TPN 
(23). A striking observation was the significant reduction in the tissue-free enrichment of  
[2H3]methionine compared with [13C]methionine; the mean ratio of [2H3]methionine/[13C]-
methionine was 0.05 in liver and 0.12 in intestine. These ratios are explained by the high rate 
of intracellular methylation and necessary loss of the deuterated methyl moiety via SAM 
synthesis. This indicates a substantial methylation rate in the intestine that is nearly half of 
that observed in the liver. It is important to note that the current estimates of methionine 
transmethylation and transsulfuration are minimal estimates, given the generous dietary 
cystine intake, and are likely higher under conditions of cysteine and folate deficiency or 
oxidant stress. Yet, it is remarkable that despite the high dietary cysteine intake, the GIT 
represent ~23% of whole-body transsulfuration and a third of all methionine used by the gut 
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was used for cysteine synthesis. This value is nearly twice as high as that reported recently for 
sheep, where they observed that ~10% of whole-body methionine oxidation occurred in GIT 
(27). It is of interest that isolated epithelial cells had the highest CBS activity among the GI 
tissues measured. Oxidant stress is known to increase methionine transsulfuration to meet 
the increased cysteine demand for cellular glutathione synthesis (34, 35). This suggests that 
the metabolic requirement for methionine and cysteine by the gut may be increased in 
conditions such as inflammatory bowel disease and enteric infection.  
We observed substantially higher whole-body rates of transmethylation (3-fold) and 
transsulfuration (6-fold) in our young pigs when compared with those reported in adult 
humans (21). Moreover, when expressed as fraction of transmethylation, we found that most 
of the body homocysteine produced in young pigs is metabolized via transsulfuration, and 
less is remethylated when compared with adult humans; it is unclear whether this is due to 
difference in species or age. A particularly important finding was that the whole-body 
transmethylation and remethylation rates were significantly higher during the enteral 
compared with the IV tracer infusion protocol. This suggests that nearly 18% and 43% of the 
whole-body transmethylation and remethylation, respectively, occurs in first-pass by 
splanchnic tissues. However, another key observation from this study was that the GIT 
preferentially utilizes methionine from the arterial circulation rather than the diet, contrary to 
our hypothesis. Thus, the results indicate that the preferential first-pass splanchnic 
metabolism of dietary methionine occurs in the liver and not the GIT. These findings are 
consistent with our evidence of substantial intracellular methylation rates in both the liver 
and intestinal tissues. Moreover, our findings support indirect evidence from separate clinical 
studies where a dual-labeled [1-13C-methyl-2H3]methionine tracer was given intravenously 
and orally (20, 21). The authors of these two studies estimated that there is no first-pass 
splanchnic metabolism when based solely on kinetics of the [1-13C-methyl-2H3]methionine 
isotopomer. However, these authors found that the enrichment of [1-13C]methionine 
isotopomer was considerably higher when the [1-13C-methyl-2H3]methionine tracer was given 
orally than after IV infusion, indicating the presence of significant first-pass splanchnic 
transmethylation and remethylation of dietary methionine. Recent in vivo studies in sheep 
also indicate that the liver and gut tissues are important sites of homocysteine remethylation 
(36). The markedly lower enrichment of the [methyl-2H3]methionine compared with [1-13C]-
methionine implies a very high fractional rate of methylation and remethylation. Therefore, 
our results together with previous reports in humans and sheep strongly suggest that the GIT 
and liver are major sites of homocysteine remethylation.  
In this study, the relative plasma [13C]homocysteine/[13C]methionine enrichments were 
considerably higher than recent reports in humans under post-absorptive (37, 38) and insulin 
stimulated conditions. Theoretically, in tissues with the enzymatic capacity for 
transmethylation the intracellular enrichment of [13C]methionine and [13C]homocysteine 
should be similar, assuming that there is one common intracellular pool. Although we did 
not measure tissue [13C]homocysteine enrichments, the tissue [13C]methionine enrichment in 
the intestine (3.07 MPE) and liver (3.79 MPE) was significantly lower than that of plasma [13C]-
homocysteine (5.52 MPE). The plasma [13C]homocysteine enrichment theoretically represents 
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the summation of transmethylation in the whole body. These results further suggest that the 
fractional rates of methionine transmethylation to homocysteine are disproportionately 
higher in the liver and GIT compared with other tissues in the body.  
In conclusion, this study provides in vivo kinetic evidence for methionine transmethylation 
and transsulfuration in the developing GIT. Moreover, we show the GIT to be a site of net 
homocysteine release into the circulation. The high rates of transmethylation in the GIT may 
be functionally linked to methyl demand for synthesis of polyamines, phosphatidylcholine, or 
creatine (39). The GIT consumed 20% of the dietary methionine intake and approximately 
two-thirds of this was used for synthesis of homocysteine and cysteine. We also show that 
the GIT contributes significantly to whole-body methionine transsulfuration and that CBS 
expression is localized to epithelial cells within the small-intestinal mucosa. We speculate 
that the high rate of methionine transsulfuration in the GIT is driven by cysteine needs for 
glutathione synthesis because of the oxidant stress associated with the high metabolic 
activity of proliferating epithelial cells. Another demand for intestinal methionine 
transsulfuration may be for synthesis of cysteine-rich mucins secreted by goblet cells 
involved in innate immune function (40). We also found significant first-pass splanchnic 
transmethylation and remethylation, but this appears to be confined only to the liver, 
because there was no first-pass methionine use by the GIT. Taken together, the results 
suggest that the GIT is a key site for regulation of homocysteine metabolism via dietary and 
other means. These studies also suggest that GI disease states may play a role in the 
development and treatment of hyperhomocysteinemia or conversely that dysregulation of 
gut homocysteine metabolism may contribute to pathologies of GI diseases, namely 
inflammatory bowel disease.  
 
 
METHODS 
 
Animals and design 
The protocol was approved by the Animal Protocol Review Committee of Baylor College of 
Medicine and conformed to the U.S. Department of Agriculture guidelines. Sixteen, 14-day-
old female piglets (Large White x Hampshire x Duroc) were adapted for 7 days to a liquid milk 
replacer diet (Litterlife; Merrick, Middleton, WI) that provided 25 g of lactose, 5 g of fat, and 
12.5 g of protein per kg body weight daily. Methionine and cystine contents were 0.52% and 
0.61%, respectively, providing a daily intake of 0.25 g methionine/kg and 0.31 g of cystine/kg. 
At 20 d of age, the piglets (n = 16) were surgically implanted with catheters as described    
(26, 41). One week after surgery, each piglet received ID and IV tracer infusions on two 
different days in a randomized, cross-over design with at least one day between the ID and IV 
infusions. To estimate whole-body CO2 production, a 2-h infusion of [13C]sodium bicarbonate 
was performed before the methionine tracer infusion (26).  
  
Tracer Protocol 
At 27 days of age, piglets were fed a bolus meal supplying 1/12 of the preceding total intake 
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after an overnight fast. Constant duodenal infusion at a rate of 1/24 of the daily intake        
(ml/(kg·h)) was started 1h after the animal had consumed its meal; this was continued for 8 h. 
Immediately after starting the duodenal feeding, all piglets received a primed, continuous IV 
infusion (5 and 10 μmol/(kg·h), respectively) of [13C]sodium bicarbonate (99% APE; 
Cambridge Isotope Laboratories, Andover, MA) for 2 h. At 120 min, the [13C]bicarbonate 
infusion ended, and an immediate infusion of [1-13C]methionine and [methyl-2H3]methionine 
(98% and 99% APE, respectively; Cambridge Isotope Laboratories) was administrated for 6 h 
either via the jugular (IV) or via the duodenal (ID) catheter. The primed, continuous infusion 
rate was 10 μmol/(kg·h) for each methionine tracer, so the total isotopic methionine infusion 
rate was 20 μmol/(kg·h). Arterial and portal blood samples were collected at 0, 90, 115, and 
120 min and 6, 7, and 8 h. Portal blood flow was monitored continuously by transit-time 
ultrasound for 30 min before the initial formula feeding and throughout the entire 8-h 
protocol as described (24, 26). After tracer infusion on the second study day, animals were 
euthanized (Beutanasia-D; Schering-Plough Animal Health, Kenilworth, NJ) and intestinal, 
pancreas, stomach, and liver tissues were collected and frozen at -80°C.  
 
Sample preparation and analysis 
Blood gases (Chiron Diagnostics, Halstead, Essex, U.K.) and hematocrit were determined 
immediately in all arterial and portal blood samples, and isotopic enrichment of 13CO2 in 
whole blood was analyzed by isotope ratio mass spectrometer as described (26). Plasma was 
obtained from arterial and portal blood, and an aliquot of plasma was combined with 
methionine sulfone (0.4 mM) and stored at  -80°C until further amino acid analysis by HPLC 
(PicoTag System; Waters, Woburn, MA).  
 
Measurement of stable isotope tracer enrichments 
Plasma isotopic enrichments of [1-13C]methionine, [methyl-2H3]methionine, and [1-13C]-
homocysteine were quantified on the heptafluorobutyric anhydride (HFBA) derivatives by  
GC-MS by using a modification of the methods described (37, 42). Blood 13CO2 enrichment 
was determined by gas isotope ratio mass spectrometry (26). Plasma homocysteine was 
determined by isotope dilution using D8-homocystine (37, 42). Briefly, plasma was acidified 
with 10% trichloroacetic acid, amino acids were separated by cation-exchange (AG 50W-X8; 
Bio-Rad, Richmond, CA), treated with DTT (DTT; Sigma–Aldrich, St. Louis, MO), and 
derivatized with HFBA (42). GC-MS was performed by negative chemical ionization on a       
GC-MS model HP-6890/5973 MSD (Hewlett– Packard, Palo Alto, CA). Ion abundance was 
monitored with selected-ion monitoring (SIM); mass-to-charge (m/z) for natural methionine 
[M + 0], [1-13C]methionine [M + 1], and [methyl-2H3]methionine [M + 3] were 367, 368, and 
370, respectively. Ions were monitored by SIM at m/z 449–553 for natural homocysteine,       
[1-13C]homocysteine and D4-homocysteine. Isotopic enrichments of both tracers were 
expressed as mole percent excess (MPE), and the concentration of homocysteine was 
calculated by isotope dilution as described (37). The frozen small intestine (n = 16) and a liver 
sample were homogenized and separated into free and bound fractions by adding 
sulfosalicylic acid (6%) to precipitate protein. The tissue-free fraction was then subjected to 
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cation exchange as described above, the eluant was dried under nitrogen, and derivatized by 
using ethylchloroformate. GC-MS analysis (Carlo Erba GC800 and Fisons MD800; Interscience 
BV, Breda, The Netherlands) was performed in electron-impact mode, and the ion abundance 
was monitored in SIM mode; m/z for natural methionine [M + 0], [1-13C]methionine [M + 1], 
and [2H3]methionine [M + 3] were 249, 250, and 252, respectively.  
 
CBS measurement 
Total RNA was isolated from the frozen porcine liver, jejunum, stomach, and pancreas 
samples and isolated jejunum cells by using RNeasy Mini kit (Qiagen, Valencia, CA). 
Approximately 100 ng of total RNA was used for each real-time qRT-PCR. Primers and probe 
designed from the porcine CBS mRNA (GenBank accession no. BP446783) were as follows: 
CBS forward primer (200 nM): CAGCGCTGCGTGGTGAT; CBS reverse primer (200 nM): 
CAGACTCTGTGCGCAACTACATGTCCAAG; and CBS TaqMan TAMRA probe (100 nM):         
6FAM-GCAGCATCCACTTGTCACTCA-TAMRA. Primers and probe of ribosomal RNA                
(18S rRNA; Applied Biosystems, Foster City, CA) were used as an internal control. Assays were 
performed in triplicate with an ABI Prism 7900 sequence detector (Applied Biosystems). Data 
were normalized to 18S ribosomal RNA (∆∆Ct analysis). CBS activity was determined as 
described (18, 43). Separate reactions were carried out in the presence and absence of         
1.0 mM SAM to test for allosteric induction of CBS.  
 
Calculations 
We quantified whole-body and GIT methionine, homocysteine, and CO2 kinetics as described 
(26, 37, 44) (see SI Appendix).  
 
Statistics 
Data are expressed as mean ± SEM. Differences in whole-body methionine kinetics between 
IV and ID infusions were analyzed by paired t test. Tissue samples were analyzed by paired      
t test and nonparametric Mann–Whitney test. A value of p < 0.05 was considered to be 
statistically significant. All statistical analyses were performed by using SPSS (version 11.0; 
SPSS Inc, Chicago, IL).  
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ABSTRACT 
 
Methionine is the only indispensable sulfur-containing amino acid and acts as a precursor 
for the dispensable sulfur amino acids homocysteine, cysteine and taurine. In preterm 
infants, however, cysteine is believed to be a conditionally indispensable amino acid as their 
enzymatic pathways involved in cysteine synthesis are still immature. The gastrointestinal 
tract plays a crucial role in methionine metabolism in newborn piglets and adult humans. 
Completely unexplored, however, is the possible role of the splanchnic tissues of human 
preterm infants in methionine metabolism, where cysteine synthesis could occur. 
Using tracer techniques we determined first-pass splanchnic methionine uptake in preterm 
infants and examined in vivo cysteine synthesis by incorporation of enteral serine in 
cysteine. Plasma methionine concentration was unchanged after 24 h of cysteine-free 
feeding, whereas the cystine concentration had decreased significantly. Fractional 
splanchnic first-pass methionine uptake accounted for 35 ± 15%. Surprisingly, cysteine was 
not synthesized de novo in first-pass. Thus, plasma cysteine concentration decreased in 
preterm infants after a period of cysteine-free feeding and splanchnic tissues do not use 
dietary serine for endogenous cysteine synthesis. These results might indicate that cysteine 
might be a conditionally essential amino acid in these infants. 
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INTRODUCTION 
 
Sulfur amino acids (SAA) have attracted much attention in the past few years mainly because 
of the link to cardiovascular disease (1) and neurological diseases (eg, Alzheimer’s disease)   
(2, 3). The SAA in humans are methionine, homocysteine and cysteine. Homocysteine was 
found to play an important role in pregnancy complications as well (4) and methionine in 
neural dysfunction (5). 
Methionine is the only indispensable amino acid and serves as a precursor for homocysteine 
and cysteine. The latter are, therefore, dispensable amino acids. Only methionine and 
cysteine are proteinogenic. Homocysteine acts as a key intracellular intermediary in the 
regulation of plasma methionine and cysteine concentrations. Methionine is crucial in several 
methylation processes, and its sulfur is indispensable to synthesize cysteine. Cysteine is a 
precursor for glutathione, which is a major intracellular antioxidant, as well as for CoA and 
taurine. 
Homocysteine formed from methionine can either be converted back to methionine or 
catabolized in the transsulfuration pathway by forming cysteine (Figure 1). In the latter 
pathway, homocysteine is condensed with serine to form cystathionine, which is regulated 
by the enzyme cystathionine ß-synthase (CBS, E.C. 4.2.1.22) in the liver. Subsequently, 
cystathionine is cleaved into α-ketobutyrate and cysteine by cystathionine γ-lyase               
(E.C. 4.4.1.1), whereby the serine carbon skeleton and the sulfur moiety of homocysteine 
together form cysteine.  
Cysteine is believed to be a conditionally indispensable amino acid in preterm infants in view 
of their biochemical immaturity (6). Several in vitro studies showed that CBS activity was 
limited or even absent in liver tissues of deceased preterm infants as compared with term 
infants (7-9). In vivo studies have reported that the transsulfuration pathway is certainly 
active and sufficient in very-low-birth-weight infants (10-12). In addition, Stegink and Den 
Besten (13) showed that besides the liver, the intestine might be important in methionine 
metabolism. This finding suggests an important role for the gut in cysteine production, which 
was confirmed in animal experiments (14). Recently, we have demonstrated in formula fed 
neonatal piglets that the gastrointestinal tissues are indeed a significant site for 
homocysteine and cysteine production (15). Yet we were not able to establish splanchnic first 
pass uptake of dietary methionine. As the piglets received a formula containing high cysteine 
concentrations, first-pass methionine metabolism could have gone unnoticed as a result of 
the methionine sparing capacity of cysteine, as described in animals and humans  (16, 17). 
Preterm infants might not be capable of synthesizing large amounts of cysteine de novo. In 
the present study we therefore determined the splanchnic methionine first-pass uptake in 
preterm infants fed a cyst(e)ine free diet. After 24-h adaptation, simultaneous enteral            
([U-13C]methionine and [1-13C]serine) and intravenous ([1-13C]methionine tracer infusions 
were performed to determine splanchnic methionine kinetics and to detect the serine carbon 
label in cysteine. 
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METHODS 
 
Subjects and study formula 
The study protocol was approved by the Central Committee on Research Involving Human 
Subjects, the Erasmus MC institutional review board and the Children’s Hospital Ethics 
Committee of Fudan University. Written and informed consent was obtained from parents of 
each subject. 
Patients eligible for the study were preterm infants born at gestational age (GA) < 37 wk with 
a birth weight < 2000 g, and admitted to the neonatal intensive care unit of the Children’s 
Hospital of Fudan University (Shanghai, China P.R.) in the first days of life. Infants needed to 
be clinically stable and those with any congenital, gastrointestinal or metabolic disease were 
excluded. Sufficient growth was ascertained from > 10 g/(kg·d) weight gain for at least four 
days. 
 Infants were enrolled in the study when they tolerated ≥ 120 mL enteral feeding/(kg·d). 
Those who did not tolerate an enteral intake of 150 mL/(kg·d) received additional glucose 
intravenously to provide a total intake of 150 mL/(kg·d). We used hydrolyzed, cyst(e)ine free 
study formula (Xcys/Neocate; Nutricia Nederland BV, Zoetermeer, the Netherlands/SHS 
International, Liverpool, UK) containing adequate amounts of methionine and vitamins B2 
(150 μg/100 mL formula), B6 (130 μg/100 mL formula), B11 (10 μm/100 mL formula) and B12 
(0.3 μg/100 mL formula). The formula amino acid profile is shown in (Table 1). 
 
Table 1. Amino acid profile of study formula. 
Amino acid 
  
Formula 
mg/100 ml 
Amino acid 
  
Formula 
mg/100 ml 
Kcal/100 ml 96   
Protein g/100 ml 2.73   
L-Alanine 128 L-Phenylalanine 152 
L-Arginine 227 L-Serine 149 
L-Aspartic acid 211 L-Threonine 167 
L-Cystine 0 L-Tryptophan 67 
L-Glycine 200 L-Tyrosine 152 
L-Histidine 129 L-Valine 218 
L-Isoleucine 206 L-Asparagine 0 
L-Leucine 335 L-Citrulline 0 
L-Lysine 232 L-Carnitine 2 
L-Methionine 54 L-Taurine 6 
L-Proline 242 L-Glutamine 287 
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Study design and tracer protocol 
The study diet was initiated 24 h before start of the tracer protocol to ensure that subjects 
could adapt to the study diet and cyst(e)ine intake. Prior to the study, all infants received 
standard formula for low-birth-weight infants (Prelactogen; Nestlé, China), which provided 70 
kcal per 100 mL. The total intake at the start of the study was left unaltered until completion 
the next day. All infants were bottle-fed every two hours. After 24-h adaptation, subjects 
simultaneously received enteral and intravenous tracer infusions to study methionine 
metabolism (Figure 1). Because interim analysis of plasma methionine enrichments showed 
low enrichments of the enteral tracer, we decided to increase infusion rates of all tracers. All 
infants simultaneously received enteral ([U-13C]methionine and [1-13C]serine (both sterile 
pyrogen free, > 99% atom percent excess (APE) and 98.7% APE, respectively; Cambridge 
Isotopes, Woburn, MA) and intravenous ([1-13C]methionine (sterile pyrogen free, > 99 % APE; 
Cambridge Isotopes) tracer infusions for 5 h. In the first 5 infants the primed continuous 
infusion rates of [U-13C]methionine, [1-13C]methionine and [1-13C]serine were 2.1 mmol/(kg·h), 
1.9 mmol/(kg·h) and 8.7 μmol/(kg·h), respectively. In the other infants the infusion rates of    
[U-13C]methionine, [1-13C]methionine and [1-13C]serine were 3.5 mmol/(kg·h), 3.0 mmol/(kg·h) 
and 14.2 μmol/(kg·h), respectively. One hour before start of the tracer infusions, the feeding 
regimen was changed into continuous drip-feeding. The enteral tracers were continuously 
infused together with the study formula by an infusion pump through a nasogastric tube.  
Altogether, 3 blood samples were obtained: the first at the start of the infusion protocol and 
2 during plateau phase after 270 and 300 min of infusion, respectively. In 6 subjects an 
additional blood sample was taken prior to the start of study formula. This sample served to 
compare plasma methionine and cysteine concentrations before initiation of the study 
formula and after 24 h of cyst(e)ine free feeding. Blood was centrifuged immediately and 
plasma was stored at -80 °C until shipment to the Netherlands by courier on dry ice. Upon 
arrival in Rotterdam, the Netherlands, the samples’ frozen state was confirmed for all 
samples, after which they were again stored at -80 °C until analysis. 
Figure 1. Study design. 
 
Analytical Methods 
Plasma amino acid concentrations (mmol/L) were determined by ion exchange 
chromatography with ninhydrin detection on a Biochrom 20 Amino Acid Analyser (Biochrom 
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Ltd, Cambridge, England). Plasma isotopic enrichments of [U-13C]methionine, remethylated 
[13C4]methionine and [1-13C]methionine, [1-13C]serine and [1-13C]cysteine were analyzed by 
gas chromatography-mass spectrometry (GC-MS). Plasma was treated with                               
1,4-dithioerythritol (0.2M) (99%, Sigma-Aldrich, St. Louis, MO, USA) for 30 min at room 
temperature to convert cystine into cysteine. Amino acids were isolated and derivatized 
using an EZ:Faast (easy-fast amino acid sampling testing) kit (Phenomenex, Torrance, CA, 
USA). Methionine and cysteine were derivatized to their propoxy-propylester (PCF, Sigma-
Aldrich, St. Louis, MO, USA) derivative. Plasma serine enrichment was measured using             
N-(t-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA, Sigma-Aldrich, St. Louis, MO, 
USA) derivative and was incubated overnight at room temperature. Analyses were performed 
on a Trace gas chromatograph coupled to a Thermo Electron DSQ mass spectrometer 
(Intersience BV, Breda, the Netherlands). A 30 m x 0.25 mm fused silica capillary column, 
coated with 0.25 μm VF1701 (Varian, Middelburg, the Netherlands) was used. Samples were 
measured with selected ion monitoring mode (SIM) and mass to charge (m/z) for natural 
methionine (M+0), [U-13C5]methionine ([M+5), [13C4]methionine (M+4), [1-13C]methionine 
(M+1) of 277, 282, 281 and 278 respectively. The m/z for natural serine (M+0) and [1-13C]-
serine (M+1) was 290 and 291, respectively. The m/z for natural cysteine (M+0) was 206 and 
[1-13C]cysteine (M+1) was 207. 
 
Kinetic Analyses and Calculations 
The methionine and serine paradigms are illustrated in Figure 2.  
Figure 2. Methionine metabolic pathways. MAT Methionine Adenosyltransferase, SAM S-adenosylmethionine, 
SAH S-adenosylhomocysteine, CBS Cystathionine ß-synthase, CGL Cystathionine γ-lyase, MS Methionine Syn-
thase, THF Tetrahydrofolate, MTHFR Methylene-tetrahydrofolate Reductase 
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The enterally administered [U-13C]methionine (M+5) that is transmethylated to homocysteine 
loses a labeled methyl group, yielding [13C4]homocysteine. This can be metabolized to 
methionine or be catabolized to form cysteine. Remethylation of [13C4]homocysteine to 
methionine with an unlabeled methyl group from 5-methyl-tetrahydrofolate results in [13C4]-
methionine (M+4). Transsulfuration of [13C4]homocysteine forms [13C4]cystathionine, which is 
then hydrolyzed to generate unlabeled cysteine. Or [1-13C]serine can be condensed with 
homocysteine to form cystathionine (M+1), whereby the sulfur moiety is transferred to the 
carbon skeleton of serine yielding [1-13C]cysteine. Besides, the C3 of serine may function as a 
methyl donor in the folate cycle via formation of glycine. (We, therefore, did not use [3-13C]-
serine, which forms [1-13C]-methionine that cannot be distinguished from the intravenously 
infused [1-13C]methionine.) The intravenously administered [1-13C]methionine is metabolized 
in the methionine cycle but yields unlabeled methionine and cysteine. 
We studied amino acid turnover according to Waterlow’s stable isotopic dilution model (18). 
Tracer dilutions were measured during steady state. Whole-body and splanchnic methionine 
kinetics were calculated using dual stable isotope tracer techniques (19, 20).  
Whole-body rate of appearance of enteral methionine was determined by the plasma [U-13C]-
methionine enrichment (M+5): 
 
 QMET_IG = iMET_IG x [(IEi/IEp)-1] 
 
where QMETIG is the rate of appearance of enterally infused [U-13C]methionine (μmol/(kg·h), 
iMET_IG is the enteral methionine infusion rate (μmol/(kg·h) and IEi and IEp are the isotopic 
enrichments (mol% excess of the M+5 enrichment) of the enterally administered [U-13C]-
methionine in the infusate and in plasma (M+5) at steady state, respectively. 
The rate of appearance of the intravenously administered methionine was based on the 
following equation: 
 
 QMET_IV = iMET_IV x [(IEi/IEp)-1] 
 
where QMET_IV is the rate of appearance of intravenously infused [1-13C]methionine           
(μmol/(kg·h), iMET_IV is the intravenous methionine infusion rate (μmol/(kg·h) and IEi and IEp are 
the isotopic enrichments (mol% excess of the M+1 enrichment) of the intravenously 
administered [1-13C]methionine in the infusate and in plasma (M+1) at steady state, 
respectively. 
First-pass methionine uptake was calculated as: 
 
 U = [(QMET_IG – QMET_IV)/QMET_IG] x I  
 
 where U is the first-pass methionine uptake (μmol/(kg·h), QMET_IG is the rate of appearance of 
the enterally administered methionine tracer (μmol/(kg·h), QMET_IV is the rate of appearance of 
the intravenously administered methionine tracer (μmol/(kg·h) and I is the intake of dietary 
methionine (μmol/(kg·h). 
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The whole-body rate of appearance of serine was calculated as follows: 
  
 QSER = iSER x [(IEi/IEp)-1] 
 
where QSER is the rate of appearance of enterally infused [1-13C]serine (μmol/(kg·h), iSER is the 
serine infusion rate (μmol/(kg·h) and IEi and IEp are the isotopic enrichments (mol% excess) of 
the [1-13C]serine in the infusate and in plasma at steady state, respectively. The plasma           
[1-13C]serine enrichment was corrected for overestimation of the intracellular [1-13C]serine 
that occurs when the enrichment of [1-13C]serine in plasma is used. The correction factor (0.4) 
is derived from adult human in vivo studies (21, 22). As no such correction factor is available 
for preterm infants, we assumed the same value would be applicable to our subjects.   
 
Statistics 
Data are expressed as mean ± SD and are obtained from the samples taken during the last 30 
min of the tracer infusions. A value of p < 0.05 was considered as statistically significant. 
Differences between plasma concentrations were analyzed by paired t test. Cysteine 
enrichments comparisons were performed by Student’s t test. Statistical analyses were 
performed by using SPSS software (version 14.0; SPSS, Inc, Chicago, IL). 
 
 
RESULTS 
 
Ten preterm infants were enrolled (Table 2). They were born at mean gestational age             
32 ± 2 wk, with a mean birth weight of 1.64 ± 0.16 kg. All infants were clinically stable at the 
time of the study and were growing > 10 g/day. Three infants received additional glucose 
intravenously to ensure sufficient caloric intake. The mean total sulfur amino acid intake was 
74 ± 9 mg/(kg·d). 
 
Table 2. Patient characteristics.  
Patient   Sex   
GA  
wk 
SA  
d 
BW  
kg 
SW  
kg 
Kcal  
kg/d 
1 M 31 15 1.64 1.70 130 65 
2 M 30 26 1.56 1.69 143 80 
3 F 32 13 1.95 1.94 125 64 
4 M 36 26 1.55 1.91 156 88 
5 M 30 16 1.84 1.81 146 82 
6 M 33 8 1.60 1.51 127 64 
7 F 31 9 1.65 1.58 117 66 
8 F 33 11 1.40 1.45 132 67 
9 M 32 14 1.74 1.72 141 79 
10 M 34 22 1.50 1.65 161 83 
Mean M/F 7/3 32 16 1.64 1.70 138 74 
SD    2 7 0.16 0.16 14 9 
Methionine  
mg/(kg·d) 
GA, gestational age; SA, study age; BW, birth weight; SW, study weight. 
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To define a possible effect of the study formula on the plasma amino acid profile, in 6 infants 
concentrations of all amino acids were determined prior to the introduction of the study 
formula and after 24 h of cyst(e)ine-free feeding (Table 3). Mean plasma methionine 
concentrations of the two feeding regimens did not differ (44 ± 5 versus 32 ± 11 μmol/L,         
p = 0.08). In contrast, plasma cystine concentrations differed significantly (37 ± 6 versus         
19 ± 8 μmol/L, p = 0.003). This finding implies that cyst(e)ine consumption exceeded 
endogenous synthesis. 
 
Table 3. Plasma amino acid profile before the introduction of the study formula (period A) and after 24 h of 
study formula feeding (period B). 
Data are expressed as mean ± SD (n=6). * Statistically significant p < 0.05. 
 
Plasma tracer enrichments after 5 h infusion and tracer kinetics are given in Table 4. 
Approximately one third of the dietary methionine was taken up by the splanchnic tissues in 
first-pass metabolism. We investigated the methionine remethylation by determining      
[13C4]methionine (see also Figure 1). Nevertheless, we were not able to detect enrichment in 
[13C4]methionine [M+4] by GC-MS, which indicates that under these conditions remethylation 
is not occurring on a large scale.  Since we found a relatively large enrichment in glycine 
(approximately 1 MPE), enough 5,10-methylene-THF, which contributes to the remethylation, 
should have been available. 
To investigate the endogenous cysteine synthesis we administered labeled serine enterally. 
Amino Acid 
 
Period A 
μmol/L 
Period B 
μmol/L 
Reference range (48) 
μmol/L 
Alanine 169 ± 61 217 ± 57 137-362 
Arginine 91 ± 17 109 ± 47 11-88 
Asparagine 65 ± 21 18 ± 8 16-21 
Aspartate 11 ± 1 9 ± 2 5-46 
Cystine 37 ± 6 19 ± 8 * 33-55 
Glutamate 74 ± 56 70 ± 28 76-551 
Glutamine 552 ± 149 384 ± 77 147-623 
Glycine 257 ± 45 329 ± 70 66-432 
Histidine 65 ± 10 71 ± 15 25-126 
Isoleucine 50 ± 8 82 ± 39 31-124 
Leucine 88 ± 11 151 ± 72 86-171 
Lysine 170 ± 53 186 ± 67 65-282 
Methionine 44 ± 5 32 ± 11 21-52 
Phenylalanine 62 ± 9 86 ± 17 35-112 
Proline 183 ± 50 264 ± 60   
Serine 162 ± 31 176 ± 17 79-227 
Taurine 66 ± 11 68 ± 16   
Threonine 316 ± 93 379 ± 110 67-143 
Tyrosine 123 ± 35 104 ± 22 48-122 
Valine 118 ± 17 163 ± 41 56-154 
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The serine carbon skeleton, together with the sulfur-moiety of homocysteine, is used for 
cysteine synthesis. We were not able, however, to detect labeled cysteine in plasma by either 
GC-MS and IRMS. The latter technique is 1000 times more sensitive and, therefore, able to 
detect enrichments below 0.1 mol % excess (MPE). Surprisingly, as mentioned above, plasma 
glycine enrichment was approximately 1 MPE, implicating that serine was metabolized to a 
large extent. 
 
Table 4. Tracer infusion rates, plasma enrichments and kinetics after 5 hours of infusion. 
Data are expressed as mean ± SD (n=10). MPE, mol % excess; WB Q, whole body flux. 
 
 
DISCUSSION 
 
In the present study we described the sulfur amino acid metabolism in enterally fed             
low-birth-weight infants. We aimed at quantifying the splanchnic first-pass uptake of dietary 
methionine and observing the endogenous cysteine synthesis by incorporation of enterally 
administered serine. Plasma cystine concentrations had decreased significantly after a period 
of cystine-free feeding. Surprisingly, under these conditions enteral administered serine had 
not been used for endogenous cysteine synthesis. 
Splanchnic tissues appear to have a key regulatory role in the distribution of dietary supplied 
amino acids in neonatal piglets and humans (23-26). The metabolic fates of sequestered 
dispensable and indispensable amino acid differ widely. For instance, the major metabolic 
fate of dietary glutamate in the splanchnic region is oxidation (27-29). In contrast, while in 
both neonatal animals and preterm infants the intestine extracts almost all threonine in first-
pass like for glutamate, yet the primary fate is mucosal (glyco-)protein synthesis instead of 
oxidation (30, 31). First-pass methionine uptake has been examined in both animals and 
humans. Studies in neonatal piglets showed that 20-50% of the dietary methionine was 
taken up by the portal drained viscera (liver, intestine, spleen, stomach and pancreas) in first-
pass metabolism (24, 32). In agreement with these findings, the total sulfur amino acid 
requirement for parenterally fed neonatal piglets, as defined by the methionine requirement 
in absence of dietary cysteine, was 30% lower than for enterally fed piglets (33). The latter 
finding indicates that also the intestine extracts dietary methionine in first-pass metabolism. 
Labeled amino acid 
  
Infusion 
  
Infusion rate 
  
Plateau enrichment 
  
WB Q 
  
First pass 
 uptake 
    μmol/(kg·h) MPE (%) μmol/(kg·h) % 
[13C5]methionine IG 2.67 ± 0.70 2.21 ± 0.70 120 ± 26 35 ± 15 
[13C1]methionine IV 2.38 ± 0.57 3.08 ± 0.55 75 ± 15   
[13C1]serine IG 10.56 ± 2.79 1.42 ± 0.27 727 ± 168   
[13C1]glycine   0 0.97 ± 0.16     
[13C1]cysteine   0 n.d.     
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In human adults the splanchnic methionine uptake ranged from 20-33% during the 
postabsorptive state (34, 35). During the fed state, no first-pass uptake was observed. 
Different from findings in fed adult humans but similar to findings in fasted adults, we found 
that 35% of the dietary methionine, in the absence of cystine, was taken up by the splanchnic 
tissues in the fed state. Furthermore, during enteral administration of [1-13C, methyl-2H3]-
methionine Raguso et al. (34) detected more [1-13C]methionine in both fed and fasted state 
than during intravenous administration. The methionine methyl group is donated in 
transmethylation and is therefore lost, while the carbon label is retained. Using the dual 
labeled methionine carries a high likelihood of underestimating first-pass metabolism 
because methionine is rapidly transmethylated to homocysteine in the gastrointestinal tract 
by losing the methyl label. Caution should be exercised in using this tracer. We therefore 
avoided the methyl labeled methionine and used two different labeled carbon tracers which 
intermediates do not overlap. 
We have previously shown that the intestine plays a key role in methionine metabolism (15). 
Approximately half of all methionine utilized by the gut was metabolized via 
transmethylation and one third via transsulfuration (cysteine synthesis). Given this 
knowledge, it is of interest to know the endogenous cysteine synthesis in humans and 
especially in preterm infants as their enzymatic pathway involving transsulfuration is likely to 
be still immature. To optimize the transsulfuration pathway, we removed cystine from the 
diet. We have previously concluded that cysteine is not a conditionally indispensable amino 
acid in low-birth weight infants (12). Consequently, it was ethically justified to eliminate 
cysteine from the diet for a short time. Transsulfuration requires vitamin B6 as a cofactor and 
was therefore adequately supplied according to estimated requirements for preterm infants 
already in the period before the infants entered the study (36). We did not determine vitamin 
B6 levels since this requires a large amount of blood, which cannot be drawn from these 
infants. To study endogenous cyst(e)ine synthesis we have used an established method 
previously applied in adult humans to study one-carbon metabolism (37-40). However, in 
these studies plasma cysteine enrichment could not be demonstrated. It is likely that the 
route of tracer administration plays a role in serine incorporation into cysteine. Stegink and 
Den Besten (13) demonstrated in adult humans fed a cystine-free diet but otherwise 
adequate amounts of methionine that plasma cystine concentrations were significantly 
lower during intravenous feeding than intragastric feeding. Thus, the intestine is an 
important site for cysteine synthesis. In contrast to previous studies, we therefore 
administered the serine tracer enterally, to amplify the effect of serine incorporation by the 
gastrointestinal tract. Nonetheless, like previously described for the intravenously 
administered labeled serine, we did not find labeled cysteine in plasma by using gas 
chromatography-mass spectrometry (GC-MS) techniques. To increase sensitivity we analyzed 
plasma cysteine enrichment again by isotope ratio mass spectrometry (IRMS), which is much 
more sensitive to detect a labeled carbon atom. Again, no labeled cysteine could be 
detected. Thus the enteral route of tracer administration did not yield labeled cysteine in 
plasma. Because approximately 95% of the serine flux is from endogenous synthesis (41), 
dilution of tracer might be an explanation. Another possible explanation is the limited tracer 
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infusion time. The infusion period lasted five hours, which could be too short for enteral 
serine to be incorporated in cysteine. Davis et al. used a nine hour tracer infusion period (39, 
40, 42). They also determined the plasma cystathionine enrichment derived from labeled 
methionine and showed that steady-state was achieved within four hours of tracer infusion. 
Thus, five hours should suffice to reach a steady-state transsulfuration rate. In addition, the  
[U-13C]methionine tracer model allows measurement of homocysteine transmethylation rate 
and remethylation rate by [13C4]homocysteine and [13C4]methionine, respectively. 
Unfortunately, we were not able to measure homocysteine enrichment in plasma. 
Surprisingly, we could not detect [13C4]methionine enrichment in plasma. Thus, 
homocysteine formed by transmethylation was not remethylated back to methionine but 
was immediately directed to transsulfuration, which yields undetectable unlabeled cysteine. 
Alternatively, the intestinal cyst(e)ine consumption exceeded the endogenous synthesis. 
Cysteine is not only needed for glutathione synthesis but also for the production of mucins, 
the building blocks of the mucus layer that contain large amounts of cysteine. A third 
possibility is use of cysteine for taurine and sulfate synthesis. We have not determined the 
presence of label in intestinal glutathione, mucin or taurine. 
We found a drop in plasma cystine concentration after a cystine-free feeding period of 24 h, 
while the plasma methionine concentration remained unchanged. Low plasma cysteine 
concentration is associated with total parenteral feeding (43-45), compared to plasma 
concentrations of the breast-fed or formula fed infant (33-55 μmol cystine/L). The initial 
cystine concentration of 37 ± 6 μmol/L plasma was within the reference range, but decreased 
significantly to 19 ± 8 μmol/L after 24 h of cystine-free feeding. Yet plasma concentration 
may not be the best primary endpoint to examine endogenous cysteine synthesis. It is a 
static measurement that does not provide information about the metabolic fate of an amino 
acid. Several studies have attempted to increase plasma cyst(e)ine concentration by cysteine 
supplementation during total parenteral feeding with no effect (46, 47). 
In conclusion, in enterally fed low-birth-weight infants at postmenstrual age of 34 wk the 
splanchnic tissues extract one third of the dietary methionine in first-pass. Under these 
conditions, enteral serine is not used for endogenous cysteine synthesis. Although recent 
studies conclude otherwise (10, 12), cysteine synthesis might be limited in preterm infants  
Further research should be aimed at examining the in vivo  transsulfuration pathway in 
preterm infants. 
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ABSTRACT 
 
The intestine is a major site of amino acid metabolism, especially in neonates. The energy 
needed for the metabolic processes in neonatal animals is derived from dietary glucose and 
amino acids. No data are available showing that dietary amino acids function as intestinal 
fuel source in human neonates as well. 
We hypothesized that preterm infants show a high splanchnic first-pass glutamate 
metabolism and the primary metabolic fate of glutamate is oxidation.  
Five preterm infants (birth weight 1.2 ± 0.2 kg, gestational age 29 ± 1 wk) were studied by 
dual tracer ([U-13C]glutamate and [D3]glutamate) techniques on two study days (within 
postnatal d 14-19). Splanchnic and whole-body glutamate kinetics were assessed by plasma 
isotopic enrichment of [U-13C]glutamate and [D3]glutamate and breath 13CO2 enrichment. 
Fractional first-pass glutamate uptake was 77 ± 18% on d 1 and 70 ± 7% on d 2, mean         
74 ± 13%. Almost all (86 ± 7%) of the glutamate used in first-pass is directed toward 
oxidation.  
There is a high splanchnic fractional first-pass uptake and a high oxidation rate of glutamate 
in preterm infants. Glutamate is an important source of energy for the splanchnic tissues in 
preterm infants receiving full enteral feeding. 
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INTRODUCTION 
 
The splanchnic tissues have much higher energy expenditure and protein synthesis rates 
than expected based on their weight. Studies in neonatal animals found that up to 50% of 
the dietary protein intake in the portal drained viscera (intestines, pancreas, spleen and 
stomach) is used for protein turnover and biosynthetic pathways; from 10 to 20% is used for 
whole-body energy expenditure (1-3). Humans also show considerable intestinal amino acid 
metabolism (4, 5) and the metabolic rate is even higher in preterm infants. Previous studies 
showed that first-pass metabolism of leucine in newborns is twice that of adults (6) and that 
in preterm infants, a great amount of dietary lysine is used in first-pass as well (7).  
Glutamate plays a pivotal role in human metabolism. It provides a critical link between 
carbohydrate and amino acid metabolism. Glutamate is the obligatory precursor of 
glutamine; it plays a central role in all transamination reactions in the body and also functions 
as a neurotransmitter. In addition, dietary glutamate is a major substrate for glutathione 
(GSH) synthesis (8). Animal studies showed that the gut of infant piglets metabolizes virtually 
all the enteral glutamate during absorption (9) and that glutamate is an important oxidative 
substrate for the intestinal mucosa (10). In human adults, most of the dietary glutamate 
(88%) is metabolized in first-pass as well (11) and it is oxidized to a great extent in the 
splanchnic region (12). These studies in animals and adult humans suggest that dietary 
glutamate serves as an important metabolic fuel source in the intestine. If so, this may have a 
particular impact on the nutritional needs of preterm infants. The intestine of preterm infant 
is immature and has a low tolerance to enteral feeding. Yet, enteral feeding is a must for 
intestinal maturation and the growth and development of other organs. Much effort should 
be directed toward understanding the nutritional needs of the intestine of preterm infants. 
The present study was developed to extend the previously mentioned observations made in 
animals and adult humans and thus gain more insight into the nutritional needs of infants. 
In the present study, we, therefore, investigated 1) the effect of first-pass splanchnic uptake 
of glutamate and 2) the metabolic fate of the used glutamate in the splanchnic bed of 
enterally fed preterm infants. Glutamate kinetics in the splanchnic region were studied by 
dual, primed, constant intravenous (IV) and enteral infusions of amino acids labeled with 
stable isotopes and preceded by an IV labeled sodium bicarbonate infusion as described 
before (2, 7). We hypothesized that preterm infants would show significant splanchnic first-
pass uptake and oxidation of glutamate.  
 
 
METHODS 
 
Patients 
The Erasmus MC Institutional Review Board approved the study. Written informed consent 
was obtained from parents or legal guardian. Eligible for this study were preterm infants 
admitted to the Neonatal Intensive Care Unit of the Erasmus MC-Sophia Children’s Hospital, 
Rotterdam, the Netherlands. Inclusion criteria were birth weight between 750 g and 1500 g, 
108 
Chapter 7 
C
ha
p
te
r 7
 
appropriate for gestational age according to the charts of Usher and Mclean and with CRIB 
scores < 5 on the first day of life (13). Exclusion criteria were congenital anomalies and 
gastrointestinal and liver diseases. All enrolled infants received full enteral feeding at the 
time of the study and were clinically stable. Nenatal (Nutricia Zoetermeer, the Netherlands) 
was the sole enteral nutrition from 10 h before start of the study and during both study days. 
 
Protocol 
To investigate splanchnic and whole-body glutamate kinetics, a crossover study design was 
applied on two consecutive study days. During the tracer infusion infants were fed 
continuously through a nasogastric tube. All received the same feeding regimen on both 
study days. A peripheral IV catheter was available for infusion of tracers during both days. 
Blood samples were obtained by heel stick. Breath samples were obtained by the direct 
sampling method as described previously (14, 15). Briefly, in mechanically ventilated 
neonates a syringe was connected to the ventilator tubing and breath samples were taken 
slowly during expiration with a total volume of 15 mL. When breathing was spontaneously a 
6F gastric tube (6 Ch Argyle; Cherwood Medical, Tullamore, Ireland) was inserted 1 to 1.5 cm 
into the nasopharynx and end-tidal breath samples were taken slowly with a syringe 
connected at the end. Collected air was transferred into 10-mL sterile, non-silicon-coated 
evacuated glass tubes (Van Loenen Instruments, Zaandam, the Netherlands) and stored at 
room temperature until analysis (15).  
Figure 1. Study design. 
 
The study design is depicted in Figure 1. Three different stable isotopes were infused during 
study d 1. First, a primed (10 μmol/kg) constant (10 μmol/(kg·h)) IV infusion of [13C]-
bicarbonate (99.0 mol% 13C; Cambridge Isotopes, Woburn, Massachusetts, USA) dissolved in 
sterile saline was administered IV for 2 h. This was immediately followed by primed 5-h 
infusions (30 μmol/kg and 30 μmol/(kg·h)) of [U-13C]glutamate (95.0 mol% 13C; Cambridge 
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Isotopes) and (30 μmol/kg and 30 μmol/(kg·h)) of [2,2,4-D3]glutamate (97.0 mol% D3; 
Cambridge Isotopes). [U-13C]glutamate was given via an IV catheter and [D3]glutamate via the 
intragastric catheter. On d 2, we switched the IV and intragastric routes. All isotopes were 
tested and found to be sterile and pyrogen free before use. On each day, baseline blood and 
breath samples were collected at time 0. During the last half hour of each tracer infusion, 
breath samples were collected at 15-min intervals and two blood samples were obtained 
after 4.5- and 5-h tracer infusion. The total amount of blood withdrawn per study day was   
1.5 mL, which is less than 2% of the blood volume in a 1000-g infant. Blood was centrifuged 
immediately and plasma was stored at -80°C for further analysis. 
 
Analytical methods 
Plasma enrichments of [U-13C]glutamate and [D3]glutamate were measured by gas 
chromatograph-mass spectrometry (GC-MS), using N-methyl-N-(tert-butyldimethyl)
silytrifluoroacetamide (MTBSTFA) derivates. Briefly, 50 μl of plasma was deproteinized with  
50 μl 0.24 M sulfosalicylic acid. After centrifugation (for 8 min at 4°C, and 14000x g), the 
supernatant passed over a Dowex cation-exchange resin column (AG 50 W-X8, hydrogen 
form, Bio-Rad Laboratories, Richmond, CA). The column was washed with 3 mL of water and 
the amino acids eluted with 1.5 mL 3 M NH4OH. The eluate was dried at 70°C under nitrogen 
and derivatives of the amino acids were finally formed by adding 35 μl acetonitrile and 10 μl 
of MTBSTFA (Pierce, Omnilabo, Breda, the Netherlands) and incubation at 60˚C for 30 min. 
Analyses were performed on a Carlo Erba GC8000 gaschromatograph coupled to a Fisons 
MD800 mass spectrometer (Intersience BV, Breda, the Netherlands) by injecting 1 μL with a 
split ratio of 50:1 on a 25 m x 0.22 mm fused silica capillary column coated with 0.11 μm HT5 
(SGE, Victoria, Australia). Ion abundance was monitored by selected ion monitoring and mass 
to charge for natural glutamate [M+0] was 432 and for D3-glutamate [M+3] and [U-13C]-
glutamate [M+5], 435 and 437, respectively.  
13CO2 isotopic enrichment in expired air was measured by isotope ratio mass spectrometry 
(ABCA; Europe Scientific, Van Loenen Instruments, Leiden, the Netherlands) and expressed as 
atom percent excess (APE) above baseline. APE was plotted relative to time. Steady state was 
defined as three or more consecutive points with a slope not different from zero. 
 
Calculations 
We studied amino acid turnover according to Waterlow’s stable isotopic dilution model (16). 
Whole-body CO2 kinetics were calculated as described previously (2). Substrate turnover was 
calculated by using dual stable isotope tracer techniques. Tracer dilutions were measured 
during steady state as described previously (7, 17, 18). The equations used to obtain the 
results are detailed in the Appendix. 
    
Statistics 
Data are expressed as mean ± SD values obtained from samples taken over the last hour of 
each tracer infusion. Differences in background and steady-state enrichments between the 
two study days were analyzed by paired t tests.  A value of p <0.05 was considered to be 
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statistically significant. Statistical analyses were performed by using SPSS software (version 
14.0; SPSS Inc, Chicago, IL). 
 
 
RESULTS 
 
Characteristics of the five enrolled infants are listed in Table 1. Their mean gestational age 
was 29 ± 1 wk and mean birth weight 1.18 ± 0.23 kg. All were clinically stable at the time of 
the study. On d 1, four infants needed supplemental oxygen by a nasal prong; on d 2 only 
two infants needed supplemental oxygen. They all needed caffeine to support breathing, but 
no other medication was prescribed. Baseline 13C enrichment in expired breath on d 1 (1.0867 
± 0.0005 APE) did not differ from that on d 2 (1.0889 ± 0.0029 APE) (p = 0.17) and were in the 
same range as we have found previously (15). Also, baseline enrichments of [U-13C]glutamate 
and [D3]glutamate in plasma did not significantly differ for the two study days. 
 
Table 1. Patient characteristics. 
GA, gestational age; BW, birth weight ; SA 1, postnatal age at day study d 1; SA 2, postnatal age at study d 2;   
SW 1, weight at study d 1; SW 2, weight at study d 2; Kcal = kilocalories/(kg·d). 
 
To calculate splanchnic and whole-body glutamate kinetics, we used plateau glutamate 
enrichment values from plasma (Table 2) and labeled carbon dioxide in expired breath. 
Although we obtained only two blood samples during the tracer infusions, a steady state 
must have been reached at the time we drew the plasma samples, because at that time the 
13CO2 excretion was at isotopic plateau. As shown in Figure 2, steady state of 13CO2 during 
enteral and IV [U-13C]glutamate infusion was achieved within 2 h of infusion. The slope of the 
line from time point 120 min to 300 min was not different from zero (p = 0.40). As expected, 
plateau enrichment (mole % excess) of the enterally administered tracer was much lower 
than that of the tracer administered IV.  
Table 3 shows the results of whole-body and splanchnic glutamate kinetics. The mean 
estimated whole-body CO2 production was 32.3 ± 5.3 mmol/(kg·h). These values are in the 
same range as we have reported previously (7, 15). The rate of appearance of [U-13C]-
glutamate or flux (Q) during IV administration on d 1 was 1287 ± 864 μmol/(kg·h).  
Patient 
 
GA 
wk 
BW 
kg 
SA 1 
d 
SA 2 
d 
SW 1 
kg 
SW 2 
kg 
Kcal 
 
1 31 1.29 9 11 1.25 1.28 108 
2 27 0.92 13 19 0.94 1.12 123 
3 29 1.45 15 17 1.46 1.48 106 
4 29 1.30 21 22 1.41 1.41 109 
5 30 0.96 12 25 0.96 0.99 101 
Mean 29 1.18 14 19 1.20 1.26 109 
SD 1 0.23 4 5 0.25 0.20 8 
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Table 2. Steady state isotopic enrichments of [U-13C]glutamate and [D3]glutamate in plasma on study d 1 and 2 
 
The [D3]glutamate flux during IV infusion on d 2 was 1900 ± 1061 μmol/(kg·h). The QIV on 
study d 1 did not significantly differ from QIV on d 2 (p = 0.34). Based on the rate of 
appearance during IV administration of [U-13C]glutamate, the mean whole-body oxidation of 
glutamate was 1052 ± 721 μmol/(kg·h). The fractional first-pass uptake is the fraction of 
dietary glutamate, directly absorbed through the splanchnic system. It amounted to 77          
± 18% and 70 ± 7% on the first and second study days, respectively.  
 
Table 3. Whole-body and splanchnic glutamate kinetics in preterm infants (n=5). 
I, glutamate intake (μmol/(kg·h)) and was equal on d 1 and 2; Q, flux (μmol/(kg·h)); FFP, fractional first pass 
uptake (%); AFP, absolute first pass uptake (μmol/(kg·h)); d 1, study d 1; d 2, study d 2; mean FFP and AFP, 
average of d 1 and 2. 
Patient 
[U-13C]glutamate 
(mol% excess) 
  Day 1 ∆ Day 2 ∆ 
  4.5h 5h mean 4.5h 5h mean 
1 0.82 0.91 0.87 0.50 - 0.72 
2 3.99 4.06 4.01 1.23 1.45 1.61 
3 3.19 3.15 3.17 0.44 0.44 0.68 
4 1.54 1.77 1.66 0.19 0.15 0.38 
5 2.22 2.27 2.25 0.18 0.18 0.50 
Mean 2.35 2.43 2.39 0.51 0.56 0.52 
SD 1.27 1.22 1.23 0.43 0.61 0.47 
Patient 
[D3]glutamate 
(mol% excess) 
  Day 1 ∆ Day 2 ∆ 
  4.5h 5h mean 4.5h 5h mean 
1 0.41 0.63 0.52 1.63 - 1.63 
2 0.53 0.51 0.52 3.57 3.65 3.60 
3 0.50 0.46 0.48 1.72 1.68 1.70 
4 0.43 0.43 0.43 0.72 0.78 0.75 
5 0.40 0.45 0.43 1.24 1.28 1.26 
Mean 0.45 0.50 0.48 1.78 1.85 1.79 
SD 0.06 0.08 0.05 1.08 1.26 1.08 
Patient 
 
I 
 
       QIV 
 d 1          d 2 
QIG 
d 1         d 2 
FFP 
d 1        d 2 
AFP 
d 1      d 2 
Mean 
FFP     AFP 
1 185 2736 1645 5084 5001 0.46 0.67 86 123 0.57 104 
2 188 584 661 5003 1684 0.88 0.61 185 101 0.75 143 
3 181 720 1607 5700 5298 0.87 0.70 159 125 0.79 142 
4 186 1357 3575 6320 13164 0.79 0.73 146 136 0.76 141 
5 173 1036 2012 6132 10705 0.83 0.81 146 138 0.82 142 
Mean 183 1287 1900 5648 7170 0.77 0.70 144 125 0.74 1344 
SD 6 864 1061 596 4656 0.18 0.07 36 15 0.13 28 
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Whole-body glutamate oxidation accounted for 82 ± 7% of the glutamate turnover, and the 
fraction of dietary glutamate that was oxidized by the splanchnic bed in first-pass was           
86 ± 7%. This latter finding emphasizes that glutamate is an important source of oxidation for 
the splanchnic system. 
Figure 2. Enrichments of 13C in expired breath during IV infusion of [U-13C]glutamate on d 1 (upper) and 
intragastric [U-13C]glutamate infusion (lower) on d 2. Rates are expressed as mean APE ± SD (n=5). 
 
 
DISCUSSION 
 
The aim of our study was to quantify the need for glutamate in the splanchnic tissues of 
premature infants by measuring splanchnic first-pass uptake and oxidation during full enteral 
feeding. Splanchnic first-pass glutamate uptake and oxidation rates were found to be very 
high. Approximately three fourths of the dietary glutamate intake was consumed in first-
pass. Most of the extracted glutamate was then oxidized, indicating that oxidation is the 
metabolic fate of dietary glutamate in the premature infant.  
Our results agree with those from animals (9) and human studies (11, 12). Additionally, and in 
agreement with our results, in this issue Haÿs et al. demonstrate that the primary fate of 
dietary glutamate in premature infants is splanchnic extraction (19). This finding, which 
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indicates that dietary glutamate is not a significant gluconeogenic substrate, is not 
surprising, seeing that we showed that oxidation is the primary metabolic pathway of 
enterally absorbed glutamate. The present data demonstrate a wide range in the mean 
glutamate flux, which expectedly was higher than observed in human adults. Both the IV and 
intragastric flux on the second study day were higher than on d 1, despite the fact that the 
infant’s glutamate intake showed little variation. Clearly, the difference is large, yet not 
significant due to a small number of subjects and therefore a wide variance. However, as the 
first-pass splanchnic uptake showed a very small range, we may assume that the data are 
reliable. No such differences have been reported in animal studies (9, 20, 21). An explanation 
of the small range in outcome in animal studies could be the identical experimental setting 
or genetic similarity because animals used in these studies usually are descended from the 
same litter. Identical experimental setting is hard, if not impossible, to organize in human 
studies.  
When glutamate is delivered enterally, it must pass through the enterocytes during 
absorption and could be used at that stage for transamination to the formation of                     
α-ketoglutarate. The labeled α-ketoglutarate enters the Krebs cycle where the first 13C label is 
lost by decarboxylation, thereby producing 13CO2. However, it does not necessarily lead to 
complete glutamate oxidation; the remaining carbon atoms could also be used for synthesis 
of other metabolic compounds, eg, pyruvate, alanine and lactate. Animal studies reported 
that only a minor proportion of labeled pyruvate, derived from intragastric administered      
[U-13C]glutamate, was converted to alanine and lactate and released into venous blood         
(1, 20). Apart from oxidation, glutamate can also act as a precursor for proline, arginine and 
GSH. In rats, approximately 64% of the glutamate was released as CO2 and 10% was 
incorporated in amino acids such as proline, ornithine and alanine; the latter accounted only 
for 3% of the carbon label incorporation (20). We were not able to determine the quantity of 
labeled alanine, lactate and pyruvate. Thus, the contribution of 13CO2 from oxidation from 
these products could not be quantified. We found a fractional glutamate oxidation of 86%, 
which indicates that complete oxidation is unlikely. However, from animal data, we 
hypothesize that the contribution of labeled CO2 from these amino acids is relatively small 
and that the fractional glutamate oxidation is not overestimated. Reeds et al. (9) showed in 
infant piglets infused with [U-13C]glutamate [M+5] that lower mass isotopomers appeared in 
plasma and determined the degree to which the 13C label is recycled in intermediary 
metabolism: 11% of the labeled glutamate appeared in [M+1] and [M+3] isotopomers. We, 
however, were not able to determine the present abundance of plasma [13C3]glutamate 
[M+3] because the [D3]glutamate tracer has a mass of [M+3] as well and thus could not be 
distinguished from the [13C3]glutamate produced from intermediary metabolism. 
Nevertheless, plasma [D3]glutamate enrichment on d 1 is very low (0.48 MPE) and 
contribution of 3-carbon products (M+3) from [U-13C]glutamate was minimal. The same held 
true for the second study day. 
Several animal studies have shown that enterally derived glutamate is preferentially 
metabolized above systemically derived glutamate (9, 20). This could have important 
consequences for preterm infants receiving full parenteral feeding, with nutrients bypassing 
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the intestine. In these infants, only systemically derived glutamate is available and uptake by 
the enterocytes will be diminished, resulting in a decrease in glutamate as an energy 
substrate. Conversely, they have lower energy requirements (90 kcal/(kg·d)) than preterm 
infants who receive full enteral feeding (120 kcal/(kg·d)) (22). This difference may be due to 
the energy needs of the splanchnic tissues, loss of nutrients, or intestinal (glyco-)protein 
synthesis and thus energy storage during enteral nutrition. In general, approximately               
8-14 kcal/(kg·d)) is lost in stools (23). Fuel sources used by the gut to generate energy for 
synthesis purposes could be glucose, amino acids, or fatty acids. We showed earlier that 
glucose is an important intestinal energy source for preterm infants (18). The splanchnic 
tissues use one third of the dietary glucose in first-pass and approximately 80% of this 
amount is oxidized; thus, most of the glucose is used for energy generation. The same 
pattern is found for glutamate, with 86% of the dietary glutamate oxidized in first-pass, 
approximately 14 mmol glucose/(kg·d) is oxidized in the splanchnic tissues, accounting for  
10 kcal/(kg·d). Glutamate first-pass oxidation yields an additional 1.7 kcal/(kg·d). Thus, 
besides glucose, glutamate oxidation by the splanchnic tissues is an important source of 
energy. It seems likely that the glutamate demand depends on other available oxidative 
substrates as well and that the splanchnic glutamate oxidation rate is related to the dietary 
glutamate load. In piglets, we found that the intestinal glutamate oxidation was significant 
lower during low protein feeding compared with normal protein intake (10). We, therefore, 
expect that the splanchnic fraction of glutamate oxidation will increase if more dietary 
glutamate is provided. 
Although glutamate is a nonessential amino acid, its availability has many clinical 
implications. Apart from oxidation and incorporation into proteins, glutamate is a precursor 
of the synthesis of several other amino acids and for GSH synthesis. This is a tripeptide 
consisting of glutamate-cysteine-glycine and is the most important intracellular antioxidant; 
especially in preterm infants receiving supplemental oxygen causing increased oxidative 
stress. Mucosal and luminal GSH both play an evident role against oxidative damage in the 
mucosa resulting from peroxidative damage and dietary toxins (24). Reeds et al. (8) showed 
that enterally derived glutamate is the preferential source for mucosal GSH synthesis in 
neonatal piglets. Approximately 85% of the mucosal GSH-glutamate derived from dietary 
glutamate, and at 500-600% per day, the fractional GSH synthesis rate was extremely high. If 
the intestine oxidizes almost all dietary glutamate, the quantity of glutamate left may be 
insufficient to maintain the preterm infant’s demand for GSH production. About 135 μmol 
glutamate/(kg·h) is used by the enterocytes in first-pass and 116 μmol glutamate/(kg·h) 
thereof is oxidized. Thus, a maximum of 19 μmol glutamate/(kg·h) is left for intestinal GSH 
synthesis or for other proteins. In neonatal piglets GSH synthesis required the provision of   
25 μmol glutamate/(kg·h) with a four times higher intake. The minimal glutamate 
requirement for GSH synthesis during stress and illness in human neonates is not yet known. 
Animal data, however, strongly indicate that mucosal GSH-glutamate derives mainly from 
dietary glutamate. This could have implications for parenterally fed infants as they lack 
supply of luminal (dietary) glutamate during parenteral feeding. The intestinal GSH synthesis 
may be restricted and therefore limit protection against oxidative injury. 
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Another important question is whether glutamate should be added to oral rehydration 
solutions (ORS). The standard ORS solutions (World Health Organization recommended) 
nowadays contain glucose and electrolytes but not glutamate. However, if the gut is at risk 
during diarrhea, glutamate might play an important role in restoring essential functions of 
the enterocytes as energy source and a precursor of protein synthesis and possibly also of 
increased GSH production. However, glutamate added to ORS will increase osmolarity. 
Clinical studies are needed to determine the precise effects of added specific amino acids 
such as glutamate. 
A limitation of this study is that we determined glutamate kinetics in only five premature 
infants. However, the results demonstrate clearly that the splanchnic bed sequesters most of 
the enteral glutamate tracer in first-pass. We hypothesized that the intestine has a very high 
first-pass effect and is a major site of oxidation in neonates. The results of this study 
demonstrate that the splanchnic tissues are indeed a major site of metabolism and oxidation. 
 
 
APPENDIX 
 
Glutamate flux during IV infusion was calculated as follows (7): 
 
QIV = iglu_iv x [(IEi/IEp)-1]      (1) 
 
where QIV is the flux of the IV infused tracer (μmol/(kg·h), iglu_iv is the IV glutamate infusion rate 
(μmol/(kg·h) and IEi and IEp are the isotopic enrichments (mol% excess) of IV administered    
[U-13C or D3]glutamate in the infusate or in plasma at steady state, respectively. 
The flux for the intragastrically administered tracer was calculated as follows: 
 
 QIG = iglu_ig x [(IEi/IEp)-1]      (2) 
 
where QIG is the flux of the intragastric infused tracer (μmol/(kg·h), iglu_ig is the intragastric 
glutamate infusion rate (μmol/(kg·h) and IEi and IEp are the isotopic enrichments               
(mol% excess) of intragastrically administered [U-13C or D3]glutamate in the infusate or in 
plasma at steady state, respectively. 
First-pass glutamate uptake was calculated as: 
 
 U = [(QIG – QIV)/QIG] x I       (3) 
 
 where U is the first-pass glutamate uptake (μmol/(kg·h), QIG is the flux of the intragastrically 
administered glutamate tracer (μmol/(kg·h), QIV is the flux of the IV administered glutamate 
tracer (μmol/(kg·h) and I is the intake of enteral glutamate (μmol/(kg·h). 
Whole-body CO2 production was estimated as: 
 
 CO2 production = IB x [(IEiB/IEB)-1]     (4) 
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where IB is the infusion rate of [13C]sodium bicarbonate (μmol/(kg·h), IEiB is the enrichment 
(mol% excess) of [13C]bicarbonate in the bicarbonate infusate and IEB is the 13CO2 enrichment 
at steady state during the labeled bicarbonate infusion (mol% excess). Splanchnic and whole-
body glutamate oxidation rates were determined under the assumption that CO2 production 
during [13C]bicarbonate infusion equals the labeled glutamate tracers infusion. Assuming a 
constant CO2 production rate during the 7 h of infusion, it is not necessary to use a correction 
factor for retention of [13C]bicarbonate in the body (25). 
Glutamate oxidation was calculated by multiplying recovery of [13C]glutamate in expiratory 
air with the rate of appearance of glutamate (7, 25). The fraction of glutamate oxidized using 
the enrichment of the IV [U-13C]glutamate infusion on study d 1 and intragastric [U-13C]-
glutamate on study d 2 was calculated as: 
 
 Fractional glutamate oxidation = [IEglu x iB]/[IEB x iglu x 5]  (5) 
 
where IEglu and IEB are 13CO2 enrichments (mol% excess) in expired breath at steady state 
during IV (d 1) or intragastric (d 2) [U-13C]glutamate and [13C]bicarbonate infusion. The iglu is 
multiplied by a factor 5 to account for the number of labeled C atoms.  
Whole-body glutamate oxidation (d 1) was calculated as: 
 
 Whole body glutamate oxidation = eqn (5)IV x eqn (1)IV  (6) 
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ABSTRACT 
 
The intestine is a major site of amino acid metabolism, especially in neonates. Neonatal 
animals derive the energy needed for metabolic processes from dietary glucose and amino 
acids. Rats were found to oxidize aspartate in the intestine as well at a high rate. We have 
previously found that glutamate and glucose are important sources of energy for the 
splanchnic tissues in preterm infants receiving full enteral feeding. However, no data are 
available on splanchnic aspartate metabolism in human preterm infants.  
The aim of our study was to investigate whole-body and splanchnic aspartate metabolism 
and to determine the primary splanchnic metabolic fate of aspartate.  
Eight, enterally fed, preterm infants (birth weight 1.34 kg ± 0.43 SD, gestational age 31 wk   
± 3 SD, range: 26-34 wk) were studied by dual tracer ([U-13C]aspartate and [D3]aspartate) 
techniques. Splanchnic and whole-body aspartate kinetics were assessed by plasma 
isotopic enrichment of [U-13C] and [D3]aspartate and breath 13CO2 enrichments.  
Splanchnic first-pass aspartate uptake was almost complete (77 ± 15%). Almost all (80 ± 9%) 
of the aspartate used in first-pass is directed toward oxidation. 
In conclusion, the splanchnic tissues extract almost all of the dietary aspartate in preterm 
infants. As is the case for glutamate, in preterm infants receiving full enteral feeding the 
major fate of dietary aspartate is oxidation within the splanchnic tissues in first-pass 
metabolism. 
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INTRODUCTION 
 
In utero the fetus obtains nutrients from cord blood. After birth the term newborn receives 
nutrients from breastfeeding or formula feeding, resulting in a shift from glucose as the main 
source of energy to a mixture of carbohydrates and fat. During enteral nutrition the gut is 
essential in digesting and absorbing nutrients. Consequently, maturation of the 
gastrointestinal tract is of crucial importance in the adaptation from intrauterine to extra 
uterine life. As preterm infants still have an immature gut, however, most of them will receive 
total parenteral nutrition (TPN) during the first period of life. Although in theory mimicking 
fetal nutrition, TPN is associated with high morbidity, e.g. cholestasis (1) or sepsis (2). It is, 
therefore, advisable to switch to enteral route of feeding as soon as possible. Transition from 
parenteral to enteral substrates has large implications for the energy balance. Energy 
expenditure and the use of substrates by the portal-drained viscera (spleen, stomach, 
intestines and pancreas; PDV) are determined by the route of nutrient administration. For 
example, enteral nutrition stimulates the secretion of gut hormones (3) and causes intestinal 
protein accretion and intestinal growth in neonatal pigs (4). The high impact of these effects 
becomes clear from the fact that the PDV account for less than 5% of the bodyweight but are 
responsible for up to 35% of whole body energy expenditure during enteral feeding (5). In 
the late seventies and early eighties, Windmueller and Spaeth found that dietary glutamate, 
aspartate and glucose and arterial glutamine are the major intestinal fuel sources in rats (6-8). 
In addition, we found that in neonatal piglets the PDV extract almost all (>90%) of the 
glutamate, glutamine and aspartate in first-pass (9). Since these amino acids do not appear in 
the portal vein we hypothesize that they are utilized by the PDV for oxidative purposes and 
energy generation. Research efforts have been directed at elucidating the substrate use of 
the human neonatal intestine. Van der Schoor et al. (10) found that in preterm infants 
approximately one-third of dietary glucose is utilized in first-pass during full enteral feeding 
and more than three-quarters is directed toward oxidation. Recently, we documented a 
similar fate for dietary glutamate: three-quarters was taken up by the intestine in first-pass 
metabolism and almost all of that was channeled toward oxidation (11). In contrast, the 
indispensable amino acid threonine was almost completely utilized in first-pass metabolism 
but was not used for oxidation (12). Clearly, these findings indicate that dispensable amino 
acids are important substrates for energy supply in the intestine.  
Aspartate is a dispensable amino acid, which means that it can be synthesized de novo. It 
serves as a major nitrogen transporter by transamination and is the second amino group 
donor in the urea cycle. Furthermore, aspartate is an excitatory neurotransmitter and is 
involved in gluconeogenesis.  
In general purpose of the present study was to quantify splanchnic and whole-body 
aspartate metabolism in premature infants on full enteral feeding. Having this knowledge 
will enable to meet the specific nutritional requirements of the premature neonate and to 
develop strategies to optimize gut function early after birth. We hypothesized that like 
glutamate, aspartate is also a major oxidative fuel for the intestine.  
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METHODS 
 
Subjects 
Eligible patients were premature infants with a birth weight ranging from 1000 to 2000 
grams born in the Children’s Hospital, Fudan University, Shanghai or the Erasmus MC - 
Sophia Children’s Hospital Rotterdam or having been admitted to the NICU of either hospital 
< 24 hours after birth. Exclusion criteria were congenital metabolic disease, congenital 
intestinal disease, malformations and abnormal liver or kidney function. The study protocol 
was approved by the Fudan Hospital Ethical Review Board (Shanghai, PR China), the Erasmus 
MC Institutional Review Board (Rotterdam, the Netherlands) and the Dutch Central 
Committee on Research Involving Human Subjects (the Hague, the Netherlands). The study 
was conducted according to European Good Clinical Practice Regulations, the Declaration of 
Helsinki and relevant Ethical and Regulatory considerations. All infants were clinically stable 
at the time of the study and tolerated full enteral feeding. Feeding regimen was according to 
standard clinical practice at the participating hospitals. All infants received a standard 
preterm formula (Nenatal Start, Nutricia, Zoetermeer, the Netherlands, 75 kcal/100 mL) as the 
sole nutrition starting at least 24 h before start of the study until completion.  
 
Protocol 
To investigate splanchnic and whole body aspartate kinetics, a crossover study design was 
performed using dual tracer techniques on two separate days. Between the study days one 
intervening day was planned to allow the isotopes to be washed out. The general outline of 
the study is depicted in Figure 1. During both study days infants were implanted with an 
intravenous catheter for stable isotopes infusion. Starting one hour before the onset of the 
tracer protocol, infants were continuously fed through an intragastric tube until completion. 
All received the same feeding regimen on both study days.  
Figure 1. Study design. 
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Breath sampling was performed by the direct sampling method as described previously     
(13, 14). In brief, a 6F gastric tube (6 Ch Argyle; Cherwood Medical, Tullamore, Ireland) was 
placed 1 to 1.5 cm into the nasopharynx and end-tidal breath was taken slowly with a syringe 
connected to the end. Collected air was transferred into 10 mL sterile, non-silicon-coated 
evacuated glass tubes (Van Loenen Instruments, Zaandam, the Netherlands) and stored at 
room temperature until analysis.  
During the first study day three different stable-isotopes infusions were performed. First, a 
primed (10 μmol/kg) continuous (10 μmol/(kg·h) intravenous infusion of [13C]bicarbonate 
(99.0 mol% 13C; Cambridge Isotopes, Woburn, Massachusetts, USA) dissolved in sterile saline 
and was administered intravenously for two hours. This served to assess individual whole-
body CO2 production. The 13C labeled bicarbonate infusion was immediately followed by two 
primed 5-h infusions (15 μmol/kg and 15 μmol/(kg·h)) of [U-13C]aspartate (98.0 mol% 13C; 
Cambridge Isotopes) intravenously and (15 μmol/kg and 15 μmol/(kg·h)) of [2,2,4-D3]-
aspartate (98.0 mol% D3; Cambridge Isotopes) enterally. The route of labeled aspartate 
administration was switched on study day 2. The simultaneous infusion of different labeled 
aspartate allowed us to determine whole-body and splanchnic aspartate kinetics. All tracers 
were found to be sterile and pyrogen free before use in our studies. Baseline blood and 
breath samples were collected at time 0. Breath samples were collected every 30 minutes. 
During the last hour of each tracer infusion, breath samples were collected at 15-min intervals 
and two blood samples were obtained after 4.5 h and 5 h tracer infusion. Blood samples were 
collected by arterial blood puncture and blood was centrifuged immediately. Plasma samples 
were stored at -80ºC until further analysis. The total amount of blood withdrawn per study 
day was 1.5 mL, which is less than 2% of total blood volume in a 1000-g infant. 
 
Analytical Methods 
Plasma enrichments of [U-13C4]aspartate and [2,2,3-D3]aspartate were measured by gas 
chromatography-mass spectrometry (GC-MS), using N-methtyl-N-(tert-butyldimethyl)silyl 
derivates. Briefly, 100 μL of plasma was deproteinized with 100 μL of 0.24 M sulfosalicyclic 
acid. After centrifugation (for 8 min at 4°C, and 14,000x g), the supernatant was passed over a 
Dowex cation-exchange resin column (AG 50W-X8, hydrogen form, Bio-Rad Laboratories, 
Richmond, CA). The column was washed with 3 mL of water and the amino acids eluted with 
1.5 mL M NH4OH. The eluate was dried at room temperature in a speedvac (Savant, 
Thermofisher, Breda, the Netherlands) and derivatives of the amino acids were finally formed 
by adding 25 μL aceto-nitrile and 50 μL of MTBSTFA (Pierce, Omnilabo, Breda, the 
Netherlands) and incubation at 60°C for 60 min. Analyses were performed on a Trace gas 
chromotograph coupled with a Thermo DSQ mass spectrometer (Interscience BV, Breda, the  
Netherlands) by injecting 0.5 μl on a PTV injector and a 30 m x 0.25-mm VF-17ms  0.25 μm 
coated fused silica capillary column (Varian, Middelburg, the Netherlands). Ion abundance 
was monitored by selective ion monitoring, and mass to charge (m/z) for natural aspartate  
[M+0] at m/z 418.3 and for [2,3,3-D3 ]aspartate [M+3] and [U-13C4]aspartate [M+4] at m/z 421.3 
and 422.3, respectively.   
13CO2 isotopic enrichment in expired air was measured by isotope ratio mass spectrometry 
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(ABCA; Europe Scientific, Van Loenen Instruments, Leiden, the Netherlands) and expressed as 
atom percent excess (APE) above baseline. APE was plotted relative to time. Steady state was 
defined as three or more consecutive points with a slope not different from zero.  
13CO2 isotopic enrichment in expired air was measured by isotope ratio mass spectrometry 
(ABCA; Europe Scientific, Van Loenen Instruments, Leiden, the Netherlands) and expressed as 
atom percent excess (APE) above baseline. APE was plotted relative to time. Steady state was 
defined as three or more consecutive points with a slope not different from zero.  
 
Calculations 
We studied amino acid turnover according to Waterlow’s stable isotopic dilution model (15). 
Whole-body CO2 kinetics were calculated as described previously (16). Substrate turnover 
was calculated by using dual stable isotope tracer techniques. Tracer dilutions were 
measured during steady state as described previously (10-12, 17, 18). The equations used to 
obtain the results are detailed in the Appendix. 
 
Statistics 
Data are expressed as mean ± SD values or as medians and 25th and 75th percentiles 
obtained from samples taken over the last hour of each tracer infusion. Differences in 
background and steady-state enrichments between the two study days were analyzed by 
paired t tests.  A  value of p < 0.05 was considered to be statistically significant. Statistical 
analyses were performed using SPSS software (version 14.0; SPSS Inc, Chicago, IL). 
 
 
RESULTS 
 
Eight preterm infants were included. Their characteristics are listed in Table 1. Mean 
gestational age was 31  ±  3 wk (range: 26 - 34 wk) and mean birth weight was 1.34 ± 0.43 kg. 
Patients 1-6 were included in the Fudan Children’s Hospital and patients 7-8 in the Erasmus 
MC-Sophia Children’s Hospital. All were clinically stable at the time of both study days and 
were breathing spontaneously. They all tolerated enteral feeding well and none of them had 
sepsis or unstable temperature, as these were exclusion criteria. Average aspartate intake 
was 109 ± 5 μmol/(kg·h). 
Mean baseline 13CO2, expressed as atom percent excess (APE), on study d 1 (1.0871 ± 0.0016 
APE) did not significantly differ (p = 0.2) from that on d 2 (1.0878 ± 0.0012 APE). Baseline 
plasma enrichments of [U-13C]aspartate and [2,2,4-D3]glutamate did not significantly differ 
between the two study days (p = 0.08, p = 0.5, respectively).  
Splanchnic and whole-body kinetics were calculated from plasma aspartate enrichments 
(Table 2) and 13CO2 enrichments in expired breath during steady-state. As shown in Figure 2, 
the 13CO2 excretion in breath reached an isotopic plateau during both IV and IG [U-13C]-
aspartate infusions on d 1 and d 2, respectively. During IV infusion the slope of the line from 
time point 300 min to 420 min was not different from zero (p = 0.5). Also during IG infusion 
the slope of the line was not significantly different from zero (p = 0.9).  Although we obtained  
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only two blood samples during the tracer infusions, we assumed that plasma enrichment also 
had reached steady-state because the 13CO2 enrichment in breath was at isotopic plateau. 
 
Table 1. Patient characteristics. 
GA, gestational age; BW, birth weight; SA 1, postnatal age at day study day 1; SA 2, postnatal age at study day 
2; SW 1, weight at study day 1; SW 2, weight at study day 2. 
 
Table 2. Steady-state isotopic enrichments of [U13C]aspartate and [D3]aspartate in plasma on study d 1 and 2. 
Rates are expressed as median; 25th–75th percentile in parentheses. 
 
Table 3 shows the results of whole-body and splanchnic kinetics. The mean estimated whole-
body CO2 production was 28.97 ± 1.54 mmol/(kg·h). The mean rate of appearance, or flux (Q) 
of [U-13C]aspartate, administered intravenously was 129 (100-170) μmol/(kg·h) on d 1 and 156 
(131-502) μmol/(kg·h) on d 2. The splanchnic fractional first-pass uptake of aspartate is the 
fraction of aspartate directly taken up from the diet by the splanchnic tissues (intestine and 
liver) and which therefore does not appear in the systemic circulation. It amounted to             
90 ± 3% on d 1 and 64 ± 10% on d 2 (mean d 1 and d 2: 77 ± 15%). Whole-body aspartate 
oxidation was calculated from the flux of the intravenously infused [U-13C]aspartate (equation 
6) on day 1. The median whole-body oxidation was 80 ± 9 μmol/(kg·h). The fraction of 
aspartate oxidized by the splanchnic tissues in first-pass was 81 ± 8% on the first study day 
and 80 ± 11% on the second day (mean d 1 and d 2: 80 ± 9%). This result confirms our 
hypothesis that aspartate, like glutamate, is an important fuel for the intestine of premature 
neonates. 
 
Patient 
 
GA 
wk 
BW 
kg 
SA 1 
d 
SA 2 
d 
SW 1 
kg 
SW 2 
kg 
Intake 
ml/(kg·d) 
Energy 
Kcal/(kg·d) 
1 34 1.50 28 30 1.79 1.79 161 121 
2 33 1.24 39 41 1.63 1.63 162 122 
3 33 1.82 17 19 1.90 1.98 158 119 
4 30 1.53 25 27 1.69 1.69 156 117 
5 32 1.30 19 21 1.31 1.44 165 124 
6 33 1.87 7 9 1.84 1.84 157 118 
7 29 0.82 28 30 1.09 1.13 142 107 
8 26 0.67 27 29 0.79 0.86 146 110 
Mean 31 1.34 24 26 1.50 1.54 110 117 
SD 3 0.43 9 9 0.40 0.38 6 6 
  D1 D2 
[U-13C]apartate (mol% excess) 9.6 (7.5-12.4) 2.6 (1.9-3.0) 
[D3]aspartate (mol% excess) 1.2 (0.9-1.8) 7.8 (4.7-8.8) 
QIV (μmol/(kg·d)) 129 (100-170) 156 (131-502) 
QIG (μmol/(kg·d)) 1181 (832-1851) 419 (332-485) 
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Figure 2. Enrichments of expired air during labeled aspartate infusion.  Enrichments of 13C in expired breath 
during IV [U-13C]aspartate infusion on d 1 (upper) and IG [U-13C]aspartate infusion on d 2 (lower). Rates are 
expressed as mean atom percent excess APE ± SD (n=8). 
 
Table 3. Whole-body and splanchnic aspartate kinetics in preterm infants. 
I, aspartate intake (μmol/(kg·d)) and was equal on d 1 and 2; FFP, fractional first-pass aspartate uptake (%); WB 
oxidation, whole-body oxidation during IV infusion on d 1 (μmol/(kg·d)); d 1, study day 1; d 2, study day 2; 
mean, average of d 1 and 2.  
 Patient I FFP FFP WB oxidation 
   d 1 d 2 Mean   
1 113 87 68 78 55 
2 114 86 74 80 46 
3 111 94 54 74 139 
4 110 89 69 79 92 
5 111 88 60 74 87 
6 110 89 75 82 100 
7 100 88 47 68 168 
8 103 95 62 79 408 
Mean 109 90 64 77 80 
SD 5 3 10 15 9 
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DISCUSSION 
 
The present study describes the splanchnic aspartate kinetics in preterm infants receiving full 
enteral feeding. Almost all dietary aspartate was taken up by the splanchnic tissues in first-
pass metabolism and there was a high fractional oxidation of the sequestered aspartate. Our 
results are in concordance with those of earlier studies performed in animals (7-9). The gut is 
an important modulator of whole-body amino acid fluxes. It controls amino acid absorption 
and is thought to modulate the metabolic fates of absorbed amino acids. During enteral 
feeding gastrointestinal tissues are the first to be exposed to nutrients so this tissues’ needs 
are met first. The possible metabolic fates of the sequestered amino acids in the splanchnic 
tissues in first-pass are: protein synthesis, intermediate metabolism, and irreversible 
oxidation to CO2 and ammonia. Amino acids incorporated into new (glyco-) proteins and 
secreted in the gut lumen could become systemically available after recycling (19). Amino 
acid requirement of neonatal piglets receiving enteral feeding is significantly higher (25-50%) 
than of parentally fed neonatal piglets (20-22). In enterally fed piglets it has been shown that 
approximately 50% of dietary amino acids appears in the systemic circulation after first-pass, 
but with substantially differing proportions for the between individual amino acids (9).  
All these findings stress the need to supply the (premature) neonate’s gut with adequate 
amounts of “fuel”, like aspartate, glutamate and glucose. This might prevent the splanchnic 
tissues from oxidizing essential amino acids like lysine (16), which otherwise would result in 
depletion of essential amino acids and consequently in inhibition of protein synthesis. Our 
results show that the intestine sequesters most of the enteral aspartate. Thus, most of the 
systemic aspartate available must derive from de novo synthesis in the body. The 
quantitatively most important aspartate synthesis pathway remains unknown. It could 
involve, for example, transamination of oxaloacetate or the removal of an amide group of 
asparagine. After premature birth most infants are fed with TPN during the first days of life, 
and consequently almost all nutrients are surpassing enteral metabolism. During TPN, 
aspartate is administered intravenously as a constituent of parenteral nutrition solutions. The 
metabolic fate of parenterally administered aspartate needs to be investigated in future 
studies. 
Apart from whole-body aspartate oxidation, we were also able to determine splanchnic 
aspartate oxidation. Our findings confirm the results from animal studies, which showed 
intestinal aspartate oxidation ranging from 39 to 52% (7, 8). As early as the 1970s 
Windmueller and Spaeth administered radio-actively labeled aspartate (L-[U-14 C]aspartate) to 
isolated segments of rat jejunum and measured the release of 14 C labeled products into the 
blood (7). In concordance with our results the most important 14 C labeled product released 
was 14CO2. Next came labeled lactate, glucose and alanine. Intragastric administration of        
[U-13C]aspartate theoretically allows to determine aspartate metabolites, so that the 
abovementioned substrates can be quantified. Because of the tremendous dilution rate, high 
amounts of labeled aspartate would be needed to measure the metabolites of quantitatively 
minor importance. We were not able to determine labeled alanine during simultaneous 
administration of [2,3,3-D3]aspartate because this tracer has a mass of [M+3] as well and 
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therefore, cannot be distinguished from the formed labeled [13C3]alanine in intermediary 
metabolism.  
Aspartate has a very high turnover rate and it is known that the pool of dispensable amino 
acids is large due to endogenous synthesis. Aspartate has many functions in the metabolism 
of the cell. Aspartate enters the urea cycle as the second amino group donor in the liver and 
condensates with citrulline to form arginosuccinate. Arginosuccinate is the precursor of 
arginine, a possible conditionally essential amino acid during periods of rapid cell growth 
(e.g. after premature birth). Depending on the cells energy status, aspartate either enters the 
Krebs cycle by prior metabolism to oxaloacetate, or it forms alanine which can be used to 
form pyruvate and subsequently glucose. It is not known if alanine is formed by 
transamination of pyruvate or if there is release of CO2 under the influence of the cytosolic 
enzyme aspartate 4-decarboxylase. Stoll et al. (23) showed very low net portal balance of 
aspartate (4-24% of the intake) in neonatal piglets. That of alanine and that of arginine, 
however, was >100%. This suggests that there is a net production of these amino acids by the 
PDV. Aspartate is also a precursor of asparagine, another non-essential amino acid. It is 
formed by transfer of an amide group from glutamine to aspartate, which reaction requires 
ATP. Aspartate also plays a crucial role in purine and pyramidine synthesis as this is 
dependent on the donation of its amino group.  
A limitation of this study is the small number of infants studied: only eight. Nevertheless, we 
do believe that these data are valid, as both the fractional first pass up-take and the fractional 
oxidation rate do not demonstrate a wide range. In conclusion, the results of this study 
demonstrate that there is a high uptake of dietary aspartate by the splanchnic tissues in first-
pass, most of which is used for oxidative purposes.  
 
 
APPENDIX 
 
We used similar calculations for aspartate metabolism as we did for glutamate, lysine and 
glucose kinetics (10, 11, 18): 
 
 Qiv=Iasp_iv x [(IEinf/IEp)-1]      (1) 
 
Where Qiv is the flux of the intravenously infused aspartate (μmol/(kg·h)), I is the infusion rate 
(μmol/(kg·h)), IEinf is the enrichment of the infusate (mol% excess) and IEp is the enrichment 
found in plasma (mol% excess).  
 
Aspartate flux of intragastrically infused aspartate was calculated as: 
 
 Qig= Iasp_ig x [(IEinf/IEp)-1]      (2) 
 
Where Qig is the flux of the intragastrically infused aspartate (μmol/(kg·d)), I is the infusion 
rate (μmol/(kg·h)), IEinf and IEp are the enrichments (mol% excess) found in plasma and of the 
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infusate, respectively.  
 
First-pass aspartate uptake was calculated as: 
 
 U= [(Qig-Qiv)/Qig] x I      (3) 
 
Where U is the first pass uptake (μmol/(kg·h)), Qig is the flux of the intragastrically infused 
tracer, Qiv is the flux of the intravenously infused tracer, and I is the intake of enteral aspartate 
intake (μmol/(kg·h)).  
 
Whole-body CO2 production was estimated as: 
 
 Whole-body CO2 production = IB x [(IEiB/IEB) – 1]   (4) 
 
Where IB is the infusion rate of the labeled bicarbonate μmol/(kg·h)) , IEiB is the enrichment of 
the infused bicarbonate (mol% excess) and IEB is the enrichment in expired CO2                            
(mol% excess) . 
This equation does not correct for [13C]bicarbonate in different body pools and will 
overestimate CO2 production rate. However, the same correction factor has to be applied to 
quantify the aspartate oxidation rate. Consequently aspartate oxidation rate is not 
overestimated.   
 
Fraction of aspartate oxidized was calculated as:  
 
 Fraction of aspartate oxidized = [IEasp x iB] / [IEB x iasp x 4]  (5) 
 
Where IEasp is the enrichment of CO2 in expired breath during [U-13C]aspartate infusion (on 
day 1 intravenously and on day 2 intragastrically infused), IEB the enrichment of CO2 during 
[13C] bicarbonate infusion (on day 1),  iB is the infusion rate of [13C bicarbonate and Iasp is the 
infusion rate of the [U-13C] aspartate (μmol/(kg·h)).  
Enrichment of aspartate is multiplied by 4 to account for the number of labeled C-atoms in  
[U-13C]aspartate.  
 
Whole-body aspartate oxidation is calculated as:  
 
 Whole-body aspartate oxidation = Equation 5  X  Equation 1IV (6) 
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INTRODUCTION 
 
Within the last decades much effort has been put into improving care for the preterm infant. 
Since the introduction of surfactant, antenatal steroids, specialized perinatal care and the 
improvement of mechanical ventilation the survival of preterm infants has increased 
substantially, even for very preterm infants (< 27 wk gestational age). Over the past years, the 
attention has partly been shifted to nutritional aspects to optimize treatment and long term 
outcome of these infants. For instance, the idea to withhold preterm infants from nutrients 
during the first days of life has been revised. Instead, introduction of amino acids and energy 
directly onwards birth is necessary to achieve a positive nitrogen balance (1-4). Protein 
synthesis is required to ensure growth and therefore supply of amino acids and energy is 
needed. The optimal composition of parenteral feeding and enteral feeding has not been 
established yet.  
Optimal feeding has a short-term effect by increasing survival and reducing complications, 
such as a reduction in severe chronic lung disease upon improvement of nutritional intakes 
in the first few weeks of life (A. Lapillonne, personal communication). Moreover, in both 
preterm and term infants with acute perinatal brain injury, a high-energy and- protein diet 
providing 120% of the estimated average recommendation (EAR), has shown increased brain 
growth and overall body growth in the first 12 months compared to infants receiving 100% 
EAR (5). 
More important, a long-term effect on later development and intelligence outcome has been 
shown as well (6). Thus, to support anabolism, early nutrition needs to be commenced 
immediately after birth. In this respect, the quantity of nutrients is of special interest. It is well 
known that the protein requirement of the preterm infant depends on several factors, such 
as gestational age, birth weight and post-conceptual age. The European Society of 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) will advise from 2008 onwards to 
provide preterm infants weighing less than 1800 grams with 3.8-4.5 gram protein/(kg·d) (in 
press, J Pediatr Gastroenterol Nutr 2008). This is substantially higher than the former 
recommendation by the American Academy of Pediatrics, which was 3.5-4.0 g protein/(kg·d) 
(7).  
Amino acid composition and protein amount of human milk varies widely and is also 
dependent on the time of birth (gestational age) and the post-conceptual age. Breast milk 
from mothers given birth prematurely contains more protein compared to milk from mothers 
given birth at term during the first few weeks post partum (Fig. 1). At around 2-4 weeks the 
composition is identical. 
Thus, preterm infants fed their mother’s milk need additional breast milk fortifier (BMF) or an 
increase in fluid intake up to 250 mL/(kg·d) to guarantee adequate daily protein intake. 
However, calcium, phosphate, and several vitamins are not sufficiently provided (11, 12), 
even at such high intakes. Sometimes, the clinical condition of the infant does not permit an 
intake > 140 mL/(kg·d), eg during bronchopulmonary dysplasia. The current amino acid 
recommendations for enterally fed preterm infants are based on the body composition of the 
fetus in utero (13). However, it is necessary to define these recommendations on actual    
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Figure 1. Protein content in preterm human milk in the first four weeks.  Based on Gross et al. (8), Anderson et 
al. (9) and Schanler et al. (10). 
 
requirements. The nutritional requirements of preterm infants differ from term infants 
because of illness, transition to extra-uterine environment and immaturity of enzymes, 
among other factors. In addition, by using the composition of fetal proteins as a gold 
standard, the requirement will give incomplete information since amino acids are not only 
needed for growth but are also involved in synthesis of functional glyco-proteins, like 
mucins, glutathione and proteins with a short lifetime such as fibrinogen and C-reactive 
protein. The need for specific age related nutritional requirements is increasing, since we are 
able to treat infants with decreasing gestational age. For instance, it is doubtful if the 
requirement for an infant born at gestational age of 25 wk is similar to that of a preterm 
infant of 33 wk since, there is a difference in the activity of several metabolic pathways such 
as cysteine synthesis. 
 
In the following section we discuss the major findings presented in this thesis in relation to 
other studies. Finally, we discuss the future research proposals arising from the findings in 
our present studies.   
 
 
CYSTEINE  
 
Requirements 
The biochemical immaturity of preterm infants limits several biosynthetic processes. Some 
amino acids are therefore conditionally indispensable for some period. Conditionally 
indispensable indicates that the metabolic need exceeds the endogenous synthetic capacity, 
caused by, for example, immaturity or critical illness. Arginine, cysteine, glycine, glutamine 
and tyrosine are considered to be conditionally indispensible amino acids (14-16). Cysteine is 
believed to be conditionally indispensable in preterm infants due to limited synthesis from 
methionine and serine, which is caused by a decreased or even absent enzyme activity due 
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to immaturity (17-19).  
Snyderman et al. (20-24) performed a number of studies investigating the requirements of 
dispensable amino acids in enterally fed term and preterm infants. She was the first to report 
in vivo evidence that cystine is an indispensable amino acid for the premature infant (25). 
Rates of nitrogen retention and weight gain were decreased in 2- to 4-month-old infants 
born prematurely who were enterally fed a synthetic diet without cyst(e)ine. The cyst(e)ine 
intakes of 44 or 66 mg/(kg·d) did not restore nitrogen retention and weight gain to control 
values and, subsequently, she recommended a minimal intake of 85 mg cyst(e)ine/(kg·d). 
However, these studies were based on nitrogen balance and weight gain rate. Over the years 
it has become clear that nitrogen balance usually overestimates nitrogen retention and that 
growth rate also depends on factors other than amino acid intake. Nitrogen losses consist not 
only of losses through faeces and urine but also by respiration and skin. The latter two are 
difficult to measure and the nitrogen method is therefore not very accurate. Moreover, 7 to 
10 days adaptation is needed to establish nitrogen equilibrium (26). This adaptation time of 
one week is another critical aspect since present clinical practice does not accept to maintain 
neonates on either deficient or excess amino acid intakes for a minimum of 7 days. This 
might have contributed to the fact that no such requirement studies have been conducted in 
preterm infants since that time. We therefore established the cysteine requirements for 
enterally fed preterm infants (Chapter 3 and 4) by the indicator amino acid oxidation (IAAO) 
method.  
In the early eighties Ball and Bayley introduced the IAAO method to determine the 
requirement of indispensable amino acids in piglets (27). Soon, this method was expanded to 
human adults (28, 29). The IAAO method is non-invasive and is based on the assumption that 
amino acids partition between protein synthesis and oxidation. If one indispensable amino 
acid is deficient this will limit overall protein synthesis. Proteolysis occurs to accomplish the 
release of this specific amino acids and the surplus of amino acids will be oxidized (30). This 
non-invasive method is therefore highly suitable to investigate amino acid requirements in 
preterm infants. To our knowledge we are the first research group who have applied this 
method in enterally fed preterm infants. Pencharz et al. (31) used this method in parenterally 
fed preterm infants.  
We hypothesize that cysteine is a conditionally indispensable amino acid during the first 
period of life. We found by using the IAAO that the cysteine requirements for enterally fed 
low-birth weight infants at postmenstrual age of 36 weeks is less than 18 mg/(kg·d) (Chapter 
3). Our estimated enteral cysteine requirement is at least 5 times lower than Snyderman 
advised (25). However, Snyderman did not provide information about the methionine intake 
and it is possible that their recommendation might be overestimated in view of an 
inadequate methionine intake. Since methionine is an indispensable amino acid, a possible 
inadequate intake could have limited protein synthesis resulting in an impaired rate of 
weight gain. On the other hand, cysteine might have a sparing effect on methionine 
requirements in both piglets (32) and humans (33). In this regard, low but adequate 
methionine intake could also have resulted in a higher cysteine requirement. In addition, 
Zlotkin and Anderson (19) demonstrated that activity of the enzyme cystathionase in the liver 
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increases rapidly after birth and reaches mature levels at about 3 months of age. This finding 
indicates that cystathionase activity is dependent on gestational age and that the cysteine 
requirement will change with postmenstrual age. We hypothesized that the requirements for 
preterm infants change (ie decrease) with increasing postnatal age. However, in very-low-
birth weight infants born at mean gestational age of 29 wk, the cysteine requirement 
determined at postmenstrual age of 32 and 35 wk did not differ and was again less than 18 
mg/(kg·d) (Chapter 4). Also, the gestational age of 29 wk versus 33 wk had no effect on the 
cysteine requirement (Chapter 3 and 4). Thus, we can conclude from our studies that 
cysteine does not seem to be a conditionally indispensable amino acid in enterally fed very-
low-birth-weight preterm infants, and that is not dependent on postmenstrual age if older 
than 32 wk. 
 
The preterm infant may be susceptible to cysteine depletion due to abrupt halt of placental 
supply after birth. In addition, the preterm infant does not tolerate full enteral feeding 
immediately after birth and therefore ,generally, the first route of feeding is parenteral during 
the first days of life. However, parenteral nutrition solutions lack cysteine because it is 
unstable in solution and oxidizes easily to cystine, which is insoluble. Many standard 
parenteral solutions therefore contain little cysteine or no cysteine. Others contain N-acetyl-
cysteine (NAC), which improves solubility dramatically. Preterm infants, however, do not 
seem to be capable of de-acetylating the acetylated cysteine efficiently, resulting in high 
plasma levels of NAC and still low levels of cysteine (34). The short and long term side effects 
of high NAC levels are unknown and need to be followed. To compensate for low cysteine 
concentrations, parenteral solutions contain relatively high levels of methionine. 
Consequently, elevated methionine levels are associated with total parenteral nutrition (35). 
Neonates receiving a high dose of methionine show high plasma methionine and low plasma 
cysteine concentrations, which implies that the excess of methionine is not used for cysteine 
synthesis (36, 37). In addition, rabbits fed a high dose of methionine intravenously               
(121 mg/(kg·d)) as part of their total parenteral nutrition or in addition to standard enteral 
feeding showed severe liver injury and thus caution should be taken to use parenteral 
nutrition solutions containing high dose of methionine (38). An optimal parenteral nutrition 
solution, especially sulfur amino acids, for the preterm infants still needs to be defined. 
Recently, the total sulfur amino acid requirement for parenterally fed term infants has been 
determined to be 49 mg/(kg·d) (Courtney-Martin et al. in press AJCN 2008).  
 
Following Snyderman (25), several studies have attempted to document clinically that           
1) cysteine is a conditionally dispensable amino acid and 2) there is a need for an exogenous 
source of cysteine during infancy. Most of these studies used the plasma cysteine 
concentration as the primary outcome measurement and were performed in parenterally fed 
infants. Pohlandt (39) observed no differences in plasma cystine concentrations in 
parenterally fed preterm infants receiving only glucose compared to infants receiving a 
mixture of synthetic amino acids free from cystine. In both groups plasma cystine 
concentrations were low, indicating that cystine synthesis was limited. Furthermore, Viňa et 
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al. (40) reported low plasma cysteine concentrations in premature infants fed only a 
parenteral solution deficient in cystine compared to term infants. On the other hand, Zlotkin 
et al. (41) did not find differences in nitrogen balance for parenterally fed term and preterm 
infants with or without cysteine supplementation indicating that cysteine was not deficient. 
However, they showed slightly higher urinary 3-methylhistidine excretion, which is an index 
for muscle protein catabolism, suggesting either muscle protein catabolism or an increase in 
muscle mass in cysteine supplemented infants. An evident relationship could not be 
detected. Malloy et al. (42) showed that cysteine supplementation increased free cysteine 
plasma concentration and sulfur balance in preterm infants. However, it did not improve 
nitrogen retention, indicating that cysteine is not a conditionally dispensable amino acid in 
these infants.  It needs to be emphasized that these studies were done in parenterally fed 
infants. No data on enterally fed preterm infants are available except for Snyderman et al. 
(25).  
In view of the above discussed studies, plasma cysteine concentration as the primary 
outcome needs to be discussed. A difference in plasma cysteine concentration in parenterally 
fed preterm infants with or without cysteine does not necessarily mean that cysteine is 
indispensable under specific conditions. It just shows a difference in plasma concentration 
but it does not indicate if there is a shortage of cysteine or that it is due to a higher 
consumption. Concentration is a static analysis instead of being dynamic and it is possible 
that the drop in plasma cysteine concentration is, for example, a result of cysteine need for 
glutathione synthesis. The parenterally fed neonate is usually sicker than the enterally fed 
infant and subsequently might have an increased oxidative stress state which requires a 
higher glutathione demand. 
 
Gut metabolism 
Besides the higher requirement for some nutrients due to immaturity of metabolic pathways, 
optimal intestinal function and integrity requires a larger quantity of indispensable as well as 
dispensable amino acids. A well-functioning small intestine is indispensable in maintaining 
optimal digestion and absorption of dietary nutrients. One of the problems in feeding the 
preterm infant is immaturity of the gastrointestinal tract, which is partly age dependent. As a 
consequence, the preterm infant is generally parenterally fed during the first period after 
birth because of intolerance of enteral feeding. It is well known that during parenteral 
feeding the gut is largely by-passed and lack of enteral nutrient support may lead to reduced 
growth and functional development of the intestinal mucosa (43). In this respect, low plasma 
cysteine concentration could also be a direct effect of total parenteral feeding. Steging and 
Den Besten (44) were the first to demonstrate the in vivo  involvement of the gastrointestinal 
tract in cysteine synthesis. Human adults were fed a cystine-free diet otherwise containing 
adequate amounts of methionine intravenously which was immediately followed by an 
intragastrical infusion. They demonstrated that plasma cysteine concentrations were 
significantly higher in these subjects fed the cystine-free diet enterally versus intravenously. 
This finding strongly suggests that the splanchnic tissues (liver and intestine) are a key site for 
cysteine synthesis. It is of particular importance to investigate the contribution of the 
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gastrointestinal tissues in cysteine production in preterm infants in view of the route of 
feeding. If a considerable part of endogenous cysteine synthesis occurs in the intestine, the 
impact of parenteral feeding is unequivocal since most standard parenteral solutions do not 
contain cysteine. Consequently, minimal endogenous cysteine synthesis results in a cysteine 
deficiency. Besides, in preterm infants the cysteine consumption is high due to oxidative 
stress as a result of oxygen supplementation, hypoxia or sepsis, resulting in disturbances in 
redox state. Redox state is regulated by glutathione (GSH) and is reduced to GSSG and 
transported from the cell (45). The reduction of the intracellular GSH pool stimulates de novo 
glutathione synthesis, which requires cysteine, glutamate and glycine. Additionally, 
glutathione plays a role in protecting the gastrointestinal epithelia against toxicity associated 
with inflammatory disease, ischemia, oxidative damage and chemotherapy (46, 47). However, 
free cysteine has a very small pool size compared to glutamate and glycine and is therefore 
believed to be the rate-limiting amino acid for glutathione synthesis (48).  
 
Further research by Shoveller et al. (32) showed that piglets enterally fed a diet containing 
methionine but no cysteine had significantly higher plasma cysteine concentrations than 
parenterally fed piglets fed the same diet. This finding suggests again that the gut is involved 
in cysteine synthesis. This is indirectly confirmed by the linear correlation between dietary 
methionine intake and plasma cysteine concentrations in the enterally, but not in 
parenterally fed piglets. Despite the clear evidence that splanchnic tissues play a major role 
in methionine metabolism, the relative contribution of the gastrointestinal tissues is not 
completely clear. In chapter 5 we, therefore, investigated the metabolic fate of dietary 
methionine in the gastrointestinal tract of neonatal piglets. We hypothesized that the 
gastrointestinal tissues have an important contribution to transmethylation, remethylation 
and transsulfuration. Human studies conducted with stable isotopes show that a significant 
proportion of methionine is transmethylated and remethylated in first-pass metabolism of 
splanchnic tissues (49, 50). However, they did not demonstrate an active transsulfuration 
pathway in these tissues. In accordance with these studies, we showed, in vivo, that the 
gastrointestinal tissues are a metabolically significant site of methionine transmethylation 
and remethylation, and confirmed the involvement of the gastrointestinal tract in 
methionine metabolism (Chapter 5). In agreement with the human studies, both trans- and 
remethylation were significantly higher in neonatal piglets during intraduodenal than 
intravenous tracer infusion, which indicates first-pass methionine metabolism. In addition, 
we found a high rate of intracellular transmethylation, by means of loss of the deuterated 
methyl moiety via S-adenosylmethionine synthesis, in both intestinal and liver tissues. This 
might be explained by the high turnover rate of intestinal mucosa which demands a high cell 
proliferation. S-Adenosylmethionine dependent methylations are essential for biosynthesis 
of a variety of cellular components DNA and RNA, and control cell proliferation and 
differentiation (51, 52).  
The higher plasma cysteine concentrations in enterally fed piglets compared to parenterally 
fed piglets (32) could also indicate that parenterally fed piglets have a higher need for 
cysteine for glutathione, taurine or sulfate synthesis. However, cysteine supplementation 
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resulted in higher plasma cysteine concentrations in parenterally than in enterally fed piglets 
(32). It is possible that luminal cysteine, like glutamate (53), is preferentially used for intestinal 
glutathione synthesis and directly channeled to glutathione. The higher plasma cysteine 
concentration during parenteral administration might also be explained by an inhibitory 
effect of dietary cysteine on the transsulfuration rate, i.e. a reduction in cysteine synthesis. In 
vitro studies showed that feeding cysteine reduces cystathionine ß-synthase (CBS) activity 
(54, 55). The same effect of dietary cysteine on transsulfuration is seen in vivo in humans (56). 
Additionally, dietary cysteine also reduced transmethylation (56) and induced remethylation 
(57). However, a clear cysteine sparing effect on methionine requirement has not yet been 
established  
Moreover, we showed that the gastrointestinal tissues are not only a site of intracellular 
homocysteine synthesis but also of net release into the circulation (Chapter 5). Case–control 
as well as prospective studies have demonstrated that the plasma total homocysteine level is 
a strong, graded, and independent risk factor for coronary heart disease and stroke (58, 59). 
Homocysteine is believed to play an important role in pregnancy complications as well       
(60, 61). Not much research has been performed to determine to which extent the intestinal 
tract contributes to homocysteine synthesis. We found that approximately a quarter of the 
methionine uptake was released as homocysteine by the portal tissues, which points out that 
the intestine is a considerable organ for homocysteine production. With regard to our results, 
Shoveller et al. (62) also investigated homocysteine plasma concentrations in enterally and 
parenterally fed piglets. They showed that plasma homocysteine concentration increased 
linearly with higher methionine intakes and this happened regardless of the route of feeding. 
Furthermore, plasma homocysteine concentration was not affected in parenterally fed 
piglets with or without cysteine. Thus, if the gut is bypassed, additional cysteine did not 
result in increased plasma homocysteine levels.  This confirms our hypothesis of intestinal 
involvement in cysteine synthesis. In contrast, enteral feeding supplemented with cysteine 
resulted in lower plasma homocysteine concentrations than cysteine-free feeding. The 
additional cysteine might have initiated a decrease in transmethylation and an increase in 
remethylation, which is also seen in adult humans (56). Given that the intestine plays an 
important role in homocysteine metabolism, this has important implications regarding the 
composition of infant formulas within the scope of homocysteine plasma concentrations.  
 
Since we have demonstrated that the intestine plays an important role in the transsulfuration 
pathway (Chapter 5), we also explored the endogenous cysteine synthesis in enterally fed 
preterm infants (Chapter 6). We found, in contrast to our expectations, that, like in 
parenterally fed infants, plasma cystine concentrations significantly dropped after 24 h 
period of cystine-free feeding,. However, in adult humans fed a methionine adequate diet, a 
sulfur amino acid free diet or a methionine free but cystine supplemented diet, cystine 
plasma levels did not significantly change (63). A sulfur amino acid devoid diet reduces the 
flow of methionine via the transmethylation and transsulfuration pathways in subjects fed 
the test diet for five days (63). Infants in our study had an adaptation period of 24 h, which 
might have been too short for the methionine cycle to adjust to the induced cystine-free diet. 
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On the other hand, the group of Pencharz (28, 30) has demonstrated that 4 h of adaptation to 
the test amino acid level is sufficient to establish a new steady state. Since methionine is the 
precursor of cysteine, the methionine intake needs to be taken into account as well. The 
current estimated methionine requirement for preterm infants is 48-69 mg/(kg·d) (64). 
Shoveller et al. (65) determined the total sulfur amino acid requirement in enterally fed 
neonatal piglets when no dietary cysteine was provided. The extrapolation from this piglet 
study results in a methionine intake of 84 mg/(kg·d) for the human neonate, which is above 
the current recommendations (64). A very recent study has determined the total sulfur amino 
acid requirements in parenterally fed neonates to be 50 mg/(kg·d) (Courtney-Martin et al. in 
press AJCN 2008). Thus taken into account that the splanchnic methionine uptake is about 
20%, the dietary intake should be approximately 70 mg/(kg·d). In our study, infants received 
a mean methionine intake of 74 mg methionine/(kg·d), which is in agreement with the above 
calculated quantity. It is slightly below the calculated requirement determined by Shoveller 
et al. but above the current recommended requirement for preterm infants (13). It might be, 
but seems unlikely, that the methionine intake in absence of cystine in our study was 
inadequate and that methionine disappeared in protein synthesis rather than that it entered 
into the transmethylation pathway.  
In addition, we were not able to demonstrate endogenous cysteine synthesis in enterally fed 
preterm infants by incorporation of labeled serine into cysteine (Chapter 6). One explanation 
might be the route of tracer administration. In human studies investigating homocysteine 
metabolism, one carbon labeled serine was administered intravenously, but like in our study, 
no labeled cysteine could be detected (66-68). Even if two carbon atoms were labeled, no 
labeling of plasma cysteine could be measured (69). Eventually, the gastrointestinal tissues 
could preferentially utilize enteral serine for cysteine synthesis. We therefore hypothesized 
that the splanchnic tissues preferentially utilize serine derived from the diet rather than 
systemically derived serine for cysteine synthesis and for this reason we administered labeled 
serine enterally. But also during enteral administration, no net cysteine production could be 
measured. It might be possible that dietary serine was taken up by the splanchnic tissues in 
first-pass and utilized for other purposes, like conversion to glycine for the folate dependent 
transmethylation reaction. To optimize transsulfuration flux, infants were given a cystine-free 
but otherwise rich in protein diet. In contrast to the studies in human adults, our subjects 
were all studied in the postprandial state. The transsulfuration pathway is most active in the 
postprandial state when methionine is consumed (70). 
Furthermore, it has been demonstrated that serine is the primary 1-C donor in the 
remethylation of homocysteine (66, 67, 71, 72). Approximately 80 to 90% of 1-C units is 
derived from the 3-C of serine. Consequently, glycine, histidine, betaine, sarcosine, and 
formate are minor sources of 1-C units for remethylation. Despite the strong dependence of 
the remethylation process on serine as a 1-C donor, only approximately 3% of the serine flux 
was used for remethylation in adults (66). Under our study conditions it is also possible that 
serine was predominantly used for conversion to glycine. Indeed, we found a significant 
amount of the serine carbon label back as [13C]glycine. We could not detect plasma 
enrichment of [13C4]methionine in our infants (Chapter 6). The latter implies that if no dietary 
144 
Chapter 9 
C
ha
p
te
r 9
 
cysteine is available, the remethylation is suppressed and likely all homocysteine is 
channeled directly towards the transsulfuration pathway. If this theory holds , we do not have 
a clear explanation for the absent cysteine enrichment. It is known that the isotopic 
enrichment of a nutritionally dispensable amino acid in plasma is lower than that for an 
equivalent tracer infusion of an indispensable amino acid because the pools of a dispensable 
are supplied not only by the diet but also from endogenous protein breakdown and the novo 
synthesis (73). 
Two earlier studies have been attempted to investigate in vivo cysteine synthesis (74, 75). 
Preterm infants received uniformly labeled glucose intravenously to asses the endogenous 
cysteine synthesis from carbon atoms provided by glucose. In the first study in parenterally 
fed preterm infants supplemented with 86 mg cysteine/(kg·d), administration of uniformly 
labeled glucose did not yield labeled cysteine and the authors concluded that cysteine 
synthesis was insufficient and indispensable for these infants (74). The second study showed 
contradictory results by suggesting that the transsulfuration pathway is active in preterm 
infants receiving total parenteral nutrition (75). Following uniformly labeled glucose 
administration, cysteine enrichment was found in both plasma and apo B-100 but was very 
low, 0.45 and 1 mol% excess respectively. Again, both studies were performed in total 
parenterally fed preterm infants and no studies assessing the transsulfuration pathway have 
been performed in enterally fed infants. From the results in chapter 3 and 4 we can conclude 
that the transsulfuration pathway is intact during enteral feeding and is likely to be ascribed 
to the intestinal cysteine synthesis. However, from the results in chapter 6, the 
transsulfuration pathway could not be determined to be active and came much to our 
surprise. Besides the route of feeding, this might be explained by the three different methods 
that were used to examine the endogenous cysteine synthesis. Shew et al. (75) were able to 
determine labeled cysteine by using a 4-h labeled glucose infusion, whereby glucose is 
converted to serine via 3-phosphoglycerate. In respect to this metabolic pathway it remains 
unexplained why Shew et al. could detect labeled cysteine and we could not. Perhaps 
ethnicity plays a role in sulfur amino acid metabolism. 
Early in vitro animal studies showed that the methionine trans- and remethylation pathways 
are present in all tissues (76-78). In contrast, enzymes involved in the transsulfuration 
pathway (cystathionine ß-synthase (CBS) and cystathionine γ-lyase) are mainly active in liver 
tissue and to a lesser extent, in extra hepatic tissues including pancreas, kidney, small 
intestine, brain, and lung (54). Also, in preterm and term infants cystathionine ß-synthase is 
not only isolated to the liver but is present in the kidneys, adrenals, and, to a small degree in 
the pancreas as well (19). To emphasize the considerable role of the intestine in the 
transsulfuration pathway we have demonstrated the presence of cystathionine ß-synthase 
mRNA and its activity as well (Chapter 5). CBS mRNA expression and CBS activity was 
presented in liver, jejunum, stomach, pancreas and intestinal epithelial cells. The relative 
expression of CBS mRNA in liver tissue was > 10-fold higher than in any GI tissue measured. 
However, the CBS activity in liver tissue was only 3- to 5-fold higher than in gastrointestinal 
tissues. It is of interest that isolated epithelial cells had the highest CBS activity among the GI 
tissues measured. Oxidant stress is known to increase methionine transsulfuration to meet 
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the increased cysteine demand for cellular glutathione synthesis (79, 80). This suggests that 
the metabolic requirement for methionine and cysteine by the gut may be increased in 
conditions such as inflammatory bowel disease, enteric infection and in preterm infants. 
 
 
SPLANCHNIC METHIONINE, ASPARTATE AND GLUTAMATE METABOLISM 
 
The gut extensively metabolizes both dietary indispensable amino acids such as lysine, 
threonine, leucine, and dispensable amino acids, such as glutamate and aspartate (81-85). It 
is important to recognize that within the portal-drained-viscera, amino acids are presented 
via both the lumen and the arterial circulation. From a quantitative perspective, the supply of 
most amino acids from the arterial circulation is substantially greater (3- to 5-fold) than that 
from the diet (Figure 2).  
Figure 2. Amino acid input into portal-drained viscera (PDV) tissues from the diet and the arterial circulation in 
piglets. With permission, Journal of Animal Science 2006 (86). 
 
However, the fractional portal-drained viscera use of dietary amino acids, ranging from 20 to 
95%, is generally much greater than amino acids derived from the arterial blood, which 
ranges from approximately 5 to 15% (86). The reason for this observation is unclear, but may 
be due to differences in amino acid transporter abundance on the basolateral and apical 
surfaces of intestinal epithelial cells. Only a small number of studies have been performed to 
examine the site of amino acid absorption by the intestine. For example, in piglets glutamine 
is preferentially metabolized from the arterial site while glutamate is extensively taken up 
from the luminal site (87). The latter is likely due to the preferential source of enteral 
glutamate for mucosal glutathione synthesis (53). In piglets, dietary threonine is mostly used 
for protein synthesis in the small intestine (83), whilst the systemic threonine is used for 
synthesis of the intestinal mucus layer (Schaart, unpublished data). In addition, under normal 
feeding conditions, lysine and threonine used by the portal drained viscera derive almost 
entirely from the arterial site. We observed, contrary to our hypothesis, that the 
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gastrointestinal tissues in piglets preferentially utilized methionine from the arterial 
circulation rather than from the diet (Chapter 5). The arterial utilization of methionine 
indicates absence of first-pass intestinal metabolism of dietary methionine and might be 
explained by methodological considerations. Studies in adult humans fed a low–methionine 
but cystine supplemented diet showed comparable results (49, 50). Plasma enrichment of    
[1-13C, methyl-2H3]methionine was similar during enteral and intravenous administration of 
the [1-13C, methyl-2H3]methionine tracer. However, plasma enrichment of the derived 
methionine specie, [1-13C]methionine, was considerably higher during enteral tracer 
administration. The remethylation and transmethylation rates were all higher when the 
enteral tracer was used than when an intravenous tracer was used. Thus, with a low 
maintenance intake of methionine, it appears that the free methionine pool undergoes 
significant methyl group transfer and remethylation during passage of dietary methionine 
through the splanchnic region, with an equivalent of the fraction of dietary methionine 
involved in this metabolic activity being released from the liver into the circulation. Likewise, 
our results showed significantly higher rates of both transmethylation and remethylation 
when the methionine tracers were administered enterally.  
It has been well established, using various approaches, that splanchnic tissues metabolize a 
significant proportion of dietary amino acids in first-pass. In vivo studies in humans based on 
dual intravenous and intragastric administration of individual isotopic amino acid tracers, 
have shown that splanchnic tissues metabolize approximately 20–96% of the enterally 
administered amino acids (Figure 3) (50, 88-93). Rat studies showed that the three 
dispensable amino acids aspartate, glutamate and glutamine play a large role in intestinal 
energy metabolism (94). It is of great importance to investigate their contribution as an 
intestinal fuel in preterm infants within the scope of optimizing nutritional strategies. 
Figure 3. Splanchnic first-pass utilization of dietary amino acids in adults humans (50, 88-93). 
  
Earlier studies performed in neonatal piglets showed that 20-50% of the dietary methionine 
was taken up by the gut in first-pass metabolism (82, 95). Additionally, the total sulfur amino 
acid requirement, as defined by the methionine requirement in absence of dietary cysteine, 
was 30% lower in parenterally, compared to enterally fed neonatal piglets (65). This 
difference suggests as well that methionine extraction by first-pass splanchnic metabolism 
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may be responsible. We also found that the intestine metabolizes an equivalent of 20% of the 
dietary methionine intake (Chapter 5) which is in agreement with previous studies.  
In contrast to the widespread animal studies exploring in vivo methionine metabolism, not 
much is known about the methionine kinetics in preterm infants. We investigated the 
splanchnic methionine uptake in low-birth-weight infants (Chapter 6). In accordance with 
piglets studies we found that one third of the dietary methionine was taken up in splanchnic 
first-pass, which includes the liver, during the fed state. Interestingly, first-pass methionine 
uptake was absent in human studies during the fed state (50). In contrast, in the fasted state 
the methionine utilization varied from 25% for the low methionine-cysteine supplemented 
diet to 33% for the diet containing only methionine. This finding indicates that a 
considerable amount of methionine was used for cysteine synthesis. Surprisingly, in adults 
methionine uptake seems to appear at the basolateral site instead of the luminal site, which 
is inconsistent to our findings. In our study we fed infants a cyst(e)ine-free but containing an 
otherwise generous amounts of methionine to achieve optimal cyst(e)ine synthesis.  
 
In contrast to methionine, aspartate and glutamate are indispensable amino acids for 
humans. In the early forties, several studies in rats already demonstrated that aspartate was a 
dispensable component for the diet (96, 97). Additional research was done to investigate the 
role of dietary glutamate and aspartate in rats and indicated that the addition of glutamate 
but not aspartate to a diet containing only the eight indispensable amino acids plus arginine 
and histidine, exerted a significant stimulatory effect on the rate of weight gain but that its 
removal from a diet containing dispensable and indispensable amino acids was followed by a 
very slightly inhibition of the weight gain (98). 
Initially, glucose was thought to be the only respiratory fuel for the intestine (99). Studies in 
rats have shown that mucosal cells of the small intestine take up large amounts of arterial 
glutamine and that one third of CO2 produced by intestine of fasted rats is derived from 
plasma glutamine and only 8% from glucose (100). A second source of metabolic substrates 
for intestinal mucosal cells, in addition to blood, is the gut lumen. To investigate the 
intestinal absorption of amino acids, an in situ method was developed and perfused intestinal 
loops of rats were examined (87, 94, 100-102). Virtually all glutamate and aspartate and 
significant amounts of glutamine and arginine absorbed from the lumen were metabolized. 
The resulting metabolic products were quantified and included CO2, lactate, proline, 
citrulline, alanine, and glucose. The primary metabolic fate of luminal glutamate was 
oxidation to CO2 (64%), followed by the formation to lactate (16%) and incorporation in 
proline, citrulline, ornithine and alanine (10%). Glutamate was found, as well as glutamine 
and glucose, to be an important contribution to energy requirements of the gut in rats        
(87, 100).  
The gut of infant piglets metabolizes virtually all of the enteral glutamate (92%) during 
absorption (103).  In human adults most of the dietary glutamate is metabolized in first-pass 
as well (88%) (104). In piglets also, glutamate is shown to be an important oxidative substrate 
for the intestinal mucosa (105). These studies in animals and adult humans suggest that 
dietary glutamate serves as an important metabolic fuel source in the intestine. Our study 
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investigating the splanchnic glutamate uptake and oxidation in preterm infants (Chapter 7) 
confirmed these observations. We found that approximately 75% of the dietary glutamate 
was taken up in splanchnic first-pass metabolism, which was slightly lower than observed in 
piglets and adult humans. Most of the extracted glutamate was channeled toward oxidation. 
This rate is comparable to the oxidation rate of glutamate in adults and indicates that this is 
the primary metabolic fate of dietary glutamate in the premature infant. Additionally, and in 
agreement with our results as well, a recent study demonstrated that the primary fate of 
dietary glutamate in premature infants is splanchnic extraction and not used for glucose 
production (106). Their findings, which indicate that dietary glutamate is not a significant 
gluconeogenic substrate, is not surprising, considering that we showed that oxidation is the 
primary metabolic pathway of enterally absorbed glutamate.  
Apart from oxidation, glutamate can also act as a precursor for proline, arginine and 
glutathione. We were not able to determine the quantity of labeled alanine, lactate and 
pyruvate (Chapter 7). Thus, the contribution of 13CO2 from oxidation from these products 
could not be quantified. However, based on animal data (87) we hypothesize that the 
contribution of labeled CO2 from these amino acids is relatively small and that the fractional 
glutamate oxidation is not overestimated. Reeds et al (103) showed that in infant piglets 
infused with [U-13C]glutamate [M+5] lower mass isotopomers appeared in plasma and 
determined the degree to which the 13C-label was recycled in intermediary metabolism. They 
showed that 11% of the labeled glutamate appeared in [M+1] and [M+3] isotopomers. We, 
however, were not able to determine the present abundance of plasma [13C3]glutamate 
[M+3] since the [D3]glutamate tracer has a mass of [M+3] as well and thus could not be 
distinguished from the [13C3]glutamate produced from intermediary metabolism. 
Enterally derived glutamate is the preferential source for mucosal glutathione synthesis in 
neonatal piglets. Approximately 85% of the mucosal GSH-glutamate derived from dietary 
glutamate (53). If the intestine oxidizes almost all dietary glutamate, the quantity of 
remaining glutamate  may be insufficient to maintain the preterm infant’s demand for 
glutathione production during periods of stress, especially if parenteral feeding is needed. 
The minimal glutamate requirement for glutathione synthesis during stress and illness in 
human neonates is not yet known. Animal data, however, strongly indicate that mucosal   
GSH-glutamate is mainly derived from dietary glutamate. This could have implications for 
parenterally fed infants as they lack the supply of luminal (dietary) glutamate during 
parenteral feeding. The intestinal GSH synthesis may be restricted and therefore limiting 
protection against oxidative injury. 
Further research revealed that besides glutamine and glutamate, aspartate was also a major 
fuel source for intestinal energy in rats (94). Indeed, virtually all aspartate was utilized in first-
pass metabolism in neonatal piglets and rats (95, 102, 105). This phenomenon was also seen 
in enterally fed preterm infants, where 86% of the enteral aspartate was extracted in 
splanchnic first-pass metabolism (Chapter 8). In addition, it was determined in rats that more 
than 50% of the extracted aspartate was oxidized to CO2 (102). Unfortunately, only in four 
infants whole-body and first-pass oxidation could be determined. In agreement to animal 
studies, three quarters of dietary aspartate uptake in first-pass was directed toward oxidation. 
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Like for glutamate, the major fate of dietary aspartate is uptake and oxidation within the 
splanchnic tissues in first-pass in preterm infants receiving full enteral feeding. Furthermore, 
almost 17% of the absorbed aspartate was recovered as lactate and 10% as alanine, 
indicating a second important role in three-carbon metabolism (102). Surprisingly, in rats 
10% of the labeled aspartate was recovered as labeled glucose which is apparently the first 
demonstration of in vivo gluconeogenesis by the intestine (102). Due to methodological 
considerations it was not possible to measure incorporation of aspartate in labeled amino 
acids or organic acids as discussed previously for glutamate (Chapter 8).  
 
 
FUTURE PERSPECTIVES 
 
Many topics related to the nutritional aspects in relation to the preterm infant are still subject 
for further research. The results obtained in this thesis can be used in future studies.  
To explore the exact cysteine requirements for enterally fed preterm infants, it would be 
necessary to perform a study like described in Chapters 3 and 4 but instead using cyst(e)ine 
intakes between zero and 18 mg/(kg·d). The study should also be performed with varying 
methionine intakes because total sulfur amino acid requirement could be provided by solely 
methionine. 
Furthermore, with the non-invasive IAAO method it is possible to chart the requirements of 
all indispensable amino acids in preterm and term infants which will allow us to further 
optimize nutrition. As discussed earlier, nitrogen balance was the primary method of choice 
to determine amino acid requirements. Until recently, recommendations were based on 
nitrogen balance studies. By the introduction of the carbon oxidation studies in human 
adults it became clear that the requirements of indispensable amino acids were much higher 
than previously assumed and the nitrogen balance estimates were in error by a factor 2 to 3 
(30, 107-109). Recently, The Food and Nutrition Board of the Institute of Medicine (110) 
recommended the estimated requirements of human adults on carbon oxidation studies. 
The requirements are variable with time and also depend on the quality and quantity of 
ingested proteins. The quality of amino acids is an important determining factor for 
improving infant formula and more importantly, is cost-cutting. Establishing exact 
requirements of indispensable and dispensable amino acids will reduce the cost for 
manufacturing, since protein is the most expensive constituent in infant formula. In addition, 
it results in a diminished nitrogen load which will probably result in improvement of renal 
function. Reduced cost might lead to a reduction in price and subsequently an increased 
availability for developing countries. Several diseases and its related medications like for HIV, 
require formula to nourish infants and, therefore, the need for cheaper formula is 
continuously increasing. 
 
In addition, the cysteine sparing capacity to reduce methionine requirements needs to be 
investigated. To date, animal and human studies have revealed different results on cysteine 
sparing capacity. Therefore, determination of minimal methionine requirements using 
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various methionine intakes in combination with variable additional cysteine intakes needs 
further investigation. 
Another issue that needs further research is the endogenous cysteine synthesis in preterm 
infants. The results from the study in Chapter 6 might imply that there might be a minimal 
requirement for cysteine, although the plasma cysteine concentration is not a well chosen 
primary end-point.  Adult studies have repeatedly failed to detect cysteine enrichment after 
administration of labeled serine. A modification of this method as described  in this thesis has 
equally failed to reveal cysteine synthesis in preterm infants. Therefore, new methods to 
explore the transsulfuration pathway need to be designed and validated in neonatal piglets. 
Subsequently, this new method should be adapted to preterm infants. It is known that 
labeled homocysteine, formed from labeled methionine, takes approximately 6-8 h to reach a 
plateau (111). It is possible that the same counts for cysteine, especially after a period of 
cysteine free feeding whereby initially cysteine is released from glutathione, which is the 
primary cysteine storage. First, a pilot study should be performed using increasing infusion 
periods. Secondly, instead of determining enrichment of cysteine, cystathionine enrichment 
should be measured, which is formed by fusion of serine and homocysteine and occurs one 
step earlier in the transsulfuration pathway. Another suggestion is to make use of sulfur 
labeled methionine. However, this is currently not commercially available. In contrast, 
radioactive labeled sulfur methionine is available and using radioactive isotopic techniques 
to evaluate endogenous cysteine synthesis is suitable for animal studies. Next to metabolic 
pathways, it is possible to determine CBS enzyme activity in gut tissue taken from biopsy in 
animal studies or in patients undergoing intestinal surgery.   
Furthermore, it needs to be established if the intestines preferentially utilize enteral or 
systemic cysteine for glutathione synthesis by use of stable isotope techniques. In our 
laboratory, we have developed a new method to measure glutathione in erythrocytes (112). 
In addition, it might be possible to collect biopsies to determine labeled glutathione in 
patients with an enterostomy. Enteral isotopic infusion should be compared to systemically 
infused labeled isotope.  
 
With respect to glutamate and aspartate metabolism, additional research investigating the 
role of these amino acids in three carbon metabolism (alanine, pyruvate and lactate) will give 
further insight in intestinal metabolism of these amino acids. Moreover, it is important with 
regard to nutritional considerations, to determine minimal glutamate, cysteine and glycine 
requirements for glutathione synthesis during stress and illness in human neonates. 
Furthermore, it needs to be investigated if enteral glutamate is the main source for 
glutathione synthesis in these infants. If this holds true, this will have great implications in 
total parenterally fed infants but also during minimal enteral nutrition. The latter should 
therefore be supplemented with glutamate and the effect could be determined in a 
randomized controlled trial. The following primary endpoints could be used: glutathione 
synthesis rate and other oxidative stress markers, such as oxidized protein products (AOPP) 
and dityrosine. In addition, clinical features as the incidence of BPD and ROP could be 
determined. 
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It has been clearly established that enteral feeding has a major influence on short-term and 
long-term outcome in preterm infants. Nutritional requirements are higher in preterm infants 
that in term infants because of rapid growth. It is, therefore, of utmost importance to 
determine the estimated requirements of all dispensable amino acids in preterm infants to 
provide these infants balanced nutrition to optimize growth and outcome. 
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SUMMARY 
 
This dissertation describes the sulfur amino acid metabolism in the neonatal period. The 
results of both human and animal studies will be presented. It is divided into 4 parts. 
 
In Chapter 1 we describe the background and aims of the studies presented in this thesis. 
We give a general introduction to nutrition in preterm infants, such as the role of early 
nutrition, amino acids and their requirements. Furthermore, the role of sulfur amino acids 
and their requirements are discussed followed by intestinal metabolism. 
 
Chapter 2 describes a study to validate the use of enteral infusion of isotopically labeled 
sodium bicarbonate in metabolic studies. Stable isotopes are often used in clinical studies to 
investigate amino acid metabolism. To determine the oxidation rate of the labeled 
substrates, the individual carbon dioxide production rate needs to be quantified. This is 
usually determined by intravenous infusion of labeled sodium bicarbonate, which requires a 
intravenous catheter. Placing an intravenous catheter is invasive in the enterally fed preterm 
infant who has no catheter and, therefore, we wish to reduce the invasiveness of the method 
that is used to determine individual carbon dioxide production. The aim of the study was to 
determine whether enteral and intravenous infusions of labeled sodium bicarbonate would 
achieve the same enrichment in expired breath. The second aim was to quantify the minimal 
tracer infusion time to achieve steady state during enteral infusion. We showed in 10 preterm 
infants that intravenous and intragastric labeled sodium bicarbonate yielded the same 
isotopic enrichment in expired breath. Secondly, the minimal enteral tracer infusion time 
required to establish steady state was 120 min. In conclusion, enteral infusion of labeled 
sodium bicarbonate may serve to estimate the carbon dioxide production rate in preterm 
infants and the infusion time is at least 120 min. We therefore administered the labeled 
sodium bicarbonate enterally in the cysteine requirement studies when infants were fully 
enterally fed. 
 
Part 1 focuses primarily on the cyst(e)ine requirement for preterm infants. 
 
In Chapter 3, we determined, one month after birth, the cyst(e)ine requirement in fully 
enterally fed preterm infants born with a gestational age of 32-34 wk. The fractional 
oxidation rate of [1-13C]phenylalanine did not differ with increasing cyst(e)ine intakes. This 
result shows that cyst(e)ine was not the limiting amino acid for protein synthesis with an 
intake of at least 18 mg cyst(e)ine/(kg·d). Thus, in 4-wk-old preterm infants, born at 
gestational ages of 32-34 wk cyst(e)ine synthesis seems not limited. Therefore, it is probably 
not a conditionally essential amino acid in these infants. The minimal cyst(e)ine requirement 
for these infants is < 18 mg cyst(e)ine/(kg·d). 
 
It is believed that the cyst(e)ine requirement depends on both gestational age and 
postmenstrual age. In Chapter 4 we investigated the influence of gestational age as well as 
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the postmenstrual age on the cyst(e)ine requirement. We studied preterm infants who were 
born with a gestational age of < 29 wk both at postmenstrual ages of 32 and 35 wk. In the 
first group, fractional oxidation of [1-13C]phenylalanine was determined ~ 1 month after birth 
(range: 31-32 wk postmenstrual age). In the second group, fractional oxidation of [1-13C]-
phenylalanine was determined ~ 2 months after birth (range: 35-38 wk postmenstrual age). 
In both groups, the fractional oxidation rates of [1-13C]phenylalanine did not differ among the 
5 graded cyst(e)ine intakes. The estimated minimal cyst(e)ine requirement in both groups 
was < 18 mg/(kg·d). From these results we can concluded that the cyst(e)ine requirement for 
preterm infants older than 32 wk postmenstrual age and who tolerate full enteral feeding is < 
18 mg cyst(e)ine/(kg·d). The cyst(e)ine requirement does, therefore, not depend on 
postmenstrual age in enterally fed infants born with a gestational age < 29 wk. Thus, in 
enterally fed preterm infants born at gestational age < 29 wk the transsulfuration pathway 
seems active and cyst(e)ine synthesis not limited.  
 
To answer the question if cyst(e)ine requirement depends on gestational age we need to 
compare the results from Chapter 3 and Chapter 4. In Chapter 3 we determined the          
cyst(e)ine requirement in preterm infants who were born with a gestational age of 32-34 wk 
and in Chapter 4, preterm infants were born with a gestational age of < 29 wk. Thus, we 
compared two groups with different gestational ages but at the same postmenstrual age. 
The cyst(e)ine requirement of both groups did not differ and was < 18 mg cyst(e)ine/(kg·d). 
Therefore cyst(e)ine requirement does not depend on either gestational age nor 
postmenstrual age. 
 
Part 2 focuses on intestinal sulfur amino acid metabolism in neonatal piglets and preterm 
infants during complete enteral feeding. 
 
Chapter 5 describes the metabolic fate of methionine in the gastrointestinal tissues (GIT) of 
neonatal pigs. We found that the GIT metabolize an equivalent of ~ 20% of the dietary 
methionine intake. Whole-body methionine transmethylation to homocysteine and 
remethylation of homocysteine to methionine was higher during enteral tracer infusion than 
intravenous infusion, and indicates that there was specific first-pass metabolism of 
methionine. The most important finding is  that ~2/3 of the methionine taken up by the GIT 
was used for homocysteine and cysteine synthesis. Thus, the GIT is indeed an important site 
for sulfur amino acid metabolism and represents 27% and 23% of whole-body rates of 
transmethylation and transsulfuration, respectively. 
Furthermore, we demonstrated cystathionine ß-synthase (CBS) mRNA expression and 
enzyme activity in various GIT (liver, jejunum, stomach, pancreas and intestinal epithelial 
cells). The CBS mRNA expression was highest in liver tissue. Interestingly, the CBS activity was 
highest in intestinal epithelial cells among the tissues measured. Activity increased 6-fold 
after incubation with S-adenosylmethionine, which is an allosteric activator of CBS.  
 
After the results obtained in neonatal piglets, we performed a similar stable isotope study in 
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preterm infants in Chapter 6. In this study we quantified the splanchnic methionine first-pass 
uptake in preterm infants with a mean gestational age of 32 wk. Furthermore, we examined 
endogenous cysteine synthesis by incorporation of enterally administered labeled serine into 
cysteine. To increase the transsulfuration activity, infants were fed a cyst(e)ine-free diet for  
24 h. Plasma methionine concentrations did not differ after 24 h of cyst(e)ine-free feeding. 
However, plasma cystine concentrations dropped significantly from 37 μmol/L to 19 μmol/L. 
This decrease in plasma cystine concentration after a cyst(e)ine-free diet implies that            
cyst(e)ine consumption exceeded endogenous synthesis. This is in contrast with the results 
shown in Chapter 3 and 4, where we concluded that the cysteine synthesis pathway was 
sufficient. Furthermore, we demonstrate that 35% of the dietary methionine intake was taken 
up in first-pass metabolism. We were not able to detect the serine carbon label in cysteine. 
However, we found a significant enrichment in plasma glycine derived from labeled serine. 
These findings indicate that under the conditions of enteral feeding and a cyst(e)ine-free diet 
enteral serine is not used for endogenous cysteine synthesis. 
 
Part 3 focuses on splanchnic metabolism of the nonessential amino acids glutamate and 
aspartate in preterm infants. 
 
In Chapter 7, we studied whole-body and splanchnic first-pass glutamate metabolism in 
preterm infants. We quantified first-pass glutamate uptake and splanchnic oxidation in 
infants with a mean gestational age of 29 wk. As expected, the fractional first-pass uptake of 
glutamate by the splanchnic tissues was high. Approximately three quarters of the enteral 
intake was sequestered by the splanchnic tissues. Furthermore, almost all (86%) was directed 
toward oxidation.  
 
Finally, in addition to the previous chapter, we investigated splanchnic aspartate metabolism 
in fully enterally fed preterm infants in Chapter 8. Like glutamate, first-pass aspartate uptake 
by the splanchnic tissues was almost complete and amounted 77%. More than three quarters 
of the aspartate used in first-pass was directed toward oxidation. The results of Chapter 7 and 
8 indicate that the primary metabolic fate of the nonessential amino acids glutamate and 
aspartate is splanchnic oxidation. 
 
Part 4 presents Chapter  9, where we discuss our findings. Furthermore, we make 
recommendations for future studies. In Chapter 10 all studies presented in this thesis are 
summarized.  
 
The main conclusions obtained from the studies described in this thesis are the following: 
 
 - The cysteine requirement for one-month-old enterally fed preterm infants born with 
 gestational age < 29 wk is < 18 mg cyst(e)ine/(kg·d). 
 
 - The cysteine requirement for preterm infants does not depend on gestational and 
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 postmenstrual age in one-month-old enterally fed infants (> 32 wk postmenstrual 
 age) who are born with a gestational age < 29 wk. 
 
- The gastrointestinal tissues are an important site for both homocysteine and cysteine 
 synthesis. 
 
 - Plasma cystine concentration decreases after a period of cysteine-free feeding in 
 preterm infants with a mean gestational age of 32 wk. This finding implies that either 
 cyst(e)ine consumption exceeded endogenous synthesis or that enzyme activity for 
 cysteine synthesis might not be fully developed. 
 
 - Enterally administered labeled serine was not used for endogenous cysteine synthesis 
 in preterm infants fed a cysteine-free diet. Other metabolic pathways for cysteine 
 synthesis may exist. 
 
 - Glutamate and aspartate are important energy sources for splanchnic tissues in 
 preterm infants. 
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SAMENVATTING 
 
Inleiding 
De zwavelhoudende aminozuren zijn: methionine, homocysteine en cysteine. Cyst(e)ine 
wordt gebruikt om elke onduidelijke combinatie van cystine en cysteine aan te duiden.  
 
Te vroeg geboren kinderen hebben na de geboorte een hoge behoefte aan voedingsstoffen 
en calorieën als gevolg van aanpassingen aan de extra-uteriene omgeving en door 
onrijpheid. Als gevolg van de vroeggeboorte zijn sommige metabole pathways nog niet 
volledig ontwikkeld. Dit heeft als gevolg dat sommige niet-essentiële aminozuren tijdelijk 
essentieel zijn; dit wil zeggen dat het lichaam niet in staat is om aan de minimale behoefte 
van dit aminozuur te voldoen. Deze aminozuren moeten dan tijdelijk in voldoende mate 
worden gesuppleerd in de voeding om aan de behoefte te voldoen. Daarnaast verschilt de 
aminozuurbehoefte van te vroeg geboren kinderen ten opzichte van a terme geboren 
kinderen als gevolg van een hogere groeisnelheid. De gewichtstoename van te vroeg 
geboren kinderen is na de geboorte een stuk lager in vergelijking met de foetus met dezelfde 
zwangerschapsduur in de baarmoeder. Om een vergelijkbare groeisnelheid als in utero te 
bereiken, is juiste en gebalanceerde voeding noodzakelijk. Het is daarom belangrijk om de 
minimale behoefte van essentiële aminozuren van te vroeg geboren kinderen te bepalen.  
 
Gedacht wordt dat cyst(e)ine tijdelijk een essentieel aminozuur is in te vroeg geboren 
kinderen als gevolg van onvoldoende cyst(e)ine productie (synthese). De cyst(e)ine synthese 
wordt gereguleerd door het enzym cystathionase. Studies uit de jaren 70 hebben laten zien 
dat de activiteit van het enzym cystathionase verminderd is en voornamelijk plaatsvindt in de 
lever. Het is mogelijk dat de maximale enzymcapaciteit afhankelijk is van zowel de 
zwangerschapsduur en de postnatale leeftijd. Het is dus van belang om de minimale          
cyst(e)ine behoefte te bepalen in te vroeg geboren kinderen, echter dit is nog niet door 
middel van klinische studies vastgesteld. 
  
Daarnaast wordt gedacht dat naast de lever de darm een belangrijke rol speelt bij de           
cyst(e)ine synthese. De darm heeft verschillende functies, waaronder digestie en absorptie 
van voedingstoffen. Aminozuren worden door de darm in first-pass opgenomen en gebruikt 
voor onder andere de synthese van (glyco)proteïnen, voor tussenliggend metabolisme of 
voor oxidatie. Dit laatste resulteert in het vrijkomen van energie. Uit dierstudies is gebleken 
dat naast glucose, de niet essentiële aminozuren glutamaat en aspartaat een belangrijke rol 
spelen in de energie voorziening van de darm.  
 
Dit proefschrift beschrijft het metabolisme van zwavelhoudende aminozuren in de neonatale 
periode en bestaat uit vier delen. De resultaten van een diermodel studie en klinische 
patiënten studies worden beschreven. In deel 1 wordt de minimale behoefte van cyst(e)ine 
in te vroeg geboren kinderen met verschillende zwangerschapsduur en op verschillende 
postnatale leeftijd beschreven. In deel 2 wordt het metabolisme van zwavelhoudende  
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aminozuren in de darm en in het splanchnisch gebied beschreven. Vervolgens wordt in deel 
3 het splanchnisch metabolisme van twee niet essentiële aminozuren in te vroeg geboren 
kinderen beschreven. In deel 4 worden de verschillende hoofdstukken samengevat en 
bediscussieerd.  
 
In hoofdstuk 1 worden de achtergronden en doelstellingen van de in dit proefschrift 
gepresenteerde studies beschreven. Het belang van voeding bij te vroeg geboren kinderen 
en de behoefte van aminozuren en het bepalen daarvan worden beschreven. Vervolgens 
wordt ingegaan op de zwavelhoudende aminozuren en aminozuur metabolisme van de 
darm. 
 
Hoofdstuk 2 beschrijft een onderzoek die als doel heeft om een bestaande methode die de 
koolstofdioxide (CO2) productie in kinderen meet eenvoudiger te maken. In studies die het 
metabolisme van aminozuren onderzoeken is het noodzakelijk om de individuele 
stofwisseling te bepalen. Dit gebeurt door middel van een stabiel isotoop via het infuus toe 
te dienen en vervolgens de hoeveelheid CO2 in de uitademinglucht te bepalen. Bij te vroeg 
geboren kinderen is het echter belastend om een infuus in te brengen indien dit enkel voor 
het onderzoek noodzakelijk is. Daarom is de huidige methode vergeleken met het toedienen 
van het stabiele isotoop via een maagsonde. De opbrengst van CO2 in de uitademinglucht 
was voor beide methoden gelijk. Uit dit onderzoek mag dus geconcludeerd worden dat de 
intraveneuze infusie van het stabiele isotoop kan worden vervangen door enterale infusie 
om de individuele CO2 productie te bepalen. De nieuwe methode om de CO2 productie te 
bepalen is dan ook in dit proefschrift gebruikt. 
 
Deel 1. Minimale cyst(e)ine behoefte in te vroeg geboren kinderen. 
 
In hoofdstuk 3 is gekeken naar de minimale behoefte van het aminozuur cyst(e)ine in te 
vroeg geboren kinderen die geboren werden met een zwangerschapsduur van 32 tot 34 
weken (gemiddeld 33 weken). De cyst(e)ine behoefte werd ongeveer een maand na de 
geboorte bepaald, op de postmenstruele leeftijd van 36 weken. De minimale behoefte bleek 
minder dan 18 mg/(kg·d) cyst(e)ine te bedragen. Ter vergelijking, standaard kunstvoeding 
voor te vroeg geboren kinderen bevat 54 mg/(kg·d) cyst(e)ine. Dit betekent wellicht dat te 
vroeg geboren kinderen op de leeftijd van een maand in staat zijn om voldoende cyst(e)ine 
te produceren om aan de behoefte te voldoen. Hieruit kan indirect worden vastgesteld dat 
cyst(e)ine waarschijnlijk geen tijdelijk essentieel aminozuur is in een maand oude kinderen 
met volledig enterale voeding die geboren zijn met een zwangerschapsduur van 32 tot 34 
weken. 
 
Uit eerdere studies is gebleken dat de activiteit van het enzym cystathionase mogelijk ook 
afhankelijk is van de leeftijd na de geboorte. In hoofdstuk 4 wordt vervolgens onderzocht of 
er een relatie bestaat tussen de postnatale leeftijd en de cyst(e)ine behoefte van te vroeg 
geboren kinderen. In kinderen geboren met een zwangerschapsduur van < 29 weken 
164 
Chapter 10 
C
ha
p
te
r 1
0 
(gemiddeld 27 weken) wordt de cyst(e)ine behoefte bepaald ongeveer een maand na de 
geboorte (gemiddelde postmenstruele leeftijd van 32 weken) en ongeveer twee maanden na 
de geboorte (gemiddelde postmenstruele leeftijd van 35 weken). Alle kinderen werden 
volledig enteraal gevoed. De behoefte bleek op beide leeftijden < 18 mg cyst(e)ine/(kg·d) te 
zijn. Hieruit kan geconcludeerd worden dat de cyst(e)ine behoefte van kinderen die geboren 
zijn met een zwangerschapsduur < 29 weken die volledig enteraal gevoed worden, niet 
afhankelijk is van de postnatale leeftijd. 
 
Tevens bestaat de idee dat de activiteit van het enzym cystathionase afhankelijk is van de 
zwangerschapsduur. De cyst(e)ine behoefte van te vroeg geboren kinderen die geboren 
werden met een zwangerschapsduur van < 29 weken (hoofdstuk 4) werd vergeleken met de 
behoefte van kinderen die geboren werden met een zwangerschapsduur van 33 weken. De 
behoefte werd in de twee groepen ongeveer een maand na de geboorte bepaald en 
bedroeg in beide groepen < 18 mg cyst(e)ine/(kg·d) en is dus niet verschillend. Hieruit mag 
worden afgeleid dat in 1 maand oude kinderen geboren met een zwangerschapsduur van 27 
weken onder de omstandigheden van volledig enterale voeding de cyst(e)ine behoefte niet 
afhankelijk is van de zwangerschapsduur noch van de postnatale leeftijd.  
 
Deel 2. Metabolisme van zwavelhoudende aminozuren in de darm en splanchnisch gebied. 
 
In dit deel wordt ingegaan op de rol van de darm in de synthese van cysteine. Aangenomen 
wordt dat de cysteine productie met name in de lever plaatsvindt. Echter, er zijn 
aanwijzingen dat de darm hier ook een grote bijdrage levert. In hoofdstuk 5 wordt het nut 
van methionine in de darm en de cysteine synthese door de darm van neonatale biggen 
onderzocht. Ongeveer twee derde van de methionine die wordt opgenomen door de darm 
werd gebruikt voor de synthese van homocysteine en cysteine. Dus de darm speelt 
inderdaad een belangrijke rol in de cysteine synthese. De bijdrage van de darm aan de 
homocysteine en cysteine synthese ten opzichte van totale lichaamshoeveelheden zijn 
respectievelijk ~30% en ~25%. Tevens wordt de mRNA expressie van het enzym 
cystathionase aangetoond in verschillende gastrointestinale weefsels, zoals lever, dunne 
darm, maag en darmepitheel. De expressie van mRNA bleek het hoogst in de lever. De 
activiteit van het enzym was het hoogst in de lever, gevolgd door darmepitheel. 
 
Na de resultaten verkregen in neonatale biggen is een vergelijkbare studie gedaan in te 
vroeg geboren kinderen. In hoofdstuk 6 wordt het metabolisme van zwavelhoudende 
aminozuren in volledig enteraal gevoede te vroeg geboren kinderen beschreven. Er is 
gebruikt gemaakt van verschillende stabiel isotoop gelabelde methionine tracers en een 
serine tracer die simultaan intraveneus en enteraal werden toegediend. Ongeveer een derde 
van de enterale methionine wordt verbruikt in first-pass metabolisme door het splanchnisch 
gebied (lever en darm). Vervolgens werd getracht om de synthese van cysteine met behulp 
van de isotoop gelabelde tracers aan te tonen. Echter, in deze studie kan de endogene 
synthese van cysteine uit methionine en serine niet worden aangetoond. Wel is aangetoond 
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dat de enterale serine werd gebruikt voor de omzetting naar een ander aminozuur namelijk 
glycine. Het einddoel en de verdere metabole route kon niet worden bepaald en zal verder 
moeten worden uitgezocht. 
Tevens werd er een significante daling van de cystine concentratie in het plasma vastgesteld 
na een cyst(e)ine vrij dieet gedurende 24 uur. Deze bevinding suggereert dat het cyst(e)ine 
verbruik de endogene synthese overschrijdt. Een andere mogelijke verklaring is dat de 
synthese niet voldoet aan de behoefte en dat in te vroeg geboren kinderen de cyst(e)ine 
behoefte tussen de 0 en 18 mg/(kg·d) ligt.  
 
Deel 3. Metabolisme van de niet essentiële aminozuren glutamaat en aspartaat in het 
splanchnisch gebied.  
 
Dierstudies laten zien dat de darm de niet essentiële aminozuren glutamaat en aspartaat in 
grote hoeveelheden als energiebron gebruikt. In hoofdstuk 7 worden de resultaten van 
splanchnisch- en totaal lichaamsmetabolisme van glutamaat in te vroeg geboren kinderen 
gepresenteerd. Het doel was om te bepalen hoeveel van de glutamaat in de voeding er door 
het splanchnisch gebied wordt opgenomen en vervolgens wordt geoxideerd (verbrand). 
Ongeveer tweederde van de enterale glutamaat inname wordt verbruikt in first-pass door 
het splanchnisch gebied in prematuur geboren kinderen. Vervolgens wordt merendeel (86%) 
hiervan geoxideerd door de darm. Glutamaat wordt dus met name gebruikt voor oxidatie in 
het splanchnisch gebied. In aansluiting hierop wordt in hoofdstuk 8 het metabole einddoel 
van enteraal aspartaat in te vroeg geboren kinderen bestudeerd. Uit deze studie blijkt dat de 
darm, evenals glutamaat, driekwart van het aspartaat uit de voeding opneemt. Daarvan 
wordt tweederde gebruikt voor oxidatieve processen. Uit de resultaten van hoofdstuk 7 en 8 
mag worden gesteld dat de niet essentiële aminozuren aspartaat en glutamaat uit de 
voeding belangrijke brandstoffen zijn voor het splanchnisch gebied in te vroeg geboren 
kinderen. 
 
In hoofdstuk 9 bevat een algemene discussie van de resultaten en met suggesties voor 
vervolg onderzoek.   
 
De belangrijkste conclusies die uit de studies beschreven in dit proefschrift kunnen worden 
getrokken, zijn: 
 
- De cyst(e)ine behoefte in enteraal gevoede te vroeg geboren kinderen die geboren 
 zijn met een zwangerschapsduur  < 29 weken is < 18 mg/(kg·d). 
 
- In enteraal gevoede prematuren die geboren zijn met een zwangerschapsduur van    
 < 29 weken is de cyst(e)ine behoefte niet afhankelijk van de zwangerschapsduur en 
 de postnatale leeftijd. 
 
- De gastrointestinale weefsels leveren een substantiële bijdrage aan de homocysteine 
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 en cysteine synthese. 
 
 - In te vroeg geboren kinderen daalt de cyst(e)ine concentratie in het plasma 
 aanzienlijk ten tijde van een cyst(e)ine vrij dieet. 
 
 - In te vroeg geboren kinderen wordt de serine uit de voeding niet gebruikt voor de 
 cyst(e)ine synthese in het lichaam tijdens een cyst(e)ine vrij dieet. 
 
 - Glutamaat en aspartaat uit de voeding zijn belangrijke energiebronnen voor de darm 
 in te vroeg geboren kinderen. 
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